Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews

RAPID REVIEW – 11 August 2020.

(The information included in this review reflects the evidence as of the date posted in the document. Updates will be developed according to new available evidence)

Disclaimer

This document includes the results of a rapid systematic review of current available literature. The information included in this review reflects the evidence as of the date posted in the document. Yet, recognizing that there are numerous ongoing clinical studies, PAHO will periodically update these reviews and corresponding recommendations as new evidence becomes available.

Ongoing Living Update of Potential COVID-19 Therapeutics: summary of rapid systematic reviews

Take home message thus far:

• More than 200 therapeutic options or their combinations are being investigated in more than 1,700 clinical trials. In this review we examined 30 therapeutic options.

• Findings from the RECOVERY Trial showed that low doses of dexamethasone (6 mg of oral or intravenous preparation once daily for 10 days) significantly reduced mortality by one-third in ventilated patients and by one fifth in patients receiving oxygen only. The anticipated RECOVERY Trial findings and WHO's SOLIDARITY Trial findings both show no benefit via use of hydroxychloroquine and lopinavir/ritonavir in terms of reducing 28-day mortality or reduced time to clinical improvement or reduced adverse events.

• Currently, there is no evidence of benefit in critical outcomes (i.e. reduction in mortality) from any therapeutic option (though remdesivir is revealing promise as one option based on 2 randomized controlled trials) and that conclusively allows for safe and effective use to mitigate or eliminate the causative agent of COVID-19.

• Currently, as to ivermectin, we found 1 *in vitro* study and 4 observational studies that were largely confounded (nonrandomized), and lacked the methodological rigor to allow much confidence in the results. They were pre-print and non-peer reviewed and were judged to be of high risk of bias and very low quality of evidence. The researchers concluded in large part that the findings could be considered hypothesis testing and urged the conduct of large sample sized RCTs to assess any clinical benefit.

• Currently, as to favipiravir, we found 1 RCT and 2 observational studies. The results were inconclusive for benefits of favipiravir, and sample sizes were small and results came via largely pre-prints and non-peer reviewed publications. The 2 nonrandomized observational designs revealed sub-optimal methods with no optimal adjustments, masking, or stratification. A recent release by Glenmark announced promising results from a Phase 3 Clinical Trial of favipiravir in patients with mild to moderate COVID-19. A Phase 3 RCT demonstrates statistically significant faster time to clinical improvement with favipiravir treatment compared to control (n=150 patients).

In addition, a 5th piece of evidence emerged via an internet publication (url: https://www.trialsitenews.com/fujita-health-university-favipiravir-trial-evidences-no-statistically-conclusive-benefit-to-covid-19-patients-a-question-mark-for-favipiravir/) of preliminary findings in a very small RCT (n=88 patients). The study initially looked at 89 infected patients with either mild or no symptoms at all at 47 sites across Japan (one patient dropped out). In 66.7% of patients who

were administered favipiravir on the first day, researchers found that the virus disappeared on day six while with the delayed group (the patients who started taking favipiravir on day 6 of the illness) the same pattern occurred where the illness started disappearing by the morning of the sixth day. The findings were inconclusive and did not yield statistically meaningful results.

Alternatively, a recent Bangladesh Society of Medicine (BSM) study concluded that Favipiravir evidences "clear cut" safety and effectivity against COVID-19 (url: https://www.trialsitenews.com/the-dhaka-trial-clear-cut-evidence-favipiravir-effective-against-covid-19-with-compelling-results/). Researchers reported that 96% of patients were found to have negative test results (RT-PCR) after the favipiravir treatment. The study involved 50 COVID-19 positive patients participating following four days of favipiravir treatment. Researchers found that 48% of the patients were COVID-19 negative and by the 10th day, that number rose to 96%. In addition, the patient group on favipiravir revealed lung function improvement three times higher than the placebo group; the favipiravir group had a 44% more viral clearance than those on the placebo; and researchers found the favipiravir subjects had no significant side effects.

• Patients with COVID-19, frequently older adults and with established comorbidities such as diabetes, hypertension, obesity, cardiovascular disease, kidney disease, and liver disease as well as malignancy, are receiving multiple concomitant medications, without considering possible adverse events and interactions. This is an area of research that is being overlooked and the potential toxicity due to concomitant treatments must be urgently addressed.

• The use of medications such as ivermectin, antivirals, and immunomodulators, among others, should be done in the context of patient consented, ethically approved, randomized clinical trials that evaluate their safety and efficacy.

• WHO/PAHO is continually monitoring ongoing research on any possible therapeutic. As evidence emerges, then WHO/PAHO will immediately assess and update its position, and particularly as it applies to any special sub-group populations such as children, expectant mothers, those with immune conditions etc.

• WHO/PAHO is also mindful of the emerging differential impact of COVID-19 on ethnic and minority groups and is continuously seeking data that could help in mitigating excess risk of severe illness or death to minority sub-groups. These groups are plagued by social and structural inequities that bring to bear a disproportionate burden of COVID illness onto them.

• The safety of the patient suffering from COVID-19 is a key priority to improve the quality of care in the provision of health services.

• There remains an urgent need for additional high-quality randomized controlled trials that includes patients with COVID-19 before any therapeutic options can be administered with any confidence. The importance of an adequately designed and reported clinical trial is paramount in evidence-based medicine. Most of the research to date on COVID has very poor methodology that is hidden and very difficult to validate. The depth of transparency that is required is very lacking.

Background:

The vast amount of data that will be coming will present important challenges and it must be interpreted quickly so that the correct most optimal treatment decisions can be made with as least harm to patients, and that manufacturers and supply chains can scale up production rapidly. This will ensure that reportedly successful drugs can be administered to as many patients and in as timely a manner as possible. Moreover, if evidence indicates that a medication is potentially sub-optimal and not effective, then the many ongoing clinical trials could change focus and pivot onto more promising alternatives. Additionally, many are using drugs already in huge volumes and also via compassionate or single use applications[1]. It is absolutely imperative therefore that prescribers be given the most updated research evidence fast to inform if what was done was optimal or if it is not optimal or even harmful to patients. The following evidence-database was complied to orient the published studies thus far and will endeavour to add to this table list as research is released into the public space. The drugs currently under review are (Box 1):

Box 1: Therapeutics reviewed

Drug name	Number of studies published thus far (RCT and observational)
Meplazumab	1
Ivermectin	5
Siltuximab	1
Danoprevir	1
Tocilizumab (IL-6)	19
Favipiravir (avigan)	4
Darunavir	1
Nelfinavir	1
Remdesivir	5
Chloroquine or hydroxychloroquine	44 (2 retracted)
Convalescent plasma	16
Corticosteroids (dexamethasone, methylprednisolone etc.)	11 (+1 combination TCZ plus methylprednisolone series)
Arbidol/Umifenovir	8
Lopinavir/ritonavir	7
Interferon-alpha	4
Interferon-beta	6
Anakinra	1
heparin (anti-coagulants)	5
α-Lipoic acid	1
Ruxolitinib	1
IVIG	2
Sarilumab	1
Famotidine	1
Lenzilumab	1
Leflunomide	1
NSAID	1
Statins	1

[1] WHO. Off-label use of medicines for COVID-19. Scientific brief. March 31st, 2020. https://www.who.int/news-room/commentaries/detail/off-label-use-of-medicines-for-covid-19

Colchicine	1
Nitric oxide	1 (commentary)
Vitamin C	1
AVIFAVIR	1
Resveratrol	1
Bevacizumab	1
kinin-kallikrein system inhibitors	1
Mesenchymal stem cell transplantation	1

Methods:

MEDLINE and EMBASE electronic databases were searched from 2020 to present (August 10th 2020) using a mix of keywords such as COVID-19 and respective drug names, along with any relevant variants. The search did not use a randomized controlled trial filter. For example, the COVID-19 terms were 'exp Coronavirus Infections/ or exp Coronavirus/ or exp Severe Acute Respiratory Syndrome/ or exp SARS Virus/ or coronavirus.mp. or severe acute respiratory syndrome coronavirus 2.mp. or 2019 nCoV.mp. or 2019nCoV.mp. or 2019 novel coronavirus.mp. or new coronavirus.mp. or novel coronavirus.mp. or SARS-CoV-2.mp. or SARS CoV-2.mp. or COVID 19.mp. or COVID-19.mp. or COVID19.mp.' The decision was to also search by a specific drug name under study.

PubMed was also searched daily during this period as a means to gain a rapid assessment of any emergent publications. Searches were conducted daily from March 15th to present to uncover any new evidence. Evidence was considered from additional sources such as manuscript reference lists, clinical trials registers (such as the International Clinical Trial Registry Platform) and online trial portals that pre-publish studies not yet having completed the peer-review process. For example, we have searched and will continue to search the largest clinical medicine preprint repository, medRxiv.org, on a daily basis.

The focus has been on any types of comparative effectiveness research (ideally RCTs studies) for all of the included therapeutic pharmacological interventions (adults and children) and this review was open to any study that could be informative, including case-series and observational designs. Adults and children exposed to or with confirmed or suspected COVID-19 were and will be included. Trials that compare interventions head-to-head or against no intervention or placebo is the focus. We have focused on comparative effectiveness studies that provide evidence on patient-important outcomes, but were open to all reported outcomes at this time[2]. No electronic database search restrictions were imposed. If meta-analytical pooling was and is possible from retrieved evidence, this review would seek to do this to derive more precise estimates of effect and derive additional statistical power.

A risk of bias assessment was applied to RCTs as well as observational studies focusing on randomization, allocation concealment, blinding, attrition, or other relevant biases to the estimates of effect, as well as selection bias, residual confounding bias, statistical adjustment, matching

[2] World Health Organization. R&D Blueprint novel Coronavirus. Outline of trial designs for experimental therapeutics. WHO reference number WHO/HEO/R&D Blueprint (nCoV)/2020.4. Available at: https://apps.who.int/iris/bitstream/handle/10665/330694/WHO-HEO-RDBlueprintnCoV-2020.4-eng.pdf?ua=1

(propensity score), stratification, or restriction, respectively[3]. The GRADE 'outcome-centric' method was applied to individual outcomes per study to derive a certainty/quality of evidence rating to establish how much confidence one could have in the estimates of effect. These are principally single studies and the approach was to consider the outcomes per study in a rapid manner to establish some sense of GRADE 'lite' rating per outcome and then to derive an overall rating. The

overall rating is based on the lowest rating from among the critical/important patient outcomes. The reporting in these studies was very poor, scarce, and the general methodologies were very weak. This has been a rapid, albeit sub-optimal application of GRADE methods, while seeking to apply as much rigor to a flawed body of evidence emerging from the current reporting across COVID-19 research in general[4].

For any meta-analytical pooling if and when data allows, we planned to pool all peer-reviewed studies with non-peer-reviewed studies. We will present the combined analysis. However, we will also apply a sensitivity analysis and separate out peer-review studies to examine the estimates of effect based on the higher quality studies that would have undergone scientific scrutiny and will present these separately. There were some drug instances whereby we provide systematic-review (meta-analysis) evidence indirectly related to COVID-19 patients e.g. corticosteroids in patients with ARDS.

[3] Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]: The Cochrane Collaboration; 2011.

[4] Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013;66(7):719–25. Epub 2013/01/15. pmid:23312392.

Results

Risk of Bias and GRADE certainty of evidence assessment

Overall, our risk of bias assessment for the limited reported RCTs resulted in high risk of bias due to sub-optimal randomization, allocation concealment, and blinding (as well as other methodological and reporting concerns). RCTs were also very small in size and had small event numbers. The methods were very poor overall and the reporting was very sub-optimal. For the observational studies which comprised the bulk of studies presently published (including a vast proportion being pre-publications that are non peer-reviewed), we had concerns with the representativeness of study groups (selection bias) and imbalance of the known and unknown prognostic factors (confounding). Many studies are also at risk of being confounded by indication. Most are not prospective in nature and the outcome measures are mainly heterogeneous with wide variation in reporting across the included studies. In general, follow-up was short and as mentioned, confounded potentially by severity of disease, comorbidities, previous or concomitant COVID-19 treatment. The Risk of Bias assessment of each randomized controlled trial is presented in the appendix.

Main findings

Corticosteroids (dexamethasone):

RECOVERY Trial on Dexamethasone
Follow-up complete for 99.9% of patients
Limitation as only studied patients in hospital
Dexamethasone reduces death by about 1/3 in hospitalized patients with severe respiratory illness and complications (COVID-19 patients)
Appears to be effective in reducing death in severely ill COVID patients needing respiratory support

- 2,104 patients randomized to dexamethasone 6 mg once daily (orally or IV) for 10 days and compared to 4,321 patients randomized to standard care alone
- Dexamethasone reduced deaths by 1/3 in ventilated patients (rate ratio 0.65, 95% CI 0.48 to 0.88, p=0.0003), and by 1/5 in other patients receiving oxygen only (rate ratio 0.80, 95% CI 0.67 to 0.96, p=0.0021), and no benefit in those who did not need respiratory support (rate ratio 1.22, 95% CI 0.86 to 1.75, p=0.14).
- Dexamethasone reduced deaths by 1/3 in ventilated patients (rate ratio 0.64, 95% CI 0.51 to 0.81), and by 1/5 in other patients receiving oxygen only (rate ratio 0.82, 95% CI 0.72 to 0.94), and no benefit in those who did not need respiratory support (rate ratio 1.19, 95% CI 0.91 to 1.55).
- Reduces 28-day mortality by 2.8%

Corticosteroids (methylprednisolone):

METCOVID Trial on methylprednisolone
Limitation as only studied patients in hospital
A tendency on mortality reduction was observed

- Overall 28-day mortality was 76/199 (38.2%) in the placebo group vs 72/194 (37.1%) in the MP group (HR 0.924 95%CI 0.669 - 1.275; P=0.629).

Figure 1: All-cause mortality of corticosteroids use in randomized control trials COVID-19 patients (RECOVERY - Dexa, METCOVID and Corral-Gudino et.al)



Corticosteroids (all RCTs including the Horby et al. 2020 RCT, with a subgroup assumption is all patients had received invasive mechanical ventilation had ARDS):

- Pooling of the existing RCTs of corticosteroid use in ARDSs patients with the emerging Horby et al. dexamethasone RCT in COVID-19 patients on invasive mechanical ventilation, we found benefit for corticosteroid use (data is sub-grouped by type of corticosteroid) (Forest plot follows).
- Urgent study is needed to address issues around drug-drug toxicity with corticosteroid use in combination with other therapeutics (often a challenge for elderly patients and significant co-treatments regimens are witnessing in COVID-19), the optimal dosing, timing of dosing, and type of corticosteroid.
- However, with different doses, time of dosing, type of corticosteroids, there is uncertainty.

Figure 2: All-cause mortality of corticosteroids use in randomized control trials patients with ARDS (low heterogeneity)



Footnotes

(1) methylprednisolone with loading dose 1 mg/kg; 1 mg/kg/day for 14 days; 0.5 mg/kg/day next 7 days; 0.25 mg/kg/day next 3 days; then...
(2) Corticosteroid methylprednisolone; loading dose of 1 mg/kg, then infusion of 1 mg/kg/day from day 1 to day 14; 0.5mg/kg/day on days 15 to...
(3) single dose of 2 mg of methylprednisolone per kilogram (kg) of predicted body weight was followed by a dose of 0.5 mg per kg of predicted...
(4) hydrocortisone 100 mg IV 3 times a day for 7 days
(5) Hydrocortisone was given daily as an intravenous bolus (50 mg in 10 ml of normal saline) every 6 h for 7 days
(6) Subgroup of those requiring invasive mechanical ventilation and given 6mg dexamethasone daily for 10 days
(7) Dexamethasone intravenous dose of 20 mg once daily from day 1 to day 5, which was reduced to 10 mg once daily from day 6 to day 10
(8) inhaled budesonide 2 mg twice a day for 12 days

Glucocorticoids

- A recent observational study in 1,806 hospitalized COVID-19 patients that focused on the optimal dosing, found that early glucocorticoid use and an initial CRP of 20 mg/dL or higher was associated with a significantly reduced risk of mortality or MV in unadjusted (odds ratio, 0.23; 95% CI, 0.08-0.70) and adjusted (aOR, 0.20; 95% CI, 0.06-0.67) analyses. Conversely, glucocorticoid treatment in patients with CRP levels less than 10 mg/dL was associated with a significantly increased risk of mortality or MV in unadjusted (OR, 2.64; 95% CI, 1.39-5.03) and adjusted (aOR, 3.14; 95% CI, 1.52-6.50) analyses.

Remdesivir:

- We found n=3 RCT comparative studies to present whereby we could meta-analytically pool n=2 of them, with both comparing remdesivir to placebo; a 3rd RCT compared duration of treatment 5 vs 10-day course
- The modelling approach considered both a fix-effect and a random effects approach and sensitivity analysis is presented (Table 1)
- The fixed-effect approach was the principle approach (when the number of pooled studies is small e.g. <3, the fix-effect approach allows for more weight to be given to the study (s) with the larger sample size/events/data) and revealed reductions in mortality (RR=0.67, 95% CI 0.46 to 0.97, p=0.03; moderate certainty), time to clinical improvement (3.95 less days, from 3.86 days less to 4.05 less days, p<0.0001; moderate certainty), serious adverse events (RR=0.77, 95% CI 0.63 to 0.94, p=0.010; moderate certainty) and all adverse events (RR=0.87, 95% CI 0.79 to 0.96, p=0.004; moderate certainty).
- Based on GRADE, all certainty was rated as 'moderate', underpinned mainly by imprecision concerns (small numbers of events, small sample sizes, wide 95% confidence intervals)
- GRADE concerns emerged for issues of imprecision (small numbers of events) and inconsistency (elevated I^2).
- Analysis found that remdesivir does have a modest and significant reduction in mortality, the time to clinical improvement, all adverse events, and the number of serious adverse events.
    - These results are promising for remdesivir and while there were elevated deaths in the drug group, analysis did uncover a significant though modest reduction.
- These results are promising and indicates benefit yet it is more than likely that as an anti-viral, remdesivir is not sufficient on its own and may be suitable in combination with other treatments. Additional research is needed and is ongoing to clarify and contextual these promising findings (Figures 2 and 3).

Table 1: Sensitivity analyses for all outcomes by fixed-effect versus random-effects modeling

Outcomes	Fixed-effect modeling	Random-effect modeling
Mortality (14-day follow up)	RR 0.67 (95% CI 0.46 to 0.97)	RR 0.72 (95% CI 0.42 to 1.23)
Time to clinical improvement (days)	MD -3.92 (-4.01 to -3.83)	MD -3.01 (-4.97 to -1.05)
Serious adverse effects	RR 0.77 (95% CI 0.63 to 0.94)	RR 0.77 (95% CI 0.63 to 0.94)
All adverse events	RR 0.87 (95% CI 0.79 to 0.96)	RR 0.91 (95% CI 0.74 to 1.11)

Hydroxychloroquine-chloroquine:

- We found n=45 studies to this date, with 11 Randomized controlled trials (RCTs) and 31 observational studies (prospective, retrospective, and case-series with or without some form of matching or adjustment (though limited)) and 2 systematic reviews/meta-analysis assessing the following combination of treatments (2 studies were retracted)
    - HCQ vs no HCQ or SoC or placebo control (n=20)
    - HCQ vs lopinavir/ritonavir (n=2)
    - HCQ high dose vs low dose (n=1)
    - HCQ + Azithromycin (AZ) vs SoC (n=14)
    - HCQ + AZ case series (n=2)
    - HCQ + doxycycline (n=1)
    - CQ vs historical controls (n=2)
    - HCQ +AZ +zinc vs combinations (n=2)
    - HCQ usage among health-care workers (HCWs) (n=1)

- The certainty or quality of studies using the GRADE approach was underpinned by typically high-risk biased estimates of effect and all were rated as very low certainty, except for one rated at low-moderate certainty and one at low certainty evidence
- There is currently sufficient evidence on the benefits of hydroxychloroquine and the vast majority of research thus far on hydroxychloroquine suggests no benefit. The RECOVERY trial found no significant difference in the primary endpoint of 28-day mortality (25.7% hydroxychloroquine vs. 23.5% usual care; hazard ratio 1.11 [95% confidence interval 0.98-1.26]; p=0.10). There was also no evidence of beneficial effects on hospital stay duration or other outcomes. Researchers reported that the data convincingly rule out any meaningful mortality benefit of hydroxychloroquine in patients hospitalised with COVID-19. The RECOVERY trial has shown that hydroxychloroquine is not an effective treatment in patients hospitalised with COVID19. Moreover, there is some accumulating evidence of harm of hydroxychloroquine use e.g. Figure 2 and no difference on the impact on all-cause mortality (Figure 3).
- While some agencies are completing RCTs to definitively answer the question on HCQ/CQ effectiveness, the vast majority of research is underpinned by weaker observational studies yet predominantly pointing to no benefit. Since January 2020, the quality of the published research even for observational research has improved, but generally still very poor across COVID-19 research and HCQ research.
- We found n=2 RCT assessing hydroxychloroquine versus placebo as postexposure prophylaxis for COVID-19. Hydroxychloroquine showed a trend on preventing the incidence of new illness compatible with COVID-19 after exposure. However certainty was low because of studies methodological limitations and imprecision.

Figure 3: Adverse effects of hydroxychloroquine use in RCTs



Figure 4: All-cause mortality of hydroxychloroquine use in principally nonrandomized observational cohort studies in COVID-19 patients (high heterogeneity)



Figure 5: Prevention of infection in those exposed to COVID-19 with hydroxychloroquine use in randomized controlled trials (Mitja et al [BCN PEP CoV-2] and Boulware et al [COVID-19 PEP])



Convalescent Plasma:

- At this time, the research on convalescent plasma (CP) is underpinned by largely observational studies that are confounded, very small sample sizes and events. This limits any confidence in the findings. One very large convenience sample of 20,000 patients on adverse events adds important information to the possible use of CP in COVID-19 patients. The convenience sample appears to indicate that CP is generally safe in hospitalized patients with COVID-19, and support the notion that earlier administration of plasma within the clinical course of COVID-19 is more likely to reduce mortality.
- A Cochrane systematic review found 20 studies (1 RCT, 3 controlled NRSIs, 16 non-controlled NRSIs) with 5443 participants, of whom 5211 received convalescent plasma. Researchers concluded there is great uncertainty on whether convalescent plasma is beneficial for people admitted to hospital with COVID-19.
- The RCT looked at CP (n=52 patients) vs standard treatment alone (n=51) with a median age of 70 and 58.3% of patients being male. Hypertension, cardiovascular disease, diabetes, kidney disease, and liver disease were the principle types of co-morbidities.
- The trial was stopped early before arriving at its targeting sample size of 200 suggestive that it was underpowered.
- Among those with severe disease, the primary outcome occurred in 91.3% (21/23) of the CP group vs 68.2% (15/22) of the control group (HR, 2.15 [95% CI, 1.07-4.32]; p= 0.03); among those with life-threatening disease the primary outcome occurred in 20.7% (6/29) of the CP group vs 24.1% (7/29) of the control group (HR, 0.88 [95% CI, 0.30-2.63]; p = .83) (P for interaction = .17). There was no significant difference in 28-day mortality (15.7% vs 24.0%; OR, 0.65 [95% CI, 0.29-1.46]; p = .30) or time from randomization to discharge (51.0% vs 36.0% discharged by day 28; HR, 1.61 [95% CI, 0.88-2.93]; p = .12). CP treatment was associated with a negative conversion rate of viral PCR at 72 hours in 87.2% of the convalescent plasma group vs 37.5% of the control group (OR, 11.39 [95% CI, 3.91-33.18]; p < .001). Two patients in the CP group experienced adverse events within hours after transfusion that improved with supportive care.
- The RCT was open-label, randomization and concealment appeared reasonably well done. Methodologically an improvement from among the COVID-19 research published to date. Larger sample sized RCTs are needed urgently to establish the benefit (or harm) of CP, and whether this treatment option will be stand-alone or work optimally in combination with other therapeutics.

Tocilizumab (IL-6):

Twenty-three tocilizumab studies (21 stand-alone and two reviews plus one combination TCZ plus corticosteroid)) are presented. These studies have not been definitive and are largely observational, while showing preliminary information that suggests urgent examination in large RCTs. We provide preliminary pooling of the data for mortality (unadjusted and adjusted) that at this time suggests no benefit. Given the high risk of bias and methodological concerns in the body of evidence, the confidence in estimates is very low. It is anticipated that ongoing RCT data will become available soon and this will be updated (Figure 4).

Figure 6: Mortality (adjusted and unadjusted) for tocilizumab



Lopinavir/ritonavir:

Four RCT studies are pooled and are presented (including the recently released data from the RECOVERY trial (Horby et al.) and WHO's SOLIDARITY trial. We provide preliminary pooling of the data for:

1) Mortality (28-day) Figure 5 including 4 RCTs, which shows no benefit, with RR of 1.06 (95% CI 0.97 to 1.17), studies showing no heterogeneity (I2=0%).

Figure 7: Mortality for lopinavir/ritonavir



2) Time to clinical improvement Figure 6 including 2 RCTs, which shows no benefit, with a mean difference of 1.27 (95% CI -1.53 to 4.07), studies showing significant unexplained heterogeneity (I2=88%).

Figure 8: Time to clinical improvement for lopinavir/ritonavir



Figure 9: Positive-to-Negative RT-PCR Conversion of Lopinavir/Ritonavir versus Control at 14 Days



3) Adverse events Figure 8 including 2 RCTs, which shows no benefit, with RR of 1.00 (95% CI 0.57 to 1.76), studies showing no appreciable heterogeneity (I2=6%).

Figure 10: Adverse events for lopinavir/ritonavir vs SoC/control



Some key drug specific contraindications and cautions should [116]

GRADE certainty of evidence

Overall, our certainty (or confidence) in the evidence was very limited since the studies were largely not randomised and they failed to use reliable methods to measure their results and confounded (high risk of bias). Furthermore, studies typically had only a small number of participants as well as events, and the methods were very sub-optimal in general. Our ratings of certainty was typically very low (with a few rated as low certainty) across the breath of COVID-19 research thus far.

Table 2: All COVID-19 *in vitro* lab and *in vivo* (clinical) human studies published from January 2020

Author; study design; year	Treatment arm vs comparator; sample size; age (mean/median); male %	Patient co-morbidities; additional medications reported besides the intervention/ control	Reported findings and author's stated conclusion Note: methodological concerns	Risk of bias (RoB)*; GRADE certainty of evidence rating**
Meplazumab (monoclonal antibody) **There is insufficient evidence to draw a conclusion on benefits and harms.** **The effectiveness is being evaluated in various randomized clinical trials.**				
OBSERVATIONAL (clinical)				
Bian[1]; observational treatment group with hospitalized concurrent control; 2020	Add-on 10 mg meplazumab (n=17 patients) vs hospitalized patients in the same period as controls (n=11); 28; mean 56.1; 53.5%	32% hypertension, 10.7% cardiovascular disease, 10.7% diabetes; lopinavir/ritonavir, recombinant human interferon α-2b, glucocorticoid, and antibiotics.	Meplazumab treatment significantly improved the discharge (p=0.006) and case severity (p=0.021) in the critical and severe patients vs control; the time to being virus negative in treatment was reduced relative to the control group (median 3, 95% CI (1.5–4.5) vs. 13, (6.5–19.5); p=0.014, HR=0.37, 95% CI (0.155–0.833)); suggested the need for further study in clinical trials as a potential therapeutic option in COVID-19. Note: non-randomized, confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, not optimally comparative, sub-optimal reporting of methods and outcomes. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]
Ivermectin **There is insufficient evidence to draw a conclusion on benefits and harms.** **The effectiveness is being evaluated in various randomized clinical trials.**				
in vitro				
Caly[2]; observational; 2020	One group: a single addition to Vero-hSLAM cells 2 hours post infection with SARS-CoV-2 isolate Australia/VIC01/2020 at a MOI of 0.1, followed by the addition of 5 μM ivermectin; NA	NA	Following a single addition to Vero-hSLAM cells 2 hours post infection, ivermectin at 24 hours contributed to a 93% reduction in viral RNA present in the supernatant of the samples treated with ivermectin compared to the vehicle DMSO. By 48 hours, there was an ~5000-fold reduction in viral RNA at 48 hours. Researchers concluded that ivermectin administration *in vitro* resulted in the effective loss of essentially all viral material by 48 hours, supporting further clinical study in COVID-19 patients. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Did not apply GRADE
OBSERVATIONAL (clinical)				
Patel[24]; observational (registry-based); 2020	Ivermectin (150 mcg/Kg once following initiation of mechanical ventilation) vs SoC (no ivermectin); 1,970; not reported; not reported	Not reported	A survival benefit was reported for ivermectin (mortality rate 18.6% vs 7.7%; HR 0.18, 95% CI (0.07-0.48), log rank (Mantel-Cox) p<0.001; length of hospital stay 10.9 +/- 6.1 days vs 15.7 +/- 8.1 days and ICU stay was 6.0 +/- 3.9 days vs 8.2 +/- 6.2 days, both p<0.001. Note: pre-print. non-randomized, confounded, optimal adjustments and steps such as stratification and masking not applied, small events, not optimally comparative, sub-optimal reporting of methods and outcomes. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]

Patel[41]; observational propensity-matched case-controlled (prospectively collected data); 2020	Ivermectin (150mcg/Kg) administered once compared with COVID-19 patients receiving medical therapy without ivermectin (704 ivermectin treated and 704 controls); 1,408; mean 53.5; 55.1%	CAD 11.1%, diabetes 11.3%, COPD 2.8%, hypertension 24.8%, immune-compromised 2.8%; hydroxychloroquine, azithromycin and corticosteroids	In patients needing mechanical ventilation, a lesser number of patients died in the ivermectin group (7.3%) vs 21.3% control and the overall mortality rates were lower with ivermectin (1.4%) vs 8.5% with a corresponding HR 0.20, CI 95% 0.11-0.37, p<0.0001). Ivermectin also contributed to reduced hospital length of stay. Note: apparent pre-print. non-randomized, potentially confounded, though propensity score matched on several variables and statistical adjustment, could not account for all unknown confounders, small events, judged as sub-optimal reporting of methods and outcomes. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	Moderate-high; Very low certainty[3]
Rajter [103]; observational retrospective; 2020	Ivermectin vs usual care (173 ivermectin, 107 usual care); 280; mean age 59.6 years (SD 17.9); 54.6 % male	Diabetes 32.1%, cardiac 15.4%, pulmonary 10%, obesity 40.7%, renal 8.6%, hypertension 17.9%, cancer 6.1%, neurologic 10%, HIV 3.2%; NR	Univariate analysis showed lower mortality in the ivermectin group (15.0 % versus 25.2%, OR 0.52, 95% CI 0.29-0.96, P=.03). Mortality was also lower among 75 patients with severe pulmonary disease treated with ivermectin (38.8% vs 80.7%, OR 0.15, CI 0.05-0.47, P=.001), but there was no significant difference in successful extubation rates (36.1% vs 15.4%, OR 3.11 (0.88-11.00), p=.07). After adjustment for between-group differences and mortality risks, the mortality difference remained significant for the entire cohort (OR 0.27, CI 0.09-0.85, p=.03; HR 0.37, CI 0.19-0.71, p=.03). Note: non-randomized, confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, not optimally comparative, sub-optimal reporting of methods and outcomes. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]
Gorial [142]; observational; 2020	16 patients received a single dose of IVM 200Mcg /kg on admission day as add on to HCQ and Azithromycin (AZT) compared with 71 controls receiving HCQ and AZT; 87; mean age ± SD of patients in the IVM group was 44.87 ± 10.64 years with a range of (28-60) years and for the controls was 45.23 ± 18.47 years with a range of (8-80) years; 72% males	Diabetes 20.6%, hypertension 19.5%, asthma 9.5%; NR	16 (100 %) of IVM group cured compared to 69 (97.2%) in the non IVM group; two patients died in the non IVM group; mean time to stay in the hospital was lower in IVM group compared with the controls and was statistically significant and clinically relevant (7.62 ± 2.75 versus 13.22 ±5.90 days, p=0.00005) with large effect size = 0.82); percentage of positive PCR patients with IVM group had significantly shorter time to become negative PCR compared to the controls. The median days of positive PCR in the IVM group was significantly lower than that of controls [7 (95% CI 6-11) vs 12 (95% CI 10-15), log rank test p < 0.001 respectively) Note: nonrandomized, small sample size, small event numbers, not optimally adjusted, nor masking or stratification; at risk of selection bias and residual confounding bias.	High; Very low certainty[1]

Siltuximab (monoclonal antibody)

There is insufficient evidence to draw a conclusion on benefits and harms.
The effectiveness is being evaluated in various randomized clinical trials.

OBSERVATIONAL (clinical)

Gritti[3]; observational (prospective cohort study); 2020	One group: patients received siltuximab at a median dose of 900 mg, ranging from 700 to 1,200 mg; received a second dose of siltuximab; 21; median 64.0 (IQR 48-75); 85.7%	43% had hypertension, 23.8% diabetes, 19% cardiovascular disease, 4.7% malignancies, 4.7% chronic kidney disease, and 4.7% cerebrovascular disease; no other	The results suggest a potential role of siltuximab in treating patients with ARDS secondary to SARS-CoV-2 infection. Note: pre-print, non-randomized, confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, not optimally comparative, sub-optimal reporting of methods and outcomes. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]

		medication reported but siltuximab		
Danoprevir (antiviral) **There is insufficient evidence to draw a conclusion on benefits and harms.** **The effectiveness is being evaluated in various randomized clinical trials.**				
OBSERVATIONAL (clinical)				
Chen[4]; observational; 2020	Treatment experienced (n=9) vs naïve patients (n=2), treatment naïve patients never received any antiviral therapies such as lopinavir/ritonavir and interferon nebulization before switching to danoprevir (all treated with danoprevir boosted by ritonavir in the presence or absence of interferon nebulization (the background therapy)); 11; median 44 (range 18-66); 36%	18% hypertension; not reported	After 4 to 12-day treatment with danoprevir boosted by ritonavir, all patients (n=11) discharged from the hospital based on normal body temperature for at least 3 days; there was substantial improvements in respiratory symptoms; the CT lung imaging revealed absorption and recovery of acute exudative lesions; there were 2 consecutive RT-PCR negative tests of SARS-CoV-2 nucleotide acid; researchers concluded that repurposing of danoprevir for COVID-19 should be considered within clinical trials. Note: pre-print, non-randomized, confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, not optimally comparative, sub-optimal reporting of methods and outcomes. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]
Tocilizumab/IL-6 (monoclonal antibody) **There is insufficient evidence to draw a conclusion on benefits and harms.** **The effectiveness is being evaluated in various randomized clinical trials.**				
OBSERVATIONAL (clinical)				
Xu[5]; observational (retrospective cohort); 2020	All patients treated with tocilizumab; 21; mean 56.8 ± SD 16.5, ranged from 25 to 88 years; 85.7%	43% hypertension, 23.8% diabetes, 9.5% CHD, 4.8% COPD, 4.8% CKD, 4.8% bronchiectasis, 4.8% brain infarct, 4.8% auricular fibrillation; none reported	75.0% lowered oxygen intake and one patient required no oxygen therapy. CT scans showed lung lesion opacity was absorbed in 90.5%. The percentage of lymphocytes in peripheral blood returned to normal in 52.6% patients on the fifth day following treatment. Abnormally elevated C-reactive protein declined significantly in 84.2% of patients. No adverse reactions reported and 90.5% (n=19) discharged from hospital mean 13.5 days following the treatment with tocilizumab and the rest; 2 are undergoing good recovery; researchers concluded that tocilizumab should be considered within clinical trials for COVID-19. Note: pre-print, non-randomized, confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, not optimally comparative, sub-optimal reporting of methods and outcomes. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]
Cellina[34]; observational case-series (1 patient); 2020	2 doses of tocilizumab (8 mg/kg), 12 hours apart, on day 7 and 8; 1 patient; 64; male	None reported; none reported	Patient without significant clinical history presented with syncope with normal vitals; ear temperature was 38 °C, oxygen saturation 99% on room air, chest X-Rays showed mild linear densities in the lower and middle left lung fields, laboratory investigations showed increased white blood cell count (10.900 per µL), elevated serum lactate level (250 U/L) and elevated reactive C protein (RCP) (89 mg/dL), other blood tests normal; COVID-19 detected in a throat swab sample by RT-PCR. Due to the worsening of the blood tests on the day 2, patient admitted; day 6, the patients developed dyspnea; decreased of oxygen saturation (90%) and further increase of CRP 336 mg/dL; white blood cell count was 10.800 per µL; interleukin-6 was 80 ng/L; day 7, unenhanced chest CT showed the presence	Not applied; Not applied

			of diffused bilateral air space opacities, including ground glass opacities and consolidation; assisted ventilation started; patient administered 2 doses of tocilizumab (8 mg/kg), 12 hours apart, on day 7 and 8; day 9, CRP declined to 96 mg/dL and white blood cell count to 2.360 per µL; patient clinical condition gradually improved and ventilatory support was gradually stopped; day 14, repeat chest CT revealed mark improvement (size reduction of air cells opacities, density reduction of consolidations, some ground glass opacities, peripheral reticular opacities, reduction of pleural effusion and mediastinal lymphadenopathy).	
Roumier[44]; observational retrospective; 2020	Treated with IL-6 vs no IL-6 in matched controls group; 59 (n=30 IL-6 group and 29 in no IL-6 group); median age 50 years; 80%	Hypertension 30.5%, cardiovascular disease 14.7%, cerebrovascular disease 5%, chronic kidney disease 8.5%, HIV/AIDS 5%, immunosuppressive therapy 11.8%; 2 patients on IL-6 got azithromycin and 2 got methyl-prednisolone	Tocilizumab significantly reduced need for subsequent mechanical ventilation (weighted OR: 0.42; 95% CI [0.20-0.89]; p=0.025), unadjusted analysis showed a trend towards a reduction of mortality (OR: 0.25 95% CI [0.05-0.95], p=0.04), this significance faded with weighted analysis; in addition, based on only 23 patients (and 16 controls) treated outside of the ICU, tocilizumab significantly reduced the risk of subsequent ICU admission (weighted OR: 0.17; 95% CI [0.06-0.48]; p=0.001); as of April 4th 2020, based on the 30 patients treated with tocilizumab, 3 (10%) died, while 4/7 (57%) and 6/30 (20%) were discharged from the ICU and from hospital, respectively; tocilizumab was well-tolerated, there is mild hepatic cytolysis in n=2 and ventilator-acquired pneumonia in n=1. Note: nonrandomized, confounded, optimal adjustments and steps not employed but the matching in the control group was an improvement (though not clear where the source of the control group was taken from e.g. was it drawn from the same population as treatment), small sample size, small events, and not optimally comparative. See reference 3 as these results differ from those of Gritti et al. who treated more severe patients requiring non-invasive ventilation with siltuximab (another IL-6R-targeted therapy). This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]
Quartuccio [6]; observational retrospective case-control; 2020	Tocilizumab (TOCI) vs SoC; 111 (42 TOCI vs 69 SoC); mean age of 58·5±13·6 years; 69.4% male	Not reported; not reported	In the TOCI group, 62% of the cases were ventilated and there were 3 deaths (17·8±10·6 days, mean follow up) with 7/26 cases remaining on ventilators, without improvement, and 17/26 developing bacterial superinfection; researchers reported 1 death in the 15 TOCI cases treated on noninvasive ventilation and 1 serious bacterial superinfection; the 69 SoC cases had no fatalities and no bacterial complication; TOCI group had higher baseline CRP and IL-6 elevations. Researchers reported more elevated inflammatory markers, more superimposed infections and poorer outcomes in ventilated TOCI cases relative to ward based TOCI therapy. Note: nonrandomized, confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, not optimally comparative, sub-optimal reporting of methods and outcomes	High; Very low certainty[1]
Wadud [77]; observational (retrospective case-control); 2020	Tocilizumab (n=44) vs control (n=50); 94; median age was 55.5 years in the study group and 66 in the control group; 76.5%	Additional medications (not optimally reported by groups etc.) were hydroxychloroquine, azithromycin, Steroids - hydrocortisone/	Average HS score was 114 in the tocilizumab group and 92 in the control group, reported difference was statistically significant with p< 0.0001 when compared to the control group; length of stay was reportedly longer, average 17.9 days in the tocilizumab; survival rate was much lower at 48 % in the control group and 61.36 % in patients who received tocilizumab with significant at p value of < 0.00001.	High; Very low certainty[1]

		methylprednisolone/ dexamethasone).	Note: nonrandomized, confounded, optimal adjustments and steps not employed but the matching (while not fully described) was an improvement (though not clear where the source of the control group was taken from e.g. was it drawn from the same population as treatment), small sample size, small events, and not optimally comparative.	
Ramaswamy [78]; observational case-control; 2020	Tocilizumab (dosed at either 400 mg fixed dose or 8 mg/kg weight-based dose with maximum single dose of 800mg) (n=21) vs no tocilizumab (n=65); 86; mean 63.7 (15.7); 66% male	Diabetes 11.6%, COPD 26.7%, hypertension 20.9%, hypertension 4.7%, cancer 2.3%, vascular disease 2.3%, atrial fibrillation 7%, stroke 2.3%; corticosteroids 20.9%, ACE 10.5%, hydroxychloroquine 67.4%	3 deaths tocilizumab, 8 deaths in untreated control; cox models and treatment effects models revealed short-term survival benefit; an associated 75% reduction in the risk of inpatient death when treated (HR 0.25; 95% CI 0.07-0.90) with tocilizumab; 52.7% reduced risk of dying while hospitalized compared to those not treated (RR 0.472; 95% CI 0.45-0.49). Note: nonrandomized, confounded, some adjusted analysis but not optimal, small sample size, small events, not optimally comparative, sub-optimal reporting of methods and outcomes. This data is also to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]
Kimmig [85]; observational retrospective; 2020	Tocilizumab (400 mg flat dosing of tocilizumab with the potential for redosing based on clinical response (e.g. oxygenation status, hemodynamic stability, inflammatory marker response) n=28 vs no tocilizumab n=32; 60; not reported; not reported	Not reported, not reported.	Tocilizumab was associated with a higher incidence of secondary bacterial infections including hospital acquired pneumonia and ventilator associated pneumonia (64.3% vs. 31.3% p=0.010); logistic regression modeling showed that tocilizumab administration was independently associated with presence of secondary bacterial infections (OR: 3.96 (95% CI 1.35-11.61), p=0.033).	High; Very low certainty[1]
Martinez-Sanz [98]; observational cohort; 2020	Tocilizumab (n=260) vs control (n=969); 1229; median treatment 65 (55 - 76), control 68 (57 - 80); 62.2%	Hypertension 22%, diabetes 22.7%, CHF 2.9%, CAD 7.9%, CKD 5.2%	Larger observational study, a total of 1,229 and 10,673 person/days were analyzed. In the adjusted marginal structural models, a significant interaction between tocilizumab use and high Creactive protein (CRP) levels was detected. Tocilizumab was associated with decreased risk of death (aHR 0.34, 95% CI 0.16–0.72, p=0.005) and ICU admission or death (aHR 0.38, 95% CI 0.19–0.81, p=0.011) among patients with baseline CRP >150 mg/L, but not among those with CRP ≤150 mg/L. Exploratory subgroup analyses yielded point estimates that were consistent with these findings. In sum, tocilizumab was associated with a lower risk of death or ICU or death in patients with higher CRP levels. Note: nonrandomized, confounded, adjusted analysis, methodology much improved over prior published COVID-19 research; as with any observational study, there is still a risk of unmeasured confounding	High; Very low certainty[1]
Garcia [99]; observational; 2020	Tocilizumab (n=77) vs control (n=94); 171; mean (SD) age of 61.5 (12.4) and 61.4 (16) years; 65.4% male	Hypertension 44%, heart disease 19.3%, respiratory diseases 11.7%, diabetes 15.2%	77 patients received tocilizumab and 94 did not. The tocilizumab group had less ICU admissions (10.3% vs. 27.6%, P= 0.005) and need of invasive ventilation (0 vs 13.8%, P=0.001). In multivariable analysis, tocilizumab remained as a protective variable (OR: 0.03, CI 95%: 0.007-0·1, P=0.0001) of ICU admission or death. Note: nonrandomized, confounded, adjusted analysis, methodology much improved over prior published COVID-19 research; as with any observational study, there is still a risk of unmeasured confounding.	High; Very low certainty[1]
Formina [111]; observational, 2020	89 patients received tocilizumab (TCZ), 17 of these patients (19%) were on mechanical ventilation, 72 (81%) treated with	Hypertension 33%, diabetes 11%, lung disease 7%, obesity 26%	Among the 89 patients who were treated with TCZ, 74 had been treated for a median of 9 days with hydroxychloroquine+ azithromycin + lopinavir/ritonavir before TCZ treatment, 4 had been treated for a median of 9 days with HCA + AZ	High; Very low certainty[1]

	supplemental oxygen without mechanical ventilation (No MV); 89; 36% < 50 years, 51% 50-69 years, 14% > 70 years; 59.6% males		before TCZ treatment and 11 had been treated for a median of 9 days with lopinavir/ritonavir before TCZ treatment. Sixty three of 72 patients were discharged from hospital, one patient died, and 8 remained in hospital at time of writing. Among 17 patients receiving mechanical ventilation, despite a rapid decrease in CRP levels from 89 to 35 mg/L (p = 0.014) and early improvements in NEWS2 scores in 10 of 17, ten patients died and seven remain in hospital at time of writing. Overall, mortality was only seen in patients who had markedly elevated CRP levels (>30 mg/L) and low lymphocyte counts (<1000*U*L) before TCZ administration. Note: nonrandomized, confounded, unadjusted analysis, no matching, stratification, and methodology somewhat improved over prior published COVID-19 research; as with any observational study, there is still a risk of selection bias and unmeasured confounding.	
Colaneri [122]; observational retrospective review; 2020	21 patients who received TCZ were matched to 21 patients who received SOC (a combination of hydroxychloroquine, azithromycin and prophylactic dose of low weight heparin) n=112 total, 91 SoC, 21 Tocilizumab; median 63.5 years; 73% males	Lung disease 47.3%, heart disease 8%, hypertension 25%, diabetes 12%, obesity 14.2%	Using propensity scores, the 21 patients who received TCZ were matched to 21 patients who received SOC (a combination of hydroxychloroquine, azithromycin and prophylactic dose of low weight heparin); no adverse event was detected following TCZ administration; treatment with TCZ did not significantly affect ICU admission (OR 0.11; 95% CI between 0.00 and 3.38; p = 0.22) or 7-day mortality rate (OR 0.78; 95% CI between 0.06 and 9.34; p = 0.84) when compared with SOC. Analysis of laboratory measures showed significant interactions between time and treatment regarding C-Reactive Protein (CRP), alanine aminotransferase (ALT), platelets and international normalized ratio (INR) levels. Variation in lymphocytes count was observed over time, irrespective of treatment. Notes: nonrandomized, confounded, small sample and events, but propensity score matched (unable to control for the effect of variables not included in the model employed to match patients)	High; Very low certainty[1]
Mikulska[127]; observational; 2020	Standard of care (SOC, controls) or SOC plus early (within 3 days from hospital admission) anti-inflammatory treatment. SOC consisted of hydroxychloroquine 400mg bid plus; 196 (Tocilizumab/ methylprednisolone/SOC (n=130) SOC (n=66)); age was 67.9 years (range, 30-100); 67.4% males	Hypertension 39.3%, diabetes 15.3%, cancer 11.2%, obesity 5.1%, heart failure 11.2%; NR	Overall, 196 adults were included; they were mainly male (67.4%), with comorbidities (78.1%) and severe COVID-19 pneumonia (83.7%). Median age was 67.9 years (range, 30-100) and median PaO2/FiO2 200 mmHg (IQR 133-289). Among them, 130 received early anti-inflammatory treatment with: tocilizumab (n=29, 22.3%), methylprednisolone (n=45, 34.6%), or both (n=56, 43.1%). The adjusted failure-free survival among tocilizumab/methylprednisolone/SOC treated patients vs. SOC was 80.8% (95%CI, 72.8-86.7) vs. 64.1% (95%CI, 51.3-74.0), HROW 0.48, 95%CI, 0.23-0.99; p=0.049. The overall survival among tocilizumab/methylprednisolone/SOC patients vs. SOC was 85.9% (95%CI, 80.7-92.6) vs. 71.9% (95%CI, 46-73), HROW 0.41, 95%CI: 0.19-0.89, p=0.025. Note: nonrandomized, confounded, small sample size, small events, single center that limits applicability; adjusted but still cannot overcome the selection bias risk and residual confounding risk.	High; Very low certainty[1]
Nasir [128]; observational retrospective; 2020	Tocilizumab; 30; mean age 62.5 ± 13.5; 83% males The median dose of tocilizumab was 600mg (Range: 320 – 680 mg).	NR; NR	No adverse effects were observed during or post-infusion. Twenty-one patients (70%) also received concomitant systemic steroids (intravenous methylprednisolone); in the 30 patients, 7 died and 20 recovered while information was missing on 3 patients who left against medical advice. The mean length of hospitalization was 12 days (SD: 6.7). The mean CRP pre and post tocilizumab treatment in those who died compared to those who survived are shown in Figure 1. Ten patients	High; Very low certainty[1]

			required ICU admission and intermittent positive pressure ventilation (IPPV) whereas 14 patients were managed on Non-invasive ventilation (NIV). Nine patients developed nosocomial infections, of which 6 of were hospital-acquired pneumonia (three with multi-drug resistant (MDR) acinetobacter, 2 with MDR Pseudomonas aeroginosa and one with methicillin resistant Staphylococcus aureus (MRSA). Additionally, 7 patients also isolated aspergillus species from their respiratory specimens out of which 3 patients were diagnosed with COVID19 associated aspergillosis and 4 were considered to be colonized. Mortality was higher in patients who developed a nosocomial infection (p-value: 0.005) and who required IPPV (p-value: 0.023). Note: nonrandomized, selection bias, residual confounding, single center, no adjustment, no matching or stratification.	
Luo [129]; observational case-series, 2020	Tocilizumab; 15; age range 62 to 80 years; 80% males	Hypertension 60%; diabetes 27%; stroke 20%; methylprednisolone 60%	37.5% receiving TCZ and MP died vs 62.5% in control; 37.5% in treatment with TCZ plus MP showed clinical stabilization vs 62.5% in the control with no stabilization Note: nonrandomized, selection bias, residual confounding, single center, no adjustment, no matching or stratification.	High; Very low certainty[1]
Guaraldi [130]; observational retrospective; 2020	Tocilizumab; 179 tocilizumab vs 365 standard care; 179; median age 64 (54–72); 71% males	Diabetes 7%, hypertension 25%, cardiovascular 8%, renal disease 4%, malignancy 3%; all patients were treated with the standard of care (ie, supplemental oxygen, hydroxychloroquine, azithromycin, antiretrovirals, and low molecular weight heparin)	Death 13 in TCZ vs 73 in SoC; 57 (16%) of 365 patients in the standard care group needed mechanical ventilation, compared with 33 (18%) of 179 patients treated with tocilizumab (p=0·41; 16 [18%] of 88 patients treated intravenously and 17 [19%] of 91 patients treated subcutaneously). 73 (20%) patients in the standard care group died, compared with 13 (7%; p<0·0001) patients treated with tocilizumab (six [7%] treated intravenously and seven [8%] treated subcutaneously). After adjustment for sex, age, recruiting centre, duration of symptoms, and SOFA score, tocilizumab treatment was associated with a reduced risk of invasive mechanical ventilation or death (adjusted hazard ratio 0·61, 95% CI 0·40–0·92; p=0·020). 24 (13%) of 179 patients treated with tocilizumab were diagnosed with new infections, versus 14 (4%) of 365 patients treated with standard of care alone (p<0·0001). Note: nonrandomized, standard of care only were older and therefore at higher baseline risk of invasive ventilation and death, open label; selection bias, residual confounding, adjusted but still biased.	High; Very low certainty[1]
Price [131]; observational; 2020	Tocilizumab; 239; median age 64; 36% black; 53% males	Diabetes 38%, immunosuppressed 15%, lung disease 38%, hypertension 60%, heart disease 30%, obesity 48%; HCQ 84%, glucocorticoid 20%, TCZ 64%,	Severe disease was associated with lower survival (78% vs 93%; p<0.001), greater proportion requiring MV (44% vs 5%; p<0.001) and longer median MV days (5.5 vs 1.0; p=0.003). Tocilizumab-treated patients (N=153, 64%) involved 90% of severe patients; 44% of non-severe patients received it for evolving CRS. Tocilizumab-treated patients with severe disease had higher admission hsCRP levels (120 vs 71mg/L; p<0.001), received tocilizumab sooner (2 vs 3 days; p<0.001), but survival was similar to non-severe patients (83% vs 91%; p=0.11). For tocilizumab-treated patients requiring MV, survival was 75% (95%CI=64%-89%); following tocilizumab, few adverse events occurred, oxygenation and inflammatory biomarkers (e.g., hsCRP, IL-6) improved; however, D-dimer and sIL2R levels increased significantly. Survival in Blacks and Hispanics, after controlling for age, was significantly higher than in whites (log-rank p=0.002). Researchers concluded that a treatment algorithm that includes tocilizumab to target CRS may influence mechanical ventilation and survival outcomes, calling for further RCTs.	High; Very low certainty[1]

			Note: nonrandomized, confounded, small sample size and event numbers, not optimally adjusted.	
Feldman [143]; observational case-series; 2020 COMBINATION TCZ + CORTICOSTEROID	Tocilizumab plus methylprednisolone; 21; NR; NR COVID-19 ICU team treated the group of seriously ill patients on ventilation with a combination of two drugs; treatment began soon after intubation	NR; NR	Twenty of the 21 patients (95 percent) were able to come off ventilators after a median duration of eight days on the combination drugs; 19 have gone home or to a post-acute care setting and two have died (since the article was published), for a mortality rate of 9.5 percent. This compares to mortality rates upward of 30-50 percent for critically ill COVID-19 patients in published studies from pandemic hot spots. Note: nonrandomized, confounded due to selection bias and confounding bias; follow-up large sample size RCT required to clarify these findings	High; Very low certainty[1]
Carvalho [146]; observational (quasi-experimental); 2020	Tocilizumab vs control; 53; median age was 55 (44-65) years in the tocilizumab group and 58.5 (51-70.8) years in the control group and most patients were male (62% x 75%, respectively)	NR; Corticosteroid 62%, HCT + AZ 73%	In the univariate analysis, tocilizumab was not associated with any of the outcomes assessed: mortality, positive cultures, use of antibiotics or need for renal replacement therapy. In the multivariable analysis, after adjusting for age and mechanical ventilation, use of tocilizumab was not associated with mortality (OR 3.97, 95% CI 0.28-57.2, p=0.3) or positive cultures (OR 1.73, 95% CI 0.22-13.82, p=0.6); no adverse events were reported that could be directly related to the administration of tocilizumab; the tocilizumab group had both higher inflammatory response markers (median CRP 20.8 mg/dL x 13.5 mg/dL in the control group, p=0.0005) and lower gas exchange ratio (165 x 264 in the control group, p=0.000, as seen in Table 4 (daily progression of variables) Note: nonrandomized, confounded, uni- and multivariable adjustment but not optimal adjustment, at risk for selection bias and residual confounding bias	High; Very low certainty[1]
Strohbehn [160]; observational; RCT	a phase 2 trial of low-dose tocilizumab in hospitalized adult patients with Covid-19; 32; median age 69 (41-73); 50% male	NR' HCQ 31.3%, AZ 40.6%, lopinavir/ritonavir 24.4%, corticosteroid 0%	Improved fever resolution (75.0% vs. 34.2%, p = 0.001) and CRP decline (86.2% vs. 14.3%, p < 0.001) in the 24-48 hours following drug administration, as compared to the retrospective controls (N=41). The probabilities of fever resolution or CRP decline did not appear to be dose-related in this small study (p=0.80 and p=0.10, respectively). Within the 28-day follow-up, 5 (15.6%) patients died. For patients who recovered, median time to clinical recovery was 3 days (IQR, 2-5). Clinically presumed and/or cultured bacterial superinfections were reported in 5 (15.6%) patients. Correlative biological studies demonstrated that tocilizumab-treated patients produced anti-SARS-CoV-2 antibodies comparable to controls. Researchers report that low-dose tocilizumab was associated with rapid improvement in clinical and laboratory measures of hyperinflammation in hospitalized patients with Covid-19. Note: non-randomized, open-label, confounded, selection bias, residual confounding bias, small sample size, small events	High; Very low certainty[1]
RCT (clinical)				
Carlo 139; RCT; 2020	Tocilizumab vs control; 126; NR; NR	NR; NR	Of the 126 randomized patients, three were excluded from the analyzes because they withdrew during the study consent. The analysis of the 123 remaining patients showed a percentage of aggravations in the former two weeks similar in patients randomized to receive Tocilizumab and compared to patients randomized to receive standard therapy (28.3% vs. 27.0%). No significant difference was observed in the number total access to Intensive Care (10.0% versus 7.9%) and in 30-day mortality (3.3% vs. 3.2%). The study shows that an early administration of Tocilizumab in patients with Covid-19 pneumonia does not provide any relevant clinical benefit for patients. The toxicity observed, however already known by	Unclear due to a preliminary report with intent to publish in a peer-reviewed journal.

			other studies, does not highlight particular problems in the administration of the drug. Although not effective in all patients with Covid-19 pneumonia, it is possible that selected patient subgroups may have a better response to the drug. Note: Unclear reporting of the methods.	
SYSTEMATIC REVIEW/META-ANALYSIS (clinical evidence)				
Kahn[58]; review, using observational retrospective case-series and case-reports; 2020	5 retrospective studies (tocilizumab, n=2 case series and two case reports; siltuximab, n=1 case series); 59; NR	Diabetes 23.8% to 27%, hypertension 42.8% to 60%; lopinavir and methylprednisolone	Xu et al 2020: All had resolution of fever within 24 hours; 75% had reduced oxygen support; CRP and lymphocytes returned to normal in 84% and 53% respectively. 91% had radiological improvement; 91% discharged; 9% remain stable Luo et al 2020: 20% died; 13% had worsening of disease; 67% demonstrated clinical stability; median CRP fell from 126.9 to 11.2 mg/L. Drop in IL-6 in 67% Gritti et al 2020: 33% improved; 43% stable; 24% worsened or died Zhang et al 2020: By Day 4 – Resolution of fever; discontinuation of supplemental oxygen therapy; radiological improvement in ground glass changes; CRP dropped from 225mg/L to 33mg/L Michot et al 2020: At 72 hours – Resolution of chest symptoms; IL-6 levels returned to normal Note: for the included studies, high risk of selection bias, unclear how the patients were enrolled, unclear information on interventions and comparators and outcomes, key design details missing and methods just overall very, very poor; multiple treatments, small sample sizes and events.	High; Very low certainty[1] AMSTAR II [7] critical appraisal of the review: low-quality, serious concerns
Boregowda [141]; Systematic-review; 2020	Tocilizumab TCZ (plus SoC) vs standard of care, studied in 13 retrospective studies and three prospective studies; 2,488 patients in the standard of care group and 1,153 patients in the Tocilizumab group.	Hydroxychloroquine was used in all studies; azithromycin was used in 6 studies, Lopinavir/Ritonavir combination was used in 6 studies, steroids were used in 12 studies, Darunavir and Cobicistat combination was used in 3 studies, and remdesivir was used in 2 studies.	The review included 5 studies were eligible and involved 3,641 patients (63% males); the mortality rate of COVID-19 patients in the TCZ group was 22.4% (258/1153), and the mortality rate in the SoC group was 26.21% (652/2488). The pooled odds ratio was 0.57 (95% CI 0.36-0.92; p=0.02). Researchers reported that TCZ added to SoC may reduce risk of death and called for large RCTs to clarify the observational review findings. Note: nonrandomized, small sample sized and small events number, most retrospective observational studies with only three prospective studies; studies were from 2 locations so results not generalizable (not a huge concern), selection bias risk and residual confounding bias risk (confounded by indication); meta-analysis revealed significant heterogeneity (study differences).	High; Very low certainty[1] AMSTAR II [7] critical appraisal of the review: low-quality, serious concerns
Kaye [145]; Systematic-review; 2020	9 case-control studies comparing mortality between TCZ and standard of care (SOC); 12 uncontrolled trials were identified for a qualitative analysis	NR; NR	9 case-control studies comparing mortality between TCZ and standard of care (SOC) were identified for a qualitative synthesis. In all of the studies, the odds ratio of mortality from COVID-19 pointed towards lower fatality with TCZ versus the SOC and a combined random effects odds ratio calculation yielded an odds ratio of 0.482 (p<0.001, 95% CI 0.326-0.713). Additionally, 12 uncontrolled trials were identified for a qualitative analysis producing a raw combined mortality rate of 13.6%. Researchers call for RCT analysis. Note: nonrandomized, small sample sized and small events number, observational studies	High; Very low certainty[1] AMSTAR II [7] critical appraisal of the review: low-quality, serious concerns

Favipiravir (antiviral)

There is insufficient evidence to draw a conclusion on benefits and harms.
The effectiveness is being evaluated in various randomized clinical trials.

RCT (clinical)				
Chen[7]; RCT (open-label); 2020	120 assigned to favipiravir group (116 assessed, routine treatment + 1600 mg on the first day twice a day, 600 mg from the second day to the end, twice a day) and 120 to arbidol group (120 assessed, 200 mg, 3 times a day to the end of the trial); 236; not reported clearly; 46.6%	27.9% hypertension, diabetes 11.4%, 95% COVID-19 pneumonia; none reported	Clinical recovery rate of day 7 between two groups, 61.2% favipiravir vs 5.7% arbidol (total patients), 71.4% vs 55.6% (moderate cases) respectively, 5.5% vs 0.0% (serious cases) respectively; patients with hypertension and/or diabetes 54.7% favipiravir vs 51.4% arbidol; adverse events 37/116 favipiravir vs 28/120 arbidol, note, 18 severe patients in the favipiravir group vs 9 severe patients in the arbidol group (imbalanced). Note: pre-print, sub-optimal randomization, allocation concealment, blinding, small sample size, small event number, and use of active comparator with unknown effectiveness for COVID-19.	High; Very low certainty[1]
Glenmark RCT [151]; RCT; 2020	n=150 patients, favipiravir vs control	NR; NR	Patients in the Favipiravir clinical trial received Favipiravir tablets 3,600 mg (1,800 mg BID) (Day 1) + 1,600 mg (800 mg BID) (Day 2 or later) for up to maximum of 14 days, along with standard supportive care. Randomization was stratified based on disease severity into mild (90 patients) and moderate (60 patients); researchers found numerical improvements for the primary efficacy endpoint with 28.6% faster viral clearance in the overall population as measured by the median time until cessation of oral shedding of virus in the Favipiravir treatment arm compared to those in the control arm (Hazard Ratio 1.367 [95%CI 0.944,1.979]; p=0.129). Key secondary outcome measures for clinical improvement demonstrated the efficacy and benefit of Favipiravir treatment arm over the control arm: 40% faster achievement of "clinical cure" defined as the physician's assessment of normalization of clinical signs – temperature, oxygen saturation, respiratory rate and cough with a statistically significant reduction in median time to clinical cure in the Favipiravir treatment arm (3 days [95%CI 3.0, 4.0]), compared to the control arm (5 days [95%CI 4.0,6.0]) (HR 1.749 [95% CI 1.096, 2.792]; p=0.029). 69.8% of patients in the Favipiravir treatment arm achieved clinical cure by Day 4, which was statistically significant compared to 44.9% observed in the control arm (p=0.019). Amongst patients who clinically deteriorated and required oxygen support, those receiving Favipiravir had a longer median time to first time use of oxygen of 5 days (95%CI 1.0,6.0) versus 2 days (95% CI 1.0-4.0) in the control arm. Note: not peer reviewed as a pre-publication and full methods not available for assessment.	Unable to assess given not yet a peer reviewed manuscript release
Ivashchenko [162]; RCT; 2020	Randomized at a 1:1:1 ratio to receive either AVIFAVIR 1600 mg BID on Day 1 followed by 600 mg BID on Days 2-14 (1600/600 mg) n=20, or AVIFAVIR 1800 mg BID on Day 1 followed by 800 mg BID on Days 2-14 (1800/800 mg) n=20, or SOC n=20; 60; NR; NR	NR; NR	In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated. Both dosing regimens of AVIFAVIR demonstrated similar virologic response. On Day 5, the viral clearance was achieved in 25/40 (62.5%) patients on AVIFAVIR and in 6/20 (30.0%) patients on SOC (p=0.018). By Day 10 the viral clearance was achieved in 37/40 (92.5%) patients on AVIFAVIR and in 16/20 (80.0%) patients on SOC (p=0.155). Thus, the required number of responders to demonstrate proof of concept was attained. The median time to body temperature normalization (< 37o C) was 2 days (IQR 1-3) in the AVIFAVIR groups and 4 days (IQR 1-8) in the SOC group (p=0.007). By Day 15, chest CT scans improved in 36/40 (90.0%) patients on AVIFAVIR	High; Very low certainty[1]

			and 16/20 (80.0%) patients on SOC (p=0.283). Adverse drug reactions to AVIFAVIR were reported in 7/40 (17.5%) patients, including diarrhea, nausea, vomiting, chest pain and an increase in liver transaminase levels. The adverse drug reactions were mild to moderate and caused early discontinuation of the study drug in 2/40 (5.0%) patients. Two patients on AVIFAVIR 1600/600 mg were moved to intensive care unit, received mechanical ventilation and later died. Both patients had the increased risk of severe disease, including diabetes mellitus, arterial hypertension, obesity, CRP > 50 mg/L, and supplemental oxygen at baseline. 13/20 (65.0%) patients on AVIFAVIR 1600/600 mg, 17/20 (85.0%) patients on AVIFAVIR 1800/800 mg and 17/20 (85.0%) patients on SOC were discharged from the hospital and/or achieved Score 2 on WHO-OSCI by Day 15.	
OBSERVATIONAL (clinical)				
Cai[6]; observational (nonrandomized open-label); 2020	Oral FPV n=35 (Day 1: 1600 mg twice daily; days 2–14: 600 mg twice daily) plus interferon (IFN) α by aerosol inhalation in the FPV arm vs LPV/RTV n=45 (days 1–14: 400 mg/100 mg twice daily) plus IFN-α; 80 (n=35 FPV and n 45=in LPV/RTV); 80; median 47 (35.75–61); 43.8%	None reported; no additional medications reported, standard care included oxygen inhalation, oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, and antiemetic drugs.	Viral clearance median time for FPV (Group A), was estimated to be 4 days (IQR: 2.5–9) and significantly shorter than the time for patients in control group (Group B), which was 11 d (IQR: 8–13) (P < 0.001); for chest CT changes, on the 14th day after treatment, the improvement rates of the chest CT in FPV significantly higher than those in the control arm (91.4% versus 62.2 %, 32/35 versus 28/45, p = 0.004). Adverse reactions in the FPV n=4 was four, significantly fewer than the 25 adverse reactions in the control arm (p < 0.001). Researchers concluded that FPV showed better therapeutic responses on COVID-19 in terms of disease progression and viral clearance. Note: nonrandomized, confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, not optimally comparative, sub-optimal reporting of methods and outcomes, and active, retrospective comparator with unknown effectiveness for COVID-19. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]
Rattanaumpawan [137]; observational; 2020	At least 1 dose of favipiravir; 63; median 48 (22–85); 61.9% males		The Day−7 clinical improvement rate [95%CI] was 66.7% [53.7−78.0%] in all patients, 92.5% [75.7%−99.1%] in patients who did not require O2−supplementation, and 47.2% [0.4%−64.5%] in patients who required O2−supplementation. No life-threatening adverse events were identified. The 28-day mortality rate was 4.8%. Multivariate analysis revealed three poor prognostic factors for Day−7 clinical improvement [odds ratio (95%CI); p−value]: older age [0.94 (0.89 to 0.99); p=0.04], higher baseline NEWS2 score [0.64 (0.47 to 0.88); p=0.006], and lower favipiravir loading dose (≤45 mg/kg/day) [0.04 (0.005 to 0.4); p=0.006]. Note: nonrandomized, confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, not optimally comparative, sub-optimal reporting of methods and outcomes	High; Very low certainty[1]
Darunavir (antiviral) **There is insufficient evidence to draw a conclusion on benefits and harms.** **The effectiveness is being evaluated in various randomized clinical trials.**				
in vitro				
De Meyer[8]; observational; 2020	Examined the *in vitro* antiviral activity of darunavir against a clinical isolate from a patient infected with SARS-CoV-2.	NA	Darunavir showed no activity against SARS-CoV-2 at clinically relevant concentrations (EC50 >100 µM). Remdesivir, used as a positive control, showed potent antiviral activity (EC50 = 0.38 µM). Researchers report that findings do not support the use of darunavir for treatment of COVID-19. This early data is to be	Definitely high[2] (risk of bias assessed for *in vitro*

			considered hypothesis generating, calling for well-designed randomised clinical studies.	studies using OHAT tool); Very low certainty[1]
Nelfinavir (antiviral) **There is insufficient evidence to draw a conclusion on benefits and harms.** **The effectiveness is being evaluated in various randomized clinical trials.**				
in vitro				
Yamamoto [9]; observational; 2020	Assessed the 50% effective concentration (EC50), the 50% cytotoxic concentration (CC50), and the selectivity index (SI, CC50/EC50); C max-EC50 ratio (C max/EC50) and C trough-EC50 ratio (C trough/EC50) were also calculated to evaluate the safety and efficacy of the 9 antivirals (plus lopinavir, ritonavir, saquinavir, atazanavir, tipranavir, amprenavir, darunavir, and indinavir).	NA	Nelfinavir effectively obstructs replication of SARS-CoV-2; the effective concentrations for 50% and 90% inhibition (EC50 and EC90) of nelfinavir was the lowest from among the 9 HIV-1 protease inhibitors. Present *in vitro* findings are positive and support further clinical study of nelfinavir in COVID-19 patients. The methodology indicates a high risk of bias. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	Definitely high[2] (risk of bias assessed for *in vitro* studies using OHAT tool); Very low certainty[1]
Remdesivir (antiviral) **Remdesivir does have a modest and significant reduction the time to clinical improvement, all adverse events, and the number of serious adverse events. There is insufficient evidence to draw a definitive conclusion on benefits to reduce mortality.** **The effectiveness is being evaluated in various randomized clinical trials.**				
OBSERVATIONAL (clinical)				
Holshue [10]; case-report; 2020	1 COVID-19 patient (first in USA), aged 35 years, male, treated with remdesivir on compassionate use authorization	NA	Treatment with IV remdesivir began on the evening of day 7, and no adverse events were observed in association with the infusion. Vancomycin was discontinued on the evening of day 7, and cefepime was discontinued on the following day, after serial negative procalcitonin levels and negative nasal PCR testing for methicillin-resistant *Staphylococcus aureus*. On hospital day 8 (which was illness day 12), it was found that the patient's clinical condition improved significantly, whereby the supplemental oxygen was discontinued, and his oxygen saturation values improved to 94 to 96% while he was breathing ambient air. Bilateral lower-lobe rales were no longer present. Appetite improved, and the patient was asymptomatic aside from intermittent dry cough and rhinorrhea. All symptoms resolved.	Not applied; Not applied
Grein,[11]; case-series; 2020	Remdesivir; 53; median IQR 64 (48–71); 75	Hypertension 25%, diabetes 17%, hyperlipidemia 11%, asthma 11%; none reported	Researchers reported that at baseline, 30 patients (57%) were receiving mechanical ventilation and 4 (8%) were receiving ECMO. Based on a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) has died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation. Thirty-two patients incurred adverse events in follow-up. Small sample size, no control group, short duration follow-up. Note: nonrandomized, confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, and not optimally comparative. This	High; Very low certainty[1]

			early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	
RCT (clinical)				
Beigel [87]; RCT; 2020	541 were assigned to the remdesivir group and 522 to the placebo group; 1063; mean 58.9 ± 15; 64.3% male	Coronary artery disease (11.6%) Congestive heart failure (5.0%) Diabetes (29.7%) Hypertension (49.6%) Asthma (11.4%) Chronic oxygen requirement (2.2%) Chronic respiratory disease (7.6%)	Those who received remdesivir showed a median recovery time of 11 days (95% confidence interval [CI], 9 to 12), as compared with 15 days (95% CI, 13 to 19) in those who received placebo (rate ratio for recovery, 1.32; 95% CI, 1.12 to 1.55; P<0.001). The Kaplan-Meier estimates of mortality by 14 days were 7.1% with remdesivir and 11.9% with placebo (hazard ratio for death, 0.70; 95% CI, 0.47 to 1.04). Serious adverse events were reported for 114 of the 541 patients in the remdesivir group who underwent randomization (21.1%) and 141 of the 522 patients in the placebo group who underwent randomization (27.0%).	Low; Moderate[3] See Figure 5
Wang [60]; RCT; 2020	IV remdesivir (200 mg on day 1 followed by 100 mg on days 2–10 in single daily infusions) n=158 vs the same volume of placebo n=79 infusions for 10 days	Hypertension 43%, diabetes 23.7%, CHD 7.2%; interferon alfa-2b 32.2%, lopinavir–ritonavir 28.4%, antibiotics 91.1%, corticosteroids 65.6%	Researchers reported that remdesivir use was not associated with a significant difference in time to clinical improvement (HR 1.23 [95% CI 0.87–1.75]); remdesivir patients had a numerically faster time to clinical improvement than those receiving placebo among patients with symptom duration of 10 days or less (HR 1.52 [0.95–2.43]); 102 (66%) of 155 remdesivir recipients had adverse events relative to 50 (64%) in 78 placebo recipients; remdesivir was stopped early due to adverse events in 18 (12%) patients versus four (5%) patients who stopped placebo early; 22 persons died in the treatment group vs 10 in the control group. Note: randomization and allocation concealment appear much better than traditional COVID-19 methods; however, insufficient statistical power to detect real differences in the outcomes (50% power instead of the needed 80% power), heavy death in treatment and control of about 14% of patients and its a huge problem; numerically higher death in remdesivir; 22 deaths vs 10 deaths; this patient group were not as sick, not as ill to begin with and so this should have meant not many deaths for they were not ill, not many on mechanical ventilation (approx. 1% to start); and so the patients should have had less bad outcomes; the remdesivir group of patients suffered many deaths (22) and it could have been remdesivir and as such, longer terms RCTs with larger sample sizes (adequately powered) are urgently needed; in addition, there were many adverse effects in the group on remdesivir; 102 patients or 66% in the remdesivir group had adverse effects.	Low; Moderate[3]
Goldman [91]; RCT (open-label); 2020	200 patients for 5 days and 197 for 10 days (200 mg of remdesivir on day 1, followed by 100 mg of remdesivir once daily for the subsequent 4 or 9 days. Both treatment groups continued supportive therapy at the discretion of the investigator throughout the duration of the trial); 397; median 5 days 61 (50-69) vs 10 days 62 (50-71); 63.7%	Diabetes 22.6%, hyperlipidemia 22.4%, hypertension 49.8%, asthma 12.3%; not clearly reported.	Deaths n=16 vs 21 (5 vs 10 days treatment); at baseline, patients randomly assigned to the 10-day group had significantly worse clinical status than those assigned to the 5-day group (p=0.02); at day 14, a clinical improvement of 2 points or more on the ordinal scale occurred in 64% of patients in the 5-day group and in 54% in the 10-day group; after adjustment for baseline clinical status, patients in the 10-day group had a distribution in clinical status at day 14 that was similar to that among patients in the 5-day group (p=0.14); the most common adverse events were nausea (9% of patients), worsening respiratory failure (8%), elevated alanine aminotransferase level (7%), and constipation (7%).	Low; Moderate[3]

Chloroquine/hydroxychloroquine

Studies show no significant benefit in reducing mortality or other primary outcomes

(see GRADE Table and Figure in appendix)

RCT (clinical)				
Chen [12]; RCT; 2020	Hydroxychloroquine (HCQ) 400 mg per day for 5 days vs control (conventional treatment); 30 (15:15); 48.5 mean; 70%	None reported; nebulization with interferon alpha, and 80% patients in the experimental group received abidol vs 66.7% in control, 2 received lopinavir / ritonavir.	Nucleic acid of throat swabs was negative in 13 (86.7%) HCQ cases and 14 (93.3%) cases in the control group (*P*>0.05), median duration from hospitalization to virus nucleic acid negative conservation was 4 (1-9) days in HCQ group, which is comparable to that in the control group [2 (1-4) days, median time for body temperature normalization in HCQ group was 1 (0-2) after hospitalization, which was also comparable to that in the control group 1(0-3), radiological progression was shown on CT images in 5 cases (33.3%) in the HCQ group and 7 cases (46.7%) in the control group. Researchers concluded that the standard dose of hydroxychloroquine sulfate does not show clinical effects in improving patient symptoms and accelerating virological suppression. Note: sub-optimal randomization, allocation concealment, blinding, small sample size, small event number, and imbalanced co-treatment assignment.	High; Very low certainty[1] See Figure 1, Table 1
Chen[13]; RCT; 2020	5-day HCQ (n=31) (400 mg/d), control (n=31) received SoC; 62; 44.7 mean (SD 15.3); 46.8%	None reported; none reported	Body temperature recovery time and the cough remission time were significantly shortened in the HCQ treatment group (mean days and SD was 2.2 (0.4) in the HCQ groups vs 3.2 (1.3) in the control, p=0.0008. They also reported a greater proportion of patients with improved pneumonia (on chest CT) in the HCQ treatment group (80.6%, 25 of 31) relative to the control group (54.8%, 17 of 31). Four patients in the control group developed severe illness (none in the treatment group) and there were 2 mild adverse events in the HCQ group. Note: the study group was generally younger, and the illness was mild on entry, suggestive that this was not an overly ill group to begin with and patients may have recovered on their own. No accounting of whether patients were taking any other medications prior to study entry or during the study; sub-optimal randomization, allocation concealment, blinding, small sample size, small event number, and imbalanced co-treatment assignment.	High; Very low certainty[1]
Huang [14]; RCT; 2020	Twice-daily oral of 500 mg Chloroquine (n=10) versus 400/100mg Lopinavir/Ritonavir (n=12) for 10 days; 22; 44.0 mean (36.5 to 57.5); 59.1%	None reported; none reported	Using RT-PCR, on day 13, all patients in the chloroquine group were negative, and 11 of 12 in the control group (lopinavir/ritonavir) were negative on day 14. Via lung CT on day 9, 6 patients in chloroquine group achieved lung clearance versus 3 in the comparison group. At day 14, the rate ratio based on CT imaging from the Chloroquine group was 2.21, 95% CI 0.81-6.62) relative to the control group. Five patients in the chloroquine group had adverse events versus no patients in the control group. Note: this small RCT appeared to show better effectiveness of chloroquine over lopinavir/ritonavir in moderate to severely ill COVID-19 patients; plagued with sub-optimal randomization, allocation concealment, blinding, small sample size, small event number, and use of active comparator with uncertain treatment effectiveness against COVID-19.	High; Very low certainty[1]
Silva Borba[15]; RCT; 2020	CQ (600mg CQ twice daily for 10 days or total dose 12g); or low dose CQ (450mg for 5 days, twice daily only on the first day, or total dose 2.7g); 81 (41 high doses vs 40 low dose); mean age 51.1; 75.3% males	Hypertension 46.2%, diabetes 25.9%, alcoholism 26%, heart disease 9.2%, asthma 6.2%, CKD 7.5%, rheumatic disease 5.6%, liver disease 3.7%, TB 3.7%, HIV/AIDS 1.9%; corticosteroids	Viral RNA was detected in 31 of 40 (77.5%) and 31 of 41 (75.6%) patients in the low-dosage and high-dosage groups, respectively. Lethality until day 13 was 39.0% in the high-dosage group (16 of 41) and 15.0% in the low-dosage group (6 of 40). The high-dosage group presented more instance of QTc interval greater than 500 milliseconds (7 of 37 [18.9%]) compared with the low-dosage group (4 of 36 [11.1%]). Respiratory secretion at day 4 was negative in only 6 of 27 patients (22.2%).	Low-moderate; Moderate certainty[3]

		5.4%, ACE inhibitors 10.3%, oseltamivir 89.6%	Note: sub-optimal randomization with randomization occurring before laboratory confirmation of SARS-CoV-2 infection, small sample size, small event number, and comparison of dose-comparison concurrent trial without a placebo control.	
Tang[16]; RCT; 2020	HCQ (a loading dose of 1, 200 mg daily for three days followed by a maintained dose of 800 mg daily for the remaining days) vs SoC; 150; mean 46.1±14.7; 54.7%	Diabetes 14.0%, hypertension 6%, others 31%; 80 patients used other drugs after randomization (not clearly reported)	The overall 28-day negative conversion rate was not different between SOC plus HCQ and SOC group (85.4% versus 81.3%, p=0.34). Negative conversion rate at day 4, 7, 10, 14 or 21. A significant efficacy of HCQ on alleviating symptoms was observed (HR, 8.83, 95%CI, 1.09 to 71.3). There was a significantly greater reduction of CRP (6.98 in SOC plus HCQ versus 2.72 in SoC, milligram/liter, p=0.045) conferred by the addition of HCQ, which also led to more rapid recovery of lymphopenia, albeit no statistical significance. Adverse events found in 8.8% of SoC and 30% of HCQ recipients with two serious adverse events in the HCQ group. Note: sub-optimal randomization, allocation concealment, no blinding, small sample size, small event number, and comparison of dose-comparison concurrent trial without a placebo control.	High; Low certainty[1]
Barbosa[28]; quasi-RCT; 2020 (submitted to NEJM for peer review, abstract form and available in the referenced blog)	HCQ + supportive care vs supportive care alone; 63 (32 HCQ vs 31 control);	Not reported; not reported (will be updated as the authors published in full)	HCQ administration was associated with worse outcomes. Note: this paper was cited on a blog and appears to be a released paper submitted to NEJM; we felt the data is important as shed important light but we do not wish this reference or material to be cited out of regard to the originating authors; what we include we have taken from the blog as referenced (https://blogs.sciencemag.org/pipeline/about-derek-lowe)	High; Low certainty[1]
Horby [101]; RCT; 2020	561 patients randomly allocated to receive hydroxychloroquine vs 3155 patients concurrently allocated to usual care; 4716; mean age 65.3 (SD 15.3) years; 62.5% males	Diabetes 26.9%, heart disease 25.4%, lung disease 21.9%, liver disease 1.3%, kidney disease 7.8%; NR	418 (26.8%) patients allocated to HCQ and 788 (25.0%) patients allocated usual care died within 28 days (rate ratio 1.09; 95% confidence interval [CI] 0.96 to 1.23; P=0.18). Consistent results were seen in all pre-specified subgroups of patients. Patients allocated to hydroxychloroquine were less likely to be discharged from hospital alive within 28 days (60.3% vs. 62.8%; rate ratio 0.92; 95% CI 0.85-0.99) and those not on invasive mechanical ventilation at baseline were more likely to reach the composite endpoint of invasive mechanical ventilation or death (29.8% vs. 26.5%; risk ratio 1.12; 95% CI 1.01-1.25). There was no excess of new major cardiac arrhythmia.	Low-moderate; Moderate certainty[3]
Boulware [107]; RCT; 2020	Postexposure prophylaxis with hydroxychloroquine after exposure to Covid-19, HCQ (n=441) vs placebo (n=407); 821; median HCQ 41 (33-51), placebo 40 (32-50); 48.2% male	Hypertension 12.1%, 7.6%; not reported	No deaths were reported for either group; incidence of new illness compatible with Covid-19 did not differ significantly between participants receiving hydroxychloroquine (49 of 414 [11.8%]) and those receiving placebo (58 of 407 [14.3%]); the absolute difference was −2.4 percentage points (95% confidence interval, −7.0 to 2.2; P=0.35). Side effects were more common with hydroxychloroquine than with placebo (40.1% vs. 16.8%); no serious adverse reactions were reported. Note: relatively larger sample size, small events, randomization and concealment much more adequate than usually seen in COVID-19 research	Low-moderate; Moderate certainty[3]
Chen [126]; RCT; 2020	HCQ (18), CQ (18), placebo (12); 48; CQ 45.22 ± 13.66, HCQ 45.67 ± 14.37, placebo 51.33 ± 15.36; 46% males	Hypertension 17%, diabetes 18.7%; NR	Adverse events were mild, except for one case of Grade 2 ALT elevation. Adverse events were more commonly observed in the CQ group (44.44%) and the HCQ group (50.00%) than in the control group (16.67%). The CQ group achieved shorter time to clinical recovery (TTCR) than the control group (P=0.019). There was a trend toward reduced TTCR in the HCQ group (P=0.049). The time to reach viral RNA negativity was significantly faster in the chloroquine group and the HCQ group than in the control group (P=0.006 and P=0.010, respectively). The median numbers of days to reach RNA	High; Low certainty[1]

			negativity in the CQ, HCQ, and control groups was 2.5 (IQR: 2.0-3.8) days, 2.0 (IQR: 2.0-3.5) days, and 7.0 (IQR: 3.0-10.0) days, respectively. The CQ and HCQ groups also showed trends toward improvement in the duration of hospitalization and findings on lung computerized tomography (CT).	
Skipper [147]; RCT; 2020	HCQ vs placebo in outpatients, 423; median age was 40 years (interquartile range [IQR], 32 to 50 years), and 44% males.	Asthma (11%), hypertension (11%), and diabetes (4%)	423 contributed primary end point data. Of these, 341 (81%) had laboratory-confirmed infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or epidemiologically linked exposure to a person with laboratory-confirmed infection; 56% (236 of 423) were enrolled within 1 day of symptoms starting. Change in symptom severity over 14 days did not differ between the hydroxychloroquine and placebo groups (difference in symptom severity: relative, 12%; absolute, −0.27 points [95% CI, −0.61 to 0.07 points]; P = 0.117). At 14 days, 24% (49 of 201) of participants receiving hydroxychloroquine had ongoing symptoms compared with 30% (59 of 194) receiving placebo (P = 0.21). Medication adverse effects occurred in 43% (92 of 212) of participants receiving hydroxychloroquine versus 22% (46 of 211) receiving placebo (P < 0.001). With placebo, 10 hospitalizations occurred (2 non–COVID-19–related), including 1 hospitalized death. With hydroxychloroquine, 4 hospitalizations occurred plus 1 nonhospitalized death (P = 0.29). Note: relatively small sample size, small events, randomization and concealment much more adequate than usually seen in COVID-19 research; a bit better quality	Low-moderate; Moderate certainty[3]
Mitja [150]; RCT; 2020	157 in the control arm and 136 in the intervention arm; 293; mean age mean age was 41.6 years (SD 12.6); 49% males	Any co-morbidity 53.2%	Researchers found no significant differences were found in the mean reduction of viral load at day 3 (-1.41 vs. -1.41 Log10 copies/mL in the control and intervention arm, respectively; difference 0.01 [95% CI -0.28;0.29]) or at day 7 (-3.37 vs. -3.44; d -0.07 [-0.44;0.29]). This treatment regimen did not reduce risk of hospitalization (7.1%, control vs. 5.9%, intervention; RR 0.75 [0.32;1.77]) nor shortened the time to complete resolution of symptoms (12 days, control vs. 10 days, intervention; p = 0.38). No relevant treatment-related AEs were reported. Note: Note: relatively small sample size, small events, randomization and concealment much more adequate than usually seen in COVID-19 research	Low-moderate; Moderate certainty[3]
Cavalcanti [154]; RCT; 2020	Patients were randomly assigned in a 1:1:1 ratio to receive standard care (control group), standard care plus HCQ at a dose of 400 mg twice daily for 7 days (HCQ-alone group), or standard care plus HCQ at a dose of 400 mg twice daily plus azithromycin at a dose of 500 mg once a day for 7 days; 665; mean age 50.3±14.6; 58.3% males	Hypertension 38.8%, diabetes 19.1%, obesity 15.5%, cancer 2.9%, COPD 1.8%, renal disease 0.8%, heart failure 1.5%; glucocorticoid 1.2%, ACE inhibitor 7.2%, ARBs 17.4%	504 patients had confirmed Covid-19 and were included in the modified intention-to-treat analysis. As compared with standard care, the proportional odds of having a higher score on the seven-point ordinal scale at 15 days was not affected by either hydroxychloroquine alone (odds ratio, 1.21; 95% confidence interval [CI], 0.69 to 2.11; P=1.00) or hydroxychloroquine plus azithromycin (odds ratio, 0.99; 95% CI, 0.57 to 1.73; P=1.00). Prolongation of the corrected QT interval and elevation of liver-enzyme levels were more frequent in patients receiving hydroxychloroquine, alone or with azithromycin, than in those who were not receiving either agent. Researchers concluded that among patients hospitalized with mild-to-moderate Covid-19, the use of hydroxychloroquine, alone or with azithromycin, did not improve clinical status at 15 days as compared with standard care. Note: RCT, randomization done reasonably well, allocation concealment	Low-moderate; Moderate certainty[3]
Lofgren [156]; RCT; 2020	Hydroxychloroquine as pre-exposure prophylaxis, post-exposure prophylaxis and early 52 treatment for	NR; NR	2,324 (84%) participants reported side effect data, and 638 (27%) reported at least one medication side effect. Side effects were reported in 29% with daily, 36% with twice weekly, 31% with once weekly hydroxychloroquine compared to 19% with	High; Very low certainty[1]

	COVID-19;2795; median age of research participants was 40 (IQR 34-49) years; 48.6% males		placebo. The most common side effects were upset stomach or nausea (25% with daily, 18% with twice weekly, 16% with weekly, vs. 10% for placebo), followed by diarrhea, vomiting, or abdominal pain (23% for daily, 16% twice weekly, 12% weekly, vs. 6% for placebo). Two individuals were hospitalized for atrial arrhythmias, one on placebo and one on twice weekly hydroxychloroquine. No sudden deaths occurred. Note: younger, multiple medications, outpatients so healthier	
Mitja[158]; RCT; 2020	open-label, cluster-randomized trial including asymptomatic contacts exposed to a PCR-positive Covid-19 case, 1,198 were randomly allocated to usual care and 1,116 to HCQ therapy; 2314; mean age 48.6 years; 27% males	Cardiovascular 13.3%, respiratory 4.8%, metabolic disease 8.3%	No significant difference in the primary outcome of PCR-confirmed, symptomatic Covid-19 disease (6.2% usual care vs. 5.7% HCQ; risk ratio 0.89 [95% confidence interval 0.54-1.46]), nor evidence of beneficial effects on prevention of SARS-CoV-2 transmission (17.8% usual care vs. 18.7% HCQ). The incidence of AEs was higher in the intervention arm than in the control arm (5.9% usual care vs 51.6% HCQ), but no treatment-related serious AEs were reported. 8 deaths control arm vs 5 in intervention. Researchers concluded the findings do not support HCQ as postexposure prophylaxis for Covid-19.	Low-moderate; Moderate certainty[3]
OBSERVATIONAL (clinical)				
[17]; observational (open-label non-randomized trial); 2020	HCQ 600 mg daily 6 d n=26 (AZ added depending on clinical presentation); 42; 26 HCQ, 16 control; 45.1 ± 22.0 (mean/SD); 41.7%	None reported; none reported	Researchers reported that 6 patients were asymptomatic, 22 had upper respiratory tract infection symptoms and eight had lower respiratory tract infection symptoms. Twenty cases were treated in this study and showed a significant reduction of the viral carriage at D 6-post inclusion compared to controls, and much lower average carrying duration than reported of untreated patients in the literature. Azithromycin (Z-Pak) added to hydroxychloroquine was significantly more efficient for virus elimination. Researchers concluded that hydroxychloroquine did not prevent illness compatible with Covid-19 or confirmed infection when used as postexposure prophylaxis within 4 days after exposure. Note: clinical follow-up and occurrence of side-effects were not discussed in the paper; non-randomized, confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, not optimally comparative, and sub-optimal reporting of methods and outcomes. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]
Gautret[18]; observational (uncontrolled non-comparative observational study); 2020	200 mg of HCQ three times per day for ten days combined with AZ (500 mg on D1 followed by 250 mg per day for the next four days); 80; 52.5 median, 52.5%	Cancer 6.3%, diabetes 11.2%, CAD 7.5%, hypertension 16.3%, chronic respiratory disease 10%, obesity 5%; immune-suppressive treatment 5%, non-steroid anti-inflammatory treatment 2.5%	Nasopharyngeal viral load tested by qPCR and negative on day 8 was found in 93.7% of patients, not contagious (with a PCR Ct value<34) at day 10 was found in 98.7%, negative virus cultures on day 5 was found in 98.7%, and length of stay in ICU (days) was a mean 4.6 days ± 2.1 SD (n=65). Researchers reported that patients were rapidly discharged from highly contagious wards with a mean length of stay of five days. Note: this study was judged to be at high risk of biased estimates due to it being a case-series observational study with no control group. Based on reporting, the cohort appears to be younger and the NEWS risk scoring system placed them all at very low risk of deteriorating, leaving one to speculate on if they would have recovered on their own. This group appears to be COVID-19 patients with mild illness. Patients may have recovered on their own; non-randomized, confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, not optimally comparative, and sub-optimal reporting of methods and outcomes. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]

Molina[19]; observational (narrative review); 2020	HCQ 600 mg/d for 10 days and AZ 500 mg Day 1 and 250 mg days 2 to 5; 11; 58.7 mean, 64%	None reported; none reported	One patient, hydroxychloroquine and azithromycin were discontinued after 4 days because of a prolongation of the QT interval from 405 ms before treatment to 460 and 470 ms under the combination; They report that in the 10 living patients, repeated nasopharyngeal swabs were positive for COVID-19 RNA in 8 of the 10 patients (80%) at days 5 to 6 following treatment initiation. Researchers also questioned the one death and 3 ICU transfers[14] that suggest a worsening clinical outcome. They conclude that there is "no evidence of a strong antiviral activity or clinical benefit of the combination of hydroxychloroquine and azithromycin for the treatment of our hospitalized patients with severe COVID-19". Note: this was a small consecutive series of patients followed to describe the response to the treatment, high risk of biased estimates; non-randomized, confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, not optimally comparative, and sub-optimal reporting of methods and outcomes. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]
Lane[20]; network cohort and case-series; 2020	Network cohort and self-controlled case series study that involved 956,374 and 310,350 users of HCQ and sulfasalazine, and 323,122 and 351,956 users of HCQ-azithromycin and HCQ-amoxicillin.	ARDS 58%, COPD 5%, depression 14.5%, diabetes 13.2%, hyperlipidemia 30%, pneumonia 5.7%, renal impairment 4.2%, UTI 14.2%	Data comprised 14 sources of claims data or electronic medical records from Germany, Japan, Netherlands, Spain, UK, and USA. Researchers found no excess risk of SAEs was when 30-day hydroxychloroquine and sulfasalazine use were compared. However, when azithromycin was added to hydroxychloroquine, researchers reported an increased risk of 30-day cardiovascular mortality HR 2.19 (95% CI 1.22-3.94), chest pain/angina HR 1.15 (95% CI 1.05-1.26), and heart failure HR 1.22 (95% CI 1.02-1.45)). The conclusion was that short-term hydroxychloroquine treatment was safe, but when azithromycin is added, it can induce heart failure and cardiovascular mortality, likely due to synergistic effects on QT length. Researchers urged caution in the use of this combination in COVID-19. Note: very confusing methods, non-randomized, confounded, not optimally comparative (e.g. comparison of hydroxychloroquine compared to hydroxychloroquine with azithromycin was not reported), sub-optimal reporting of methods and outcomes.	High; Very low certainty[1]
Chorin[21]; observational (retrospective cohort study); 2020	HQC plus azithromycin; 84; mean 63 ±15; 74%	CAD 11%, hypertension 65%, CKD 7%, diabetes 20%, COPD 8%, congestive heart failure 2%; Levofloxacin, Lopinavir/Ritonavir, or Tacrolimus 8%, Norepinephrine, Phenylephrine, or Vasopressin 13%, Amiodarone 7%	The QTc was prolonged maximally from baseline (days 3-4) and in 25 patients, the QTc increased more than 40ms. They also found that in 9 patients (11%), the QTc increased to >500 ms, indicative of a high-risk group for malignant arrhythmia and sudden cardiac death. Note: nonrandomized, confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, not optimally comparative, sub-optimal reporting of methods and outcomes. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]
Mahévas[22]; observational (retrospective cohort study); 2020	HCQ at a daily dose of 600 mg in the first 48 hours after hospitalisation vs no HCQ; 181; median 60 years (IQR 52 to 68 years); 71.1%	Respiratory disease 11%, heart failure 3.3%, hypertension (cardiovascular illnesses) 51.9%, diabetes 8.3%, CKD 5%, immuno-	In terms of deaths or transfer to the ICU, 19% vs 21.6% occurred in the HCQ vs no HCQ groups respectively (RR 0.93 (0.48 to 1.81)), for day 7 mortality, 3.6% died in HCQ group vs 4.1% in the no-HCQ group (RR 0.61 (0.13 to 2.90)), occurrence of acute respiratory distress syndrome, 28.6% occurred in HCQ group vs 24.1% in no HCQ group (RR 1.15 (0.66 to 2.01)); in the 84 patients receiving HCQ within the first 48 hours, 8 (9.5%) experienced ECG modifications requiring	Low-moderate; Very low certainty[1]

	Note: in the HCQ group, 20% received concomitant azithromycin	depression 11.6%; none reported	HCQ discontinuation at a median of 4 days (3-9) after it began. Researchers report that the results do not support HCQ use in patients admitted to hospital with covid-19 who require oxygen Note: one of the stronger methodologies from among COVID-19 research releases; inverse probability of treatment weighting (IPTW) approach was used to closely approximate randomisation and try to balance the differences in baseline prognostic variables between treatment groups; some potentially important prognostic variables were not balanced in the modelling; overall, nonrandomized, confounded, optimal adjustments and steps such as masking not applied, small sample size, small events, and not optimally comparative. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	
[42]; observational (retrospective analysis study); 2020	One of three cohorts based on medication exposure to hydroxychloroquine (HC) and azithromycin (AZ): 1) HC-treated (97); 2) HC- and AZ-treated (113); or 3) HC-untreated (158), all received standard support care; 368; median age (IQR) HC 70 (60-75), HC + AZ 68 (59-74), no HC 69 (59-75); 100%	Hyperlipidemia 15.7%, asthma 5.9%, 4.9%, congestive heart failure 20.4%, peripheral vascular disease 17.4%, cerebrovascular disease 12.8%, COPD 19.6%, diabetes 67.6%, renal disease 25%, cancer 16%, liver disease 1.1%; ACE inhibitor 13.9%, ARBs 8.9%	27 deaths (27.8%) HC group, 25 deaths (22.1%) HC+AZ group, 18 deaths (11.4%) no HC group, mechanical ventilation in 13.3% HC group, 6.9% HC+AZ group, and 14.1% no HC group (Table 4). Relative to the no HC group, there was higher risk of death from any cause in HC group (adjusted HR, 2.61; 95% CI, 1.10 to 6.17; p=0.03) but not in HC+AZ group (adjusted HR, 1.14; 95% CI, 0.56 to 2.32; P=0.72), no significant difference in the risk of ventilation in either the HC group (adjusted HR, 1.43; 95% CI, 0.53 to 3.79; p=0.48) or the HC+AZ group (adjusted HR, 0.43; 95% CI, 0.16 to 1.12; p=0.09), compared to the no HC group; no evidence that HCQ, with or without AZ, reduced the risk of mechanical ventilation and an association of increased overall mortality in HCQ alone. Note: adjusted for a large number of confounders including comorbidities, medications, clinical and laboratory abnormalities; however, even with propensity score adjustment for a large number of relevant confounders, one cannot discount the potential of selection bias or residual confounding; 100% male with median age was over 65 years, so not applicable directly to women or younger hospitalized populations; most were black; small sample size, small events number, though reporting was an improvement over COVID-19 reporting in general. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]
Ramireddy[57]; observational case-series; 2020	HCQ 10%, Azithromycin 28%, both 62%; 98; mean age 62±17; 61% Note: 73 patients COVID-19 positive and 25 suspected	Heart failure 20%, hypertension 60%, diabetes 22%, CKD 14%, COPD 26%; none reported	Significant prolongation was observed only in males (18±43 ms vs -0.2±28 ms females, p=0.02); researchers reported 12% of patients reached critical QTc prolongation, multivariable logistic regression, age, sex, Tisdale score, Elixhauser score, and baseline QTc were not associated with critical QTc prolongation (p>0.14). HCQ + AZ revealed the greatest changes in QTc relative to each drug; changes were highest with combination treatment relative to either drug, with many-times greater prolongation using combination vs. azithromycin alone (17±39 vs. 0.5±40 ms, p=0.07); researchers reported that no patients experienced torsades de pointes. Note: pre-publication and not yet peer-reviewed, nonrandomized, potentially confounded even with adjustments, small sample size, sub-optimal reporting. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]

Mathian [62]; case-series; 2020	HCQ treatment in SLE patients; 17; median age 53.5 (26.6–69.2); 23%	CHD 12%, cerebrovascular disease 18%, hypertension 35%, cancer 6%, COPD 12%, CKD 47%; prednisone 71%, ACE inhibitors 35%, anticoagulants 29%	HCQ did not prevent COVID-19 in severe forms, in patients with SLE. Note: nonrandomized, confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, not optimally comparative, sub-optimal reporting of methods and outcomes. This early data in this SLE patient group with SARS-CoV-2 infection is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]
Yu [63]; observational (retrospective); 2020	HCQ for 7–10 days (200 mg twice per day) vs no HCQ (basic treatment); all 568 critically ill COVID-19 patients who were confirmed by pathogen laboratory tests; median 68 (57-76); 63% Note: HCQ age 68 (60-75) vs 68 (57-77)	Hypertension 44%, CHD 10.4%, COPD 2.8%, diabetes 17.1%;	Died=247 patients, 8 in HCQ and 238 in non-HCQ; time of hospital stay before patient death was 15 (10 to 21) days and 8 (4 to 14) days for the HCQ and NHCQ groups, respectively ($p<0.05$). The level of inflammatory cytokine IL-6 was significantly lowered from 22.2 (8.3 to 118.9) pg/mL at the beginning of the treatment to 5.2 (3.0 to 23.4) pg/ml ($p<0.05$) at the end of the treatment in the HCQ group but there is no change in the NHCQ group; researchers concluded that HCQ seemed to play a role in decreased mortality in critically ill patients with COVID-19 via a role in mitigating the inflammatory cytokine storm. Note: nonrandomized, small sample sized and events (especially in HCQ group), not optimally comparative; conducted adjusted analysis (Cox regression) including baseline drugs, but still cannot account for all known and unknown confounders; methods were sub-optimal but an improvement over the general methods across COVID19 and the reporting was not optimal but still an improvement.	Moderate to high; Very low certainty[1]
Chorin [64]; observational case-series; 2020	HCQ/Azithromycin combination; 251; 64 +-13; 75% Note: HCQ orally at 400 mg BID for one day (loading dose) followed by 200 mg BID for 4 days. Azithromycin orally at a dose of 500 mg daily for 5 days.	CAD 12%, hypertension 54%, CKD 115, diabetes 27%, COPD 7%, congestive heart failure 3%; not reported	Researchers reported that QTc was prolonged in parallel with increasing drug exposure and incompletely shortened following its completion; of concern was the extreme new QTc prolongation to > 500 ms which is an established marker of high risk for TdP and this developed in 15.9% of patients; reporting suggested that 1 patient developed TdP requiring emergent cardioversion and 7 patients required premature termination of therapy; HCQ combined with azithromycin macrolide significantly prolonged the QTc in patients with COVID-19 and the prolongation may be responsible for life threating arrhythmia in the form of TdP. Note: nonrandomized, confounded, some logistic regression adjustments employed but optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, not optimally comparative, sub-optimal reporting of methods and outcomes; weaker evidence but raises concern about the combination of HCQ and AZ. Note, adjusted analysis is an improvement over unadjusted analysis whereby the estimates are very unreliable but still is unable to adjust for all unknown confounders.	High; Very low certainty[1]
Mallat [66]; observational retrospective cohort; 2020	HCQ; 34 (23 HCQ vs 11 non-HCQ); median age 37; 73.5% male	Asthma 8.8%, diabetes 5.9%, hypertension, 14.7%, malignancy 8.8%, chronic heart failure 2.95, chronic kidney disease 29%; immunosuppressive 2.9%, NSAID 11.8%	Researchers reported that HCQ treatment was independently associated with longer time to SARS-CoV-2 test negativity; at day 14, virologic clearance was significantly higher in patients who did not receive HCQ, and HCQ treatment did not result in improvement of inflammatory markers or lymphopenia rate. Note: nonrandomized, confounded, steps such as masking not applied, small sample size, small events, adjustment could not control for all unknown confounders and did not adjust for key prognostic variables, sub-optimal reporting of methods and outcomes.	High; Very low certainty[1]

Huang [67]; observational prospective; 2020	197 CQ patients and 176 patients as historical controls; 373; mean age 44.78; 46.9% male	Hypertension 6.4%, diabetes 2.4%; not reported	53 adverse events in CQ vs 57 in non-CQ group; time to undetectable viral RNA, median no. of days (IQR) CQ 3.0 (3.0, 5.0) vs non-CQ 9.0 (6.0, 12.0) (absolute difference in medians -6.0 days; 95% CI -6.0 to -4.0); length of hospital stay, median no. of days (IQR) CQ 19.0 (16.0, 23.0) vs non-CQ 20.0 (15.8, 24.0). Note: nonrandomized, confounded, sub-optimal reporting of methods and outcomes.	High; Very low certainty[1]
Membrillo et al. [69]; observational cohort; 2020	166 patients, HCQ 123 and 43 no HCQ; 166; mean age HCQ 61.5 (16.2) vs 68.7 (18.8) non HCQ; 62% male	Hypertension 42.7%, diabetes 17.4%, cardiopathy 22.2%, malignancy 13.8%, pulmonary disease 14.4%, dyslipidaemia 28.3%; none reported	Hydroxychloroquine treatment was associated with an increase in the mean cumulative survival; HCQ group 22% vs 48.8%; mean hospital stay days mean 6 (SD 5) HCQ vs 5 (7) non HCQ group; median (IQR) from symptoms begin to the start of treatment with HCQ: 7(6) days. Note: nonrandomized, confounded design, small sample sized, small number of events, plagued by selection bias, residual confounding bias.	High; Very low certainty[1]
Geleris [71]; observational prospective; 2020	HCQ (n=811) vs no HCQ (n=565), HCQ 600 mg twice on day 1, then 400 mg daily for a median of 5 days; n=118 <40 yrs, n=287 40-59 yrs, n=485 60-79 yrs, and n=206 >=80 yrs, 58.5% males (propensity score matched HCQ 811 vs 274 matched controls 811 patients received Hydroxychloroquine and 565 supportive care.	Chronic lung disease 17.9%, diabetes 36.4%, hypertension 50.1%, cancer 13.2%, chronic kidney disease 17.8%, transplantation, HIV infection, or immune-suppressive medications 4.7%; statin 38.5%, ACEi or ARBs 29.5%, corticosteroid 23.7%, anticoagulant 9.2%, azithromycin 54.1%, antibiotic 72.5%, tocilizumab 6.2%, remdesivir 2.5%	Primary end point of respiratory failure developed in 346 patients (25.1%); 180 patients were intubated; 166 died without intubation; in unadjusted analysis, patients who had received hydroxychloroquine were more likely to have had a primary end-point event than were patients who did not (HR 2.37; 95% CI 1.84 to 3.02); there was no significant association between hydroxychloroquine use and the composite primary end point (HR 1.04; 95% CI 0.82 to 1.32); there was no significant association between treatment with azithromycin and the composite end point (HR 1.03; 95% CI 0.81 to 1.31). Researchers concluded that results do not support the use of hydroxychloroquine unless within confines of randomized clinical trials testing. Note: nonrandomized, potentially confounded design, decent sample sized though control group markedly smaller, small number of events, compositive end-point (time to intubation or death), plagued by selection bias, residual confounding bias even with propensity-score matching and adjustment (these steps strengthen the weaker nonrandomized design but still is unable to correct for selection and residual confounding/confounded by indication biases).	Low-moderate; Very low certainty[1]
Carlucci [72]; observational retrospective; 2020	n=411 HCQ (400 mg load followed by 200 mg twice daily for five days) plus Azithromycin (500 mg once daily) plus zinc (220 mg capsule containing 50 mg elemental zinc twice daily for five days) plus SoC vs n=521 HCQ plus Azithromycin plus SoC; mean age zinc 63.19 + 15.18 vs no zinc 61.83 + 15.97; 63% males	Hypertension 38.8%, hyperlipidemia 26.5%, CAD 8.2%, heart failure 5.1%, COPD 11.3%, diabetes 25.2%, cancer 6%, CKD 9.7%, BMI zinc 29.17 (25.8-33.42) vs no zinc 29.29 (25.77-33.2); NSAID 13.6%, anticoagulant 97%, ACE or ARB 33.5%, corticosteroid 9.3%, beta blocker 23.9%	Reporting suggested that zinc did not impact the length of hospitalization, duration of ventilation, or ICU duration; based on univariate analyses, zinc sulfate increased the frequency of patients being discharged home (p=0.003), and decreased the need for ventilation (p=0.014), admission to the ICU (p=0.004), and mortality (p<0.0001) or transfer to hospice (p=0.004) for patients who were never admitted to the ICU. Adjusted comparison of categorical hospital outcomes when zinc sulfate was added, an increased frequency of being discharged home (OR 1.53, 95% CI 1.12-2.09, p=0.008) reduction in mortality (p=0.002) or transfer to hospice remained significant (OR 0.449, 95% CI 0.271-0.744, p=0.002). Note: nonrandomized, potentially confounded design, decent sample sized, roughly small number of events in terms of OIS, compositive end-point (hospice/death), plagued by selection bias, residual confounding bias even with the adjusted analysis (these steps strengthen the weaker nonrandomized design but still is unable to correct for selection and residual confounding/confounded by indication biases).	Low-moderate; Very low certainty[1]
Davido et al. [74]; observational	Day 1 with 800 mg/day was administered followed by	Cardiovascular disease 45.1%,	Researchers reported that 91.1% of cases who received HCQ and AZ had a favourable outcome (OR=6.2, p=0.002) versus	High;

retrospective; 2020 RETRACTED	maintenance dose of 400 mg/day up to 600 mg/day in case of obesity (body mass index (BMI) > 30) for a total 10 days plus 500 mg of azithromycin was prescribed the first day, followed by 250 mg for 4 days n=45 vs other treatments (n=87) azithromycin alone (n=28) lopinavir/ritonavir (n=14) no targeted therapy (n=36) HCQ+AZI <48 hours (n=9) before achieving the primary outcome; 132; mean 58.6 years; 65% males	COPD 16.6%, diabetes 18.9%, CKD 3%, obesity 10.6%, immunodepression 8.3%; not reported clearly.	others regimen (n=87); for patients that needed transfer to ICU (n=27) (for mechanical ventilation), median delay for transfer was 2 days (IQR 1-3); there was one case with an adverse event (a prolonged QT interval on EKG) in which HCQ was stopped. Note: nonrandomized, potentially confounded design (though there is adjustment but not optimal), small sample sized (n=132), small number of events, plagued by selection bias, residual confounding bias.	Very low certainty[1]
Rosenberg [75]; observational retrospective; 2020	HCQ + AZ vs HCQ alone vs AZ alone, or neither alone; 735 (51.1%) received hydroxychloroquine + azithromycin, 271 (18.8%) received hydroxychloroquine alone, 211 (14.7%) received azithromycin alone, and 221 (15.4%) received neither drug; 1438; Median patient age was similar in the 4 groups (hydroxychloroquine + azithromycin, 61.4 years; hydroxychloroquine alone, 65.5 years; azithromycin alone, 62.5 years; and neither drug, 64.0 years; 59.6% male	Obesity 30.5%, cancer 3.8%, kidney disease 13%, diabetes 35%, cardiovascular disease 30.4%; none reported clearly	Patients receiving hydroxychloroquine, azithromycin, or both were more likely than those not receiving either drug to have diabetes, respiratory rate >22/min, abnormal chest imaging findings, O_2 saturation lower than 90%, and aspartate aminotransferase greater than 40 U/L; the overall in-hospital mortality was 20.3% (95% CI, 18.2%-22.4%); the risk of death for patients receiving HCQ + AZ was 189/735 (25.7% [95% CI, 22.3%-28.9%]), HCQ alone, 54/271 (19.9% [95% CI, 15.2%-24.7%]), AZ alone, 21/211 (10.0% [95% CI, 5.9%-14.0%]), and neither drug, 28/221 (12.7% [95% CI, 8.3%-17.1%]); compared with patients receiving neither drug, there were no significant differences in mortality for patients receiving HCQ + AZ (HR, 1.35 [95% CI, 0.76-2.40]), HCQ alone (HR, 1.08 [95% CI, 0.63-1.85]), or AZ alone (HR, 0.56 [95% CI, 0.26-1.21]); compared with patients receiving neither drug cardiac arrest was significantly more likely in patients receiving HCQ + AZ (adjusted OR, 2.13 [95% CI, 1.12-4.05]), but not HCQ alone (adjusted OR, 1.91 [95% CI, 0.96-3.81]) or AZ alone (adjusted OR, 0.64 [95% CI, 0.27-1.56]); a greater proportion of patients receiving HCQ + AZ experienced cardiac arrest (15.5%) and abnormal ECG findings (27.1%), as did those in the HCQ alone group (13.7% and 27.3, respectively), compared with AZ alone (6.2% and 16.1%, respectively) and neither drug (6.8% and 14.0%, respectively); there were no significant differences in the relative likelihood of abnormal electrocardiogram findings. Note: nonrandomized, potential residual confounding, confounded by indication, small sample size and events in certain groups, patients were selected by hospital-stratified random sampling; potential confounders such as inflammatory markers associated with severity of COVID-19 in prior studies were not frequently measured and thus not available for modeling; adjusted analysis was a step in the right direction and the methods used in this observational study is somewhat improved from the typical COVID-19 research methods	Low-moderate; Very low certainty[1]
Million [81]; observational retrospective; 2020	SARS-CoV-2 positive tested patients treated for at least three days with the following regimen: HCQ (200 mg three times daily for ten days) + AZ (500 mg on day 1 followed by250 mg daily for the next four days); 1061; mean age 43.6 (15.6); 46.4%	Cancer 2.6%, diabetes 7.4%, CAD 4.3%, hypertension 14%, respiratory illness 11.5%, obesity 5.8%; diuretics 3.3%, metformin 1.9%, selective beta blocking agents 3.2%,	Prolonged viral carriage was observed in 47 patients (4.4%) and was associated with a higher viral load at diagnosis ($p < 0.001$) but viral culture was negative at day 10; all but one, were PCR-cleared at day 15; poor clinical outcome (PClinO) was observed for 46 patients (4.3%) and 8 died (0.75%) (74–95 years old). All deaths resulted from respiratory failure and not from cardiac toxicity. Five patients are still hospitalized (98.7% of patients cured so far). PClinO was associated with older age (OR 1.11), severity of illness at admission (OR10.05) and low HCQ serum concentration. PClinO was independently associated with the	Low-moderate; Very low certainty[1]

		dihydropyridine derivatives 3.2%, angiotensin II receptor blockers 3.8%, HMG CoA reductase 3.6%	use of selective beta-blocking agents and angiotensin II receptor blockers ($p < .05$). A total of 2.3% of patients reported mild adverse events (gastrointestinal or skin symptoms, headache, insomnia and transient blurred vision). Note: nonrandomized, selection bias, potential residual confounding, confounded by indication, some adjustment conducted but not optimal and not controlling for all unknown confounding factors, small sample size and events in certain groups	
Singh [83]; observational retrospective (propensity-matched); 2020	Propensity matched, HCQ (n=910) vs no HCQ (n=910); 1820; mean age HCQ 62.17±16.81 vs no 62.55±17.62; 54.4% males	Hypertension 61.5%, diabetes 35.2%, obesity 30%, ischemic heart disease 28.8%, kidney disease 32.4%, heart failure 18.6%, prolonged QT interval 2.5%, COPD 14.2%, cerebrovascular 14.9%, asthma 13.1%, liver disease 9.9%	Treatment Hydroxychloroquine vs Control (Matched Cohorts) Mortality 30-Day treatment 11.43% (104) vs control 11.98% (109) RR 0.95 (0.74-1.23); Treatment Hydroxychloroquine combined with Azithromycin vs. Control (Matched Cohorts) Mortality treatment 12.27% (86) vs control 10.27% (72) RR 1.19 (0.89-1.60); treatment hydroxychloroquine vs control (matched cohorts) mechanical ventilation treatment 5.05% (46) vs control 6.26% (57) RR 0.81 (0.55-1.18); the analysis of a large retrospective cohort of hospitalized COVID-19 patients treated with HCQ did not show benefits in mortality or the need for mechanical ventilation when compared to a matched cohort of patients who did not receive HCQ. Note: nonrandomized, selection bias, potential residual confounding, confounded by indication, some matching adjustment conducted but not optimal; all unknown confounding factors uncontrolled for, small sample size	Moderate-high; Very low certainty[1]
Yu [84]; observational retrospective; 2020	HCQ vs no HCQ (48 vs 502); 550; median 68 (59–77); 62.5% male	Hypertension 45.8%, CHD 10.7%, COPD 2.9%, diabetes 17.1%; not clearly reported	Deaths HCQ 9/48 (18,8%) vs 238/502 (47.4%) $p<0.001$; Hospital stay time before death (d) HCQ 15 (10–21) vs 8 (4–14) $p= 0.027$ Note: nonrandomized, confounded, adjusted analysis but not fully optimal, small events, sub-optimal reporting of methods and outcomes.	Moderate-high; Very low certainty[1]
Mehra [86]; observational retrospective; 2020 RETRACTED	One of four treatment groups (chloroquine alone, chloroquine with a macrolide, hydroxychloroquine alone, or hydroxychloroquine with a macrolide) vs control group with none of the drugs; 96,032 whereby 14 888 patients were in the treatment groups (1868 received chloroquine, 3783 received chloroquine with a macrolide, 3016 received hydroxychloroquine, and 6221 received hydroxychloroquine with a macrolide) and 81 144 patients were in the control group; 53·8 years (SD 17·6); 53.7% male	29, 510 [30·7%] were obese with BMI ≥30 kg/m², 64220 (66·9%) were white, 9054 (9·4%) were black, 5978 (6·2%) were Hispanic, and 13 519 (14·1%) were of Asian origin (appendix p 4). In terms of comorbidities, 30 198 (31·4%) had hyperlipidaemia, 25 810 (26·9%) had hypertension, 13 260 (13·8%) had diabetes, 3177 (3·3%) had COPD, 2868 (3·0%) had an underlying immunosuppressed condition; 12 137 (12·6%) had coronary artery disease, 2368 (2·5%) had a history of congestive heart	10698 (11·1%) patients died in hospital; control group (n=81 144) 7530 (9·3%) deaths, Chloroquine (n=1868) 307 (16·4%) deaths, Chloroquine with macrolide* (n=3783) 839 (22·2%) deaths, Hydroxychloroquine (n=3016) 543 (18·0%) deaths, Hydroxychloroquine with macrolide* (n=6221) 1479 (23·8%) deaths; after controlling for multiple confounding factors (age, sex, race or ethnicity, body-mass index, underlying cardiovascular disease and its risk factors, diabetes, underlying lung disease, smoking, immunosuppressed condition, and baseline disease severity), when compared with mortality in the control group (9·3%), hydroxychloroquine (18·0%; hazard ratio 1·335, 95% CI 1·223–1·457), hydroxychloroquine with a macrolide (23·8%; 1·447, 1·368–1·531), chloroquine (16·4%; 1·365, 1·218–1·531), and chloroquine with a macrolide (22·2%; 1·368, 1·273–1·469) were each independently associated with an increased risk of in-hospital mortality. Compared with the control group (0·3%), hydroxychloroquine (6·1%; 2·369, 1·935–2·900), hydroxychloroquine with a macrolide (8·1%; 5·106, 4·106–5·983), chloroquine (4·3%; 3·561, 2·760–4·596), and chloroquine with a macrolide (6·5%; 4·011, 3·344–4·812) were independently associated with an increased risk of de-novo ventricular arrhythmia during hospitalisation. Note: nonrandomized, confounded, adjusted analysis but not fully optimal though a very strong approach methods wise in the adjustment but adjustment cannot adjust for all unknown confounders	Low-moderate; Very low certainty[1]

		failure, and 3381 (3·5%) had a history of arrhythmia; use of other antivirals was recorded in 38 927 (40·5%) patients as treatment for COVID-19. The most common antivirals were lopinavir with ritonavir (12 304 [31·6%]), ribavirin (7904 [20·3%]), and oseltamivir (5101 [13·1%]).		
Ip [89]; observational retrospective; 2020	HCQ vs no-HCQ (Hydroxychloroquine, 2) Hydroxychloroquine in combination with Azithromycin, 3) Azithromycin alone, and 4) neither drug); 2,512; median 64 (52 - 76); 62.3% males Note: 134 patients received tocilizumab in the ICU	Diabetes 32.3%, COPD 14.9%, hypertension 55.2%, coronary disease 15.8%, cancer 11.5%, renal failure 7.5%, cerebrovascular disease 4.9%, obesity 35.1%; not reported	Hospitalized patients; researchers reported that after adjusting for imbalances via propensity modeling, relative to receiving neither drug, there were no significant differences in associated mortality for patients receiving any hydroxychloroquine during the hospitalization (HR, 0.99 [95% CI, 0.80-1.22]), hydroxychloroquine alone (HR, 1.02 [95% CI, 0.83-1.27]), or hydroxychloroquine with azithromycin (HR, 0.98 [95% CI, 0.75-1.28]); the 30-day unadjusted mortality for patients receiving hydroxychloroquine alone, azithromycin alone, the combination or neither drug was 25%, 20%, 18%, and 20%, respectively; among 547 evaluable ICU patients, including 134 receiving tocilizumab in the ICU, an exploratory analysis found a trend towards an improved survival association with tocilizumab treatment (adjusted HR, 0.76 [95% CI, 0.57-1.00]), with 30 day unadjusted mortality with and without tocilizumab of 46% versus 56%. Note: nonrandomized, potentially confounded, though there is adjusted analysis via some propensity score matching, possible misclassification, small sample sizes/events limited analysis, selection bias.	Low-moderate; Very low certainty[1]
Ahmad [90]; observational, case-series; 2020	Case-series, all received HCQ and doxycycline; 54; median 68 (22-97); 61% males	Hypertension 91%, diabetes 40%, CAD 58%, CHD 18%, COPD 38%; not reported	A series of fifty-four (54) high-risk patients, who developed a sudden onset of fever, cough, and shortness of breath (SOB) and were diagnosed or presumed to have COVID-19, were started with a combination of DOXY-HCQ and 85% (n=46) patients showed clinical recovery defined as: resolution of fever and SOB, or a return to baseline setting if patients are ventilator-dependent.; 11% (n=6) of patients were transferred to acute care hospitals due to clinical deterioration and 6% (n=3) patients died in the facilities; indirect comparison suggests these data were significantly better outcomes than the data reported in MMWR (reported on March 26, 2020) from a long-term care facility in King County, Washington where 57% patients were hospitalized, and 22% patients died. Note: nonrandomized, potentially confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, not optimally comparative, sub-optimal reporting of methods and outcomes. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]
Bhattacharya [108]; observational cohort; 2020	Cohort 1 (n=54) all the health care workers with history of intake of at least the loading dose of hydroxychloroquine	Comorbidities in 3.7%; not reported	The comparative analysis of incidence of infection between the two groups demonstrated that voluntary HCQ usage was associated with lesser likelihood of developing SARS-CoV-2 infection, compared to those who were not on it, X2=14.59,	High; Very low certainty[1]

	prophylaxis as per ICMR guidelines; Cohort 2 (n=52), all the health care workers either no history of HCQ prophylaxis or had history of inadequate intake of HCQ as per ICMR guidelines; 106; mean HCQ 26.46 ± 3.93, no HCQ 27.71 ± 7.24; 47% male		p<0.001. None of the HCQ users noted any serious adverse effects. Note: nonrandomized, potentially confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, not optimally comparative, sub-optimal reporting of methods and outcomes.	
Oteo [109]; observational cohort; 2020	HCQ 400 mg twice in a loading dose followed by 200 mg twice for 5 days, plus AZM 500 mg on the first day followed by 250 mg daily for 5 days; 80; median 52 (22 to 75); 47% male	32.5% had comorbidities; not reported	Twelve patients (15%), 11 of whom had pneumonia, experienced side effects affecting mainly the digestive. In another patient a QTc interval prolongation (452 msc) was observed. In total 3 of these patients had to be admitted in the Hospital, 2 because of vomiting and 1 because a QTc interval lengthening. None of the patients needed to stop the HCQ or AZM and all the 80 patients finished the therapeutic strategy. From the group without pneumonia only a patient developed diarrhea that did not require hospitalization or stop the medication. Note: nonrandomized, potentially confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, not optimally comparative, sub-optimal reporting of methods and outcomes.	High; Very low certainty[1]
Magagnoli [110]; Observational retrospective; 2020	Hydroxychloroquine alone (HC) n=198 or with azithromycin (HC+AZ) n=214 or no HC as treatments n=395; median age 70; 95.6% males	Hyperlipidemia 18.2%, asthma 3%, MI 5.1%, CHF 25.3%, cerebrovascular 17.7%, pulmonary disease 23.2%, diabetes with complications 28.8%, renal disease 32.8%, cancer 17.2%, liver disease 9.1%, diabetes without complications 48.5%; NR	There were 38, 49, and 37 deaths respectively in HCQ, HCQ +AZ, and no HCQ groups; relative to the no HC group, after propensity score adjustment for clinical characteristics, the risk of death from any cause was higher in the HC group (adjusted hazard ratio (aHR), 1.83; 95% CI, 1.16 to 2.89; P=0.009) but not in the HC+AZ group (aHR, 1.31; 95% CI, 0.80 to 2.15; P=0.28). Both the propensity score-adjusted risks of mechanical ventilation and death after mechanical ventilation were not significantly different in the HC group (aHR, 1.19; 95% CI, 0.78 to 1.82; P=0.42 and aHR, 2.11; 95% CI, 0.96 to 4.62; P=0.06, respectively) or in the HC+AZ group (aHR, 1.09; 95% CI, 0.72 to 1.66; P=0.69 and aHR, 1.25; 95% CI, 0.59 to 2.68; P=0.56, respectively), compared to the no HC group; researchers reported that among patients hospitalized with COVID-19, there was no significant reduction in mortality or in the need for mechanical ventilation with hydroxychloroquine treatment with or without azithromycin. Note: Nonrandomized, confounded, and fraught with selection bias and residual confounding bias, but propensity-matching performed adjusting for comorbidities, medications, clinical and laboratory values; methodology an improvement.	High; Very low certainty[1]
Bhattacharyya [112]; observational longitudinal; 2020	HCQ was given in the dose of 400 mg twice on day one, and then 400 mg weekly for seven weeks; 391 HCWs; mean age of 34±8 years; 58.6% males	Diabetes 1.9%, respiratory disease 1.2%, kidney disease 0.3%, cardiovascular disease 1.9%, liver disease 1.2%; NR	17.5% of HCW experienced adverse events due to HCQ use. This study was a descriptive report on HCW who used HCQ when infected with COVID-19. The majority of the data is based on perceptions of use. Note: case series, single arm, nonrandomized, confounded, no adjustment, no masking or stratifications, very low certainty evidence.	High; Very low certainty[1]
Macias [113]; observational retrospective; 2020	Patients with autoimmune inflammatory diseases n=722 and 40% received HCQ n=290 vs 432 non-HCQ; median age 56 (45-65) HCQ	NR; NR	290 (40%) patients were receiving HCQ; during the seven-week study period, five (1.7% [95% CI: 0.5%-4.0%] cases of COVID-19 were registered among patients with hydroxychloroquine and five (1.2% [0.4%-2.7%]) (p=0.523) in without hydroxychloroquine; COVID-19 was confirmed by PCR in one (0.3%, 95% CI 0.008-1.9%) patient with	High; Very low certainty[1]

	vs 58 (48-68) no HCQ; 17.1% males		hydroxychloroquine and two (0.5%, 95% CI 0.05%-1.6%) without hydroxychloroquine (p=1.0); one patient on hydroxychloroquine and two subjects without hydroxychloroquine were admitted to the hospital, none of them required to be transferred to the intensive care unit and no patient died during the episode. Researchers concluded that the incidence and severity of COVID-19 among patients with autoimmune rheumatic diseases with and without hydroxychloroquine was not significantly different. Hydroxychloroquine does not seem to be an appropriate therapy for post-exposure prophylaxis against COVID-19. Note: Nonrandomized, confounded, and fraught with selection bias and residual confounding bias.	
Giacomelli [114]; observational retrospective; 2020	LPV/r + HCQ, early treatment n=43 vs delayed treatment n=129; 172; median age 61.7 (50.9-72.7); 72% male	NR; remdesivir (n=33, 19.2%), tocilizumab (n=36, 20.9%) or both (n=10, 5.8%).	The rate of clinical improvement increased over time to 73.3% on day 30, without any significant difference between the two groups (Gray's test p=0.213); after adjusting for potentially relevant clinical variables, there was no significant association between the timing of the start of treatment and the probability of 30-day mortality (adjusted odds ratio [aOR] ET vs DT=1.45, 95% confidence interval 0.50-4.19); 8% of the patients discontinued the treatment because of severe gastrointestinal disorders attributable to LPV/r. The timing of the start of LPV/r+HCQ treatment does not seem to affect the clinical course of hospitalised patients with COVID-19. Together with the severe adverse events attributable to LPV/r, this raises concerns about the benefit of using this combination to treat COVID-19. Note: Nonrandomized, confounded, and fraught with selection bias and residual confounding bias.	High; Very low certainty[1]
Sbidian [120]; observational retrospective; 2020	3 groups: (i) receiving HCQ alone, (ii) receiving HCQ together with AZI, and (iii) receiving neither HCQ nor AZI; median age HCQ alone n=623, 63 (53-74), HCQ plus AZ1 n=227, 61 (53-72), neither drug n=3792, 69 (54-82); 58.9% males	Obesity 13.9%, hypertension 5.8%, diabetes 33.6%, COPD 7.2%, malignancy 21.3%; NR	A total of 4,642 patients (mean age: 66.1 ± 18; males: 2,738 (59%)) were included, of whom 623 (13.4%) received HCQ alone, 227 (5.9%) received HCQ plus AZI, and 3,792 (81.7%) neither drug. 28-day discharge rates were statistically significantly higher in the 'HCQ' group. AIPTW absolute difference in ATE (+11.1% [3.30 to 18.9]), ratio in ATE (1.25 [1.07 to 1.42]). As for the 'HCQ+AZI' vs neither drug, trends for significant differences and ratios in AIPTW ATE were found suggesting higher mortality rates in the former group (difference in ATE +9.83% [-0.51 to 20.17], ratio in ATE 1.40 [0.98 to 1.81]; p=0.062); researchers found no evidence for efficacy of HCQ or HCQ combined with AZI on 28-day mortality. Our results suggested a possible excess risk of mortality associated with HCQ combined with AZI, but not with HCQ alone. Significantly higher rates of discharge home were observed in patients treated by HCQ, a novel finding warranting further confirmation in replicative studies. Note: Nonrandomized, confounded, and fraught with selection bias and residual confounding bias. Some adjustment performed but not optimal.	High; Very low certainty[1]
Arshard [135]; observational retrospective; 2020	Hydroxychloroquine alone, hydroxychloroquine + azithromycin, azithromycin alone, and neither treatment; 2541; 63.7 ± 16.5; 51.1% males	Lung disease 63.7%, immunodeficiency 1.2%, cardiovascular 8.7%, kidney disease 43.3%, COPD 12.8%, hypertension 65.4%, asthma 9.9%, cancer 15%, diabetes 37.6%; steroid	Overall in-hospital mortality was 18.1% (95% CI:16.6%-19.7%); by treatment: hydroxychloroquine + azithromycin, 157/783 (20.1% [95% CI: 17.3%-23.0%]), hydroxychloroquine alone, 162/1202 (13.5% [95% CI: 11.6%-15.5%]), azithromycin alone, 33/147 (22.4% [95% CI: 16.0%-30.1%]), and neither drug, 108/409 (26.4% [95% CI: 22.2%-31.0%]). Primary cause of mortality was respiratory failure (88%); no patient had documented torsades de pointes. From Cox regression modeling, predictors of mortality were age≥65 years (HR:2.6 [95% CI:1.9-3.3]), white race (HR:1.7 [95% CI:1.4-2.1]), CKD	High; Very low certainty[1]

		68.2%, tocilizumab 4.5%	(HR:1.7 [95%CI:1.4-2.1]), reduced O2 saturation level on admission (HR:1.5 [95%CI:1.1-2.1]), and ventilator use during admission (HR: 2.2 [95%CI:1.4-3.3]). Hydroxychloroquine provided a 66% hazard ratio reduction, and hydroxychloroquine + azithromycin 71% compared to neither treatment ($p < 0.001$). Researchers concluded when controlling for COVID-19 risk factors, treatment with hydroxychloroquine alone and in combination with azithromycin was associated with reduction in COVID-19 associated mortality. Note: nonrandomized, confounded, did apply multi-variable adjustment, propensity matching and as such, a much better design; larger sample size, events were small; on balance, still confounded and a major limitation was no indication of if the HCQ group were milder patients. Existing SOLIDARITY trial results and RECOVERY results dispute these findings.	
SYSTEMATIC REVIEW/META-ANALYSIS (clinical evidence)				
Tleyjeh [124]; observational review; 2020	19 studies with a total of 5652 patients, 2719 patients treated with CQ or HCQ; NR; NR	NR; NR	Among 13 studies of 4334 patients, the pooled incidence of discontinuation of CQ or HCQ due to prolonged QTc or arrhythmias was 5%, 95% CI (1-11), I2=98%. The pooled incidence of change in QTc from baseline of ≥ 60 ms was 7%, 95% CI (3-14), I2=94% (12 studies of 2008 patients). The pooled incidence of QTc ≥ 500 ms was 6%, 95% CI (2-12), I2=95% (16 studies of 2317 patients). Among 11 studies of 3127 patients, the pooled incidence of change in QTc from baseline of ≥ 60 ms or QTc ≥ 500 ms was 9%, 95% CI (3-17), I2=97%. Mean/median age, coronary artery disease, hypertension, diabetes, concomitant QT prolonging medications, ICU care, and severity of illness in the study populations explained between-studies heterogeneity. Researchers concluded that treatment of COVID-19 patients with CQ or HCQ is associated with a significant risk of drug-induced QT prolongation, which is a harbinger for drug-induced TdP/VT or cardiac arrest.	Moderate-high[7] AMSTAR II critical appraisal of the review: high-quality
Patel [125]; observational, review; 2020	14 clinical studies (3 randomized and 11 non-randomized) analyzing the effects of HCQ in COVID-19 patients; 2908; NR; NR	NR; NR	Meta-analysis of observational studies found 251 deaths in 1331 participants of the Hydroxychloroquine arm and 363 deaths in 1577 participants of the control arm. There was no difference in odds of mortality events amongst Hydroxychloroquine and supportive care arm [1.25 (95% CI: 0.65, 2.38); $I^2 = 80\%$]. A similar trend was observed with moderate risk of bias studies [0.95 (95% CI: 0.44, 2.06); $I^2 = 85\%$]. The odds of mortality were significantly higher in patients treated with Hydroxychloroquine + Azithromycin than supportive care alone [2.34 (95% CI: 1.63, 3.34); $I^2 = 0\%$]. A pooled analysis of recently published studies suggests no additional benefit for reducing mortality in COVID-19 patients when Hydroxychloroquine is given as add-on to the standard care. Note: the body of evidence is conflicted by studies with differences in age group, co-morbidity, co-interventions and severity of disease in HCQ and supportive care patients.	Moderate-high[7] AMSTAR II critical appraisal of the review: high-quality
Corticosteroids **One RCT (RECOVERY) show benefit in those needing respiratory support** **The effectiveness is being evaluated in various randomized clinical trials.**				
OBSERVATIONAL (clinical)				
Lu[23]; observational (retrospective	Corticosteroid (methylprednisolone, dexamethasone, and	Hypertension 45%, diabetes 17.7%, CVD 6.5%, COPD 1.5%; oseltamivir,	28-day mortality rate was 39% (12 out of 31) in case subjects and 16% (5 out of 31) in control subjects (p=0.09). Increased corticosteroids dosage was significantly associated with elevated mortality risk (p=0.003) in matched cases after adjustment for	High; Very low certainty[1]

cohort study); 2020	hydrocortisone) vs no drug; 61 (31:31); 57.5 mean; 52%	arbidol, lopinavir/ritonavir, ganciclovir, interferon-α	administration duration; every ten-milligram increase in hydrocortisone dosage was associated with additional 4% mortality risk (adjusted HR: 1.04, 95% CI: 1.01-1.07). Note: nonrandomized, confounded, optimal adjustments and steps such as masking not applied, small sample size, small events, not optimally comparative, sub-optimal reporting of methods and outcomes. Note: nonrandomized, confounded, optimal adjustments and steps such as masking not applied, small sample size, small events, not optimally comparative, sub-optimal reporting of methods and outcomes. Note: one study (Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study) by Zhou et al.[51] reported 26 of 57 deaths in COVID-19 patients taking corticosteroids vs 28/134 deaths in those not on corticosteroids. Wu et al. [52] reported that among the patients with ARDS in a retrospective cohort study, of those who received methylprednisolone treatment, 23 of 50 (46.0%) patients died, while of those who did not receive methylprednisolone treatment, 21 of 34 (61.8%) died. Guan et al. [53] reported 5 deaths among 204 who got corticosteroids vs 10 of 895 COVID-19 patients who did not. In a retrospective observational study, Shang et al [55] reported 43 deaths in 196 COVID-19 patients who received corticosteroids vs 8 of 220 who did not.	See Figure 3.
Wang[54]; observational (retrospective); 2020	Methylprednisolone (n=26) 1-2mg/kg/d for 5-7 days via intravenous injection vs no drug (n=20); median 54 (48-64); 57%	Cardiovascular disease 13%, pulmonary disease 6.5%, cerebrovascular 4.3%, malignancy 4.3%, diabetes 8.7%, hypertension 30%; antiviral therapy (a-interferon), lopinavir/ritonavir), immune-enhancement therapy (thymosin)	There were 2 deaths of 26 in the treatment group vs 1 of 20 in the control group, mean days for body temperature back to the normal significantly shorter in patients with methylprednisolone ns no drug (2.06 + - 0.28 vs. 5.29 + - 0.70, p=0.010), methylprednisolone group had faster improvement of SpO2, while patients without administration of methylprednisolone had a significantly longer interval supplemental oxygen use (8.2days (IQR 7.0-10.3) versus 13.5days (IQR 10.3-16); p<0.001); there was increased absorption degree of the focus in the methylprednisolone treatment group. Note: nonrandomized, confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, sub-optimal reporting of methods and outcomes.	High; Very low certainty[1]
Wang[56]; observational (retrospective); 2020	IV methylprednisolone 0.5-1.0g per day for 2-3 days; or intravenous methylprednisolone at 1-3 mg/kg per day for 3-10 days (n=73) vs n=42 in non-corticosteroid group; 115; median 59 (IQR 40-67); 50.4%	Hypertension 26%, cardiovascular 12.2%, diabetes 10.4%; empirically treated with intravenous moxifloxacin, arbidol, ribavirin, interferon-alpha, immunoglobulin	Age, C-reactive protein, D-dimer and albumin were similar in both groups, corticosteroid group had more adverse outcomes than non-corticosteroid group respectively (32.9% vs. 11.9%, p=0.013). In multivariate analysis, corticosteroid treatment was associated with a non-significant 2.155-fold increase in risk of either mortality or ICU admission (p=0.308). Note: nonrandomized, confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, sub-optimal reporting of methods and outcomes.	High; Very low certainty[1]
Fadel [68]; quasi-experimental pre-post; 2020	213 patients (pre n=81 and post n=132 corticosteroid group using a composite endpoint) (early, short-course, methylprednisolone 0.5 to 1 mg/kg/day divided in 2 intravenous doses for 3 days); 213; median age 62 (51-62); 51.2% male	Asthma 15.5%, CKD 46%, COPD 12.7%, CHF 12.2%, CAD 17.8%, diabetes 49.3%, hypertension 74.2%, malignancy 11.3%; empiric antibiotics 76.5%, lopinavir/ritonavir	The composite endpoint occurred at a significantly lower rate in post-corticosteroid group compared to pre-corticosteroid group (34.9% vs. 54.3%, p=0.005). Primary composite pre corticosteroid protocol vs post protocol= 54.3 vs 34.9%, OR 0.45 (0.26 – 0.79), p=0.005 Death 26.3% vs 13.6%, OR 0.45 (0.22 – 0.91), p=0.024 Respiratory failure requiring mechanical ventilation 36.6% vs 21.7%, OR 0.47 (0.25-0.92), p=0.025 Escalation from GMU to ICU 44.3% vs 21.3%, OR 0.47 (0.25 – 0.88), p=0.017	High; Very low certainty[1]

		4.7%, remdesivir 2.3%, hydroxychloroquine 75.6%, tocilizumab 6.6%, corticosteroid 63.8% (at any time)	An early short-course of corticosteroid seems to reduce escalation of care and improve clinical outcomes. Steroids used in early stages of COVID-19 diagnosis may prevent need for ventilator Note: nonrandomized, confounded, use of composite outcome though individual components were significant, small sample sized, small events, regression to the mean and maturation due to quasi-experimental study design, corticosteroid administration was not universal as per protocols, data is lacking for the pre and post corticosteroid groups discharged from hospital.	
Corral-Gudino [119]; partial RCT, 2020	Multicentric, partially randomized, preference, open-label trial, including adults with COVID-19 pneumonia, impaired gas exchange and biochemical evidence of hyper-inflammation; 85 patients (34, randomized to methylprednisolone (MP); 22, assigned to MP by clinician's preference; 29, control group); mean age 69±12; 58% males	Hypertension 46%, diabetes 15%, cardiac 11%, respiratory disease 8%; Azithromycin 89%, HCQ 95%, Lopinavir/Ritonavir 79%	MP as an immune-modulator was associated with a reduced risk of the composite endpoint in the ITT, age-stratified analysis (combined risk ratio -RR- 0.55 [95% CI 0.33-0.91]; p=0.024). In the per-protocol analysis, RR was 0.11 (0.01-0.83) in patients aged 72 yr or less, 0.61 (0.32-1.17) in those over 72 yr, and 0.37 (0.19-0.74, p=0.0037) in the whole group after age-adjustment by stratification. The decrease in C-reactive protein levels was more pronounced in the MP group (p=0.0003); hyperglycemia was more frequent in the MP group. Researchers reported that a short course of MP had a beneficial effect on the clinical outcome of severe COVID-19 pneumonia, decreasing the risk of the composite end point of admission to ICU, NIV or death. Note: Small sample size, a preferential arm distorts baseline balance, partial randomization, methods were improved but not clearly reported.	High; Very low certainty[1]
Salton [121]; observational; 2020	Methylprednisolone (MP) vs control (n=173) 83 MP-treated exposed and 90 untreated controls); mean 65.8; 63.6% males	Hypertension 44.5%, diabetes 25.4%, COPD 9.2%, kidney disease 5.2%, malignancy 6.3%, CHF 3.4%; NR	The composite primary endpoint was met by 19 vs. 40 [adjusted hazard ratio (HR) 0.41; 95% confidence interval (CI): 0.24-0.72]. Transfer to ICU and need for invasive MV was necessary in 15 vs. 27 (p=0.07) and 14 vs. 26 (p=0.10), respectively. By day 28, the MP group had fewer deaths (6 vs. 21, adjusted HR=0.29; 95% CI: 0.12-0.73) and more days off invasive MV (24.0 plus-or-minus sign 9.0 vs. 17.5 plus-or-minus sign 12.8; p=0.001). Study treatment was associated with rapid improvement in PaO2:FiO2 and CRP levels. The complication rate was similar for the two groups (p=0.84). Conclusion In patients with severe COVID-19 pneumonia, early administration of prolonged MP treatment was associated with a significantly lower hazard of death (71%) and decreased ventilator dependence. Researchers call for RCTs to confirm these findings. Note: small sample size and small number of events, composite primary endpoint included admission to ICU, need for invasive MV, or all-cause death by day 28; nonrandomized, potential for confounding, selection bias; crude and adjusted analysis but methods flaws and high uncertainty in estimates.	High; Very low certainty[1]
Monreal [148]; observational; 2020	High doses n=177 (HD, 250mg/day or more of methylprednisolone) of corticosteroids or the standard doses n=396 (SD, 1.5mg/kg/day or more of methylprednisolone); 573; median age 64 (54 – 73); 74.7% males	Hypertension 46.8%, diabetes 19.7%, obesity 39.4%, cardiovascular 17.3%, renal disease 7.9%, liver disease 6.3%, lung disease 16.4%, malignancy 10%, autoimmune 4.5%; NR	In HD cohort, a worse baseline respiratory situation was observed and male sex, older age and comorbidities were significantly more common. After adjusting by baseline characteristics, HD were associated with a higher mortality than SD (adjusted-OR 2.46, 95% CI 1.58-3.83, p<0.001) and with an increased risk of needing MV or death (adjusted-OR 2.50, p=0.001). Conversely, the risk of developing a severe ARDS was similar between groups. Interaction analysis showed that HD increased mortality exclusively in elderly patients. Researchers suggest against exceeding 1-1.5mg/kg/day of corticosteroids for severe COVID-19 with an ARDS, especially	High; Very low certainty[1]

			in older subjects. This reinforces the rationale of modulating rather than suppressing immune responses in these patients. Note: nonrandomized, confounded, uni- and multi-variable adjustments performed which is an improvement but still unable to adjust for all potential unknown confounders; methods issues with the dose groups in terms of selection bias and residual confounding bias (and confounding by indication) that only adequate randomization can address.	
Keller [153]; observational; 2020	140 (7.7%) treated with glucocorticoids within 48 hours of admission and 1,666 who never received glucocorticoids. Reasons for exclusion of 1,192 patients are provided in the Appendix. Among patients who remained hospitalized and were excluded, 169 of 962 (17.6%) received glucocorticoids; mean age 62.2 SD 17.8; 53.4% males	Hypertension 71.3%, COPD 12.8%, diabetes 46.1%, CAD 19.7%, asthma 19%, renal disease 3.1%; NR clearly	Early glucocorticoid use and an initial CRP of 20 mg/dL or higher was associated with a significantly reduced risk of mortality or MV in unadjusted (odds ratio, 0.23; 95% CI, 0.08-0.70) and adjusted (aOR, 0.20; 95% CI, 0.06-0.67) analyses (Table 2B). Conversely, glucocorticoid treatment in patients with CRP levels less than 10 mg/dL was associated with a significantly increased risk of mortality or MV in unadjusted (OR, 2.64; 95% CI, 1.39-5.03) and adjusted (aOR, 3.14; 95% CI, 1.52-6.50) analyses. Note: nonrandomized, confounded by indication, selection bias, residual confounding bias; small sample size and events.	High; Very low certainty[1]
Rahman [167]; observational; 2020	Corticosteroids 72, control 64; median age steroids 60.5 (50.8 – 70.5) vs control 65 (56.5 – 67.5); males 57%	COPD 11%, asthma 12%, diabetes 39%, hypertension 62.5%, cardiovascular 38.9%; HCQ, lopinavir, remdesivir, tocilizumab, convalescent plasma, azithromycin	Corticosteroid group had increased severity of illness: PaO2/FiO2 (113 vs. 130; p .014) and SOFA (8 vs. 5.5; p < .001). Overall mortality (21% vs. 30%; p .234) or proportion of patients intubated (78 vs. 64%; p .078) was similar. Mortality was similar among mechanically ventilated (27% vs. 15%; p .151) however there were no deaths among patients who were not mechanically ventilated and received corticosteroids (0% vs. 57%; p <.001). Early administration (within 48 hours) showed decrease in proportion of intubation (66% vs. 87 vs. 100%; p.045), ICU days (6 vs., 16 vs. 18; p <.001), and ventilator days (3 vs. 12 & 14; p <.001). 45% received methylprednisolone. Early administration of corticosteroids improved survival in non-mechanically ventilated patients; decreased ICU stay and may have prevented intubation. Note: Note: nonrandomized, confounded by indication, selection bias, residual confounding bias; small sample size and events.	High; Very low certainty[1]
RCT (clinical)				
RECOVERY trial. Horby et al.[115]; RCT; 2020	Dexamethasone trial arm 2,104 vs 4,321 in standard care alone; Mean (SD) age 66.1 (15.7), male 64%.	At least one comorbidity (56%), diabetes (24%), heart disease (27%), chronic lung disease (21%); Azithromycin use (24% in treatment arm and 25% in control), 0 to 3% of patients received hydroxychloroquine, lopinavir–ritonavir, or interleukin-6 antagonists during follow-up. Five patients receives remdesivir (3 in treatment arm and 2 in control).	• Corticosteroids (dexamethasone), typically used to reduce inflammation: • Follow-up complete for 99.9% of patients • Limitation as only studied patients in hospital • Dexamethasone reduces death by about 1/3 in hospitalized patients with severe respiratory illness and complications (COVID-19 patients) • Appears to be effective in reducing death in severely ill COVID patients needing respiratory support • 2,104 patients randomized to dexamethasone 6 mg once daily (orally or IV) for 10 days and compared to 4,321 patients randomized to standard care alone • Dexamethasone reduced deaths by 1/3 in ventilated patients (rate ratio 0.64, 95% CI 0.51 to 0.81), and by 1/5 in other patients receiving oxygen only (rate ratio 0.82, 95% CI 0.72 to 0.94), and no benefit in those who did not need respiratory support (rate ratio 1.19, 95% CI 0.91 to 1.55). • Reduces 28-day mortality by 2.8%	Low-moderate; Moderate certainty[3]

			• Appears to improve survival in COVID-19 patients who require oxygen in hospital	
METCOVID trial, Pardo et al. [175]; RCT; 2020	Intravenous sodium succinate methylprednisolone (0.5 mg/kg), twice daily for 5 days (n=194), or placebo (saline solution) (n=199); Mean (SD) age 55 (15), male (64.6%)	Hypertension (48.9%), diabetes (29.1%), Alcohol use disorder (27%), heart disease (6.9%), asthma, (2.5%), liver disease (5.5%), COPD (0.5%), No patient received anti-IL-6, anti-IL-1, remdesivir or convalescent plasma therapy.	Overall 28-day mortality was 76/199 (38.2%) in the placebo group vs 72/194 (37.1%) in the MP group (HR 0.924 95%CI 0.669 - 1.275; P=0.629). Notes: Small sample size, small number of events (not suitably powered)	Low-moderate; Low certainty[8]
SYSTEMATIC REVIEW/META-ANALYSIS (clinical evidence)				
Mammen[39]; meta-analysis; 2020	7 RCTs focusing on ARDS and not directly on the COVID-19 patient with ARDS; examining corticosteroids (hydrocortisone, methylprednisolone, dexamethasone, or inhaled budesonide) vs no-corticosteroids; n=851 patients; typically, > 50 years of age, hospitalized patients; typically >50 years	Not studied; not studied	Three of seven trials (43%) enrolling 51.5% of the total sample had a low risk of bias. The loss to follow-up was rare: six trials (85.7%) had a near-complete follow-up with loss that was deemed not biasing, and with only one study, we judged had attrition greater than 5%; Corticosteroids reduced all-cause mortality (risk ratio [RR] 0.75, 95% CI: 0.59 to 0.95, p=0.02, moderate certainty) and duration of mechanical ventilation (mean difference [MD] -4.93 days, 95% CI: -7.81 days to -2.06 days, p<0.001, low certainty), and increased ventilator-free days (VFD) (MD 4.28 days, 95% CI: 2.67 days to 5.88 days, p<0.001, moderate certainty), when compared to placebo. Corticosteroids also increased the risk of hyperglycemia (RR 1.12%, 95% CI: 1.01 to 1.24, p=0.03, moderate certainty), and the effect on neuromuscular weakness was unclear (RR 1.30, 95% CI 0.80 to 2.11, p=0.28, low certainty).	Low[5]; i) mortality, moderate certainty ii) duration of mechanical ventilation, low certainty iii) increased ventilator-free days, moderate iv) risk of hyperglycemia, moderate v) neuro-muscular weakness, low AMSTAR II [7] critical appraisal of the review: high-quality
CONVALESCENT PLASMA (CP) **There is insufficient evidence to draw a conclusion on benefits and harms.** **The effectiveness is being evaluated in various randomized clinical trials.**				
OBSERVATIONAL (clinical)				
Shen[25]; case-series; 2020	Convalescent plasma (CP) to all; 5; age range 36-73 years; 60% Note: CP administered to all between 10 and 22 days after admission	1 has hypertension and mitral insufficiency; antivirals (lopinavir/ ritonavir; interferon alfa-1b; favipiravir; arbidol; darunavir) and corticosteroid methylprednisolone	Following plasma transfusion, body temperature normalized within 3 days in 4 of 5 patients, the SOFA score decreased, and PAO2/FIO2 increased within 12 days (range, 172-276 before and 284-366 after). Viral loads also decreased and became negative within 12 days after the transfusion, and SARS-CoV-2–specific ELISA and neutralizing antibody titers increased following the transfusion (range, 40-60 before and 80-320 on day 7). ARDS resolved in 4 patients at 12 days after transfusion, and 3 patients were weaned from mechanical ventilation within 2 weeks of treatment. Of the 5 patients, 3 have been discharged from the hospital (length of stay: 53, 51, and 55 days), and 2 are in stable condition at 37 days after transfusion. Note: nonrandomized, confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, not optimally comparative, sub-	High; Did not apply GRADE

			optimal reporting of methods and outcomes. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	
Duan[26]; case-series; 2020	CP to all; 10; median age was 52.5 years (IQR, 45.0–59.5); 60%	Hypertension 30%, cardiovascular and cerebrovascular disease 10%; arbidol, ribavirin, remdesivir, Interferon-α, oseltamivir, peramivir and corticosteroid methylprednisolone	Following transfusion, the level of neutralizing antibody quickly increased to 1:640 in five cases, and maintained at a high level (1:640) in remaining of cases. Researchers reported that the clinical symptoms were substantially improved. They also found an increase in oxyhemoglobin saturation within 3 days. Several parameters tended to improve as compared to pre-transfusion. Improved parameters included "increased lymphocyte counts and decreased C-reactive protein. Radiological examinations showed varying degrees of absorption of lung lesions within 7 days. The viral load was undetectable after transfusion in seven patients who had previous viremia". No severe adverse effects. Note: case-series, nonrandomized, confounded, optimal adjustments and steps such as stratification and masking not applied, not optimally comparative, sub-optimal reporting of methods and outcomes.	High; Did not apply GRADE
Zhang[27]; case-series; 2020	CP to all; 4; 31, 55, 69, 73 years old and F, M, M, and pregnant F respectively	None reported; arbidol, lopinavir-ritonavir, ribavirin, interferon alpha inhalation, oseltamivir, albumin, zadaxin and immunoglobulin, antibacterial and antifungal drugs	Researchers reported no serious adverse reactions and all 4 patients recovered from COVID-19. Note: nonrandomized, confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, not optimally comparative, sub-optimal reporting of methods and outcomes. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Did not apply GRADE
Pei[29]; case-series; 2020	CP to all three; 3; not reported; not reported	Not reported; not reported	There were 2 patients with negative conversions and 1 failure due to anaphylaxis shock (discontinued); 1st patient treated on 12th day admission, turned severe, 2nd treatment, then significantly improved (nucleic acid test became negative and symptoms improved) and met discharge criteria on 26th day, 2nd patient, treatment on 27th day, the nucleic acid test became negative 4 days later, 3rd patient was a 51-year old pregnant woman who suffered anaphylaxis shock and CP was discontinued). Note: pre-print, small, only 3 patients, confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, not optimally comparative, sub-optimal reporting of methods and outcomes.	High; Did not apply GRADE
Shi[48]; case-series; 2020	1 patient, 50-year old female	Antiviral therapy plus interferon-α2b, followed by lopinavir and ritonavir and empiric ceftriaxone	IVIG (20g) and thymalfasin were initiated, corticosteroid (intravenous 80 mg methylprednisolone) was also commenced and halved to 40mg two days later, symptoms deteriorated and ceftriaxone was replaced with piperacillin-tazobactam; initiated the administration of three consecutive sessions of PE with 6000ml plasma (frozen plasma served as the sole replacement solution) followed by 20g IVIG from DOI 14 to DOI 17; symptoms were almost all rapidly relieved, with three consecutive sessions of PE treatment; no adverse events or complications were seen during PE treatment; oxygenation index increased with oxygen saturation of 96%; patient was breathing ambient air oxygen and the blood pressure was re-established. Note: small case-series of n=1	High; Did not apply GRADE
Zheng [61]; retrospective observational; 2020	CP (n=6) vs no CP (15); 21; CP median 61.5 (31.5-77.8) vs control median 73 (60-79); 76%	Hypertension 19%, diabetes 28.5%, liver disease 9.5%, cardiovascular 4.7%,	There was respiratory failure in 100%, ARDS 85%, septic shock 52%, secondary infection 76%; 5 deaths in treatment (83%) vs 14 (93%) in control group, 100% SARS-CoV-2 clearance in treatment group vs in 4 patients (26.7%) in the control group	High; Very low certainty[1]

		kidney 4.7%; antiviral treatment 76%, IVIG 90%, glucocorticoid pulse 76%. There was fever 85.7%, cough 90.5%, fatigue 67%, dyspnea 76%, bilateral pneumonia in 95%	and there was SARS-CoV-2 clearance before death in 5/5 fatal patients in treatment group vs 3/14 (21%) in control; the 6 treatment patients with respiratory failure received convalescent plasma at a median of 21.5 days after first detection of viral shedding; overall, it appears that CP treatment may halt SARSCoV-2 shedding but failed in reducing mortality in critically end-stage COVID-19 patients; researchers suggested that treatment should be stated earlier. Note: nonrandomized, confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, a small number of events, sub-optimal reporting of methods and outcomes.	
Ahn [76]; observational case-series; 2020	CP; 2; ages 67 and 71; 1 males and 1 female	Both critical; a medical history of hypertension, previous treatments (e.g. experimental drug therapies, oxygen therapy, ventilation): Concomitant therapy: 400 mg of hydroxychloroquine once daily and lopinavir/ritonavir 400 mg/100 mg twice daily, empirical antibiotics, intubation and mechanical ventilator care, IV methylpred nisolone (0.5/1 mg/kg/day daily).	Both received lopinavir/ritonavir and hydroxychloroquine but showed persistent fever, rapidly aggravated hypoxemia and progressive bilateral infiltrations in accordance with the criteria of severe ARDS; following CP infusion, the patients showed improved oxygenation and chest X-rays with decreased inflammatory markers and viral loads; researchers reported that when used with systemic corticosteroids, there is the possibility of reducing excessive inflammatory response by corticosteroids as well as promoting the reduction of viral loads by convalescent plasma simultaneously. Note: small case series of 2 patients, not blinded for outcome detectors, not adjusted for confounding.	High; Did not apply GRADE
Joyner [78]; observational (retrospective case-series); 2020	5000 patients (of 8,932 enrolled patients with COVID-19) received CP; 5000; median age 62.3 (18.5, 97.8); 63.1% male	72% respiratory failure, 63% dyspnea, 62% blood oxygen saturation ≤ 93%, 43% had lung infiltrates >50% within 24-28 hours of enrollment, 38% had a respiratory frequency ≥ 30 breaths·minute-1 , 34% had partial pressure of arterial oxygen to fraction of inspired oxygen ratio < 300, 18% had multiple organ dysfunction or failure, and 15% had septic shock.	81% patients had severe or life-threatening COVID-19 and 949 (19%) were judged to have a high risk of progressing to severe or life-threatening COVID-19; prior to COVID-19 convalescent plasma transfusion, a total of 3,316 patients (66%) were admitted to the ICU; incidence of all serious adverse events (SAEs) in the first four hours after transfusion was <1%, Of the 36 reported SAEs, there were 25 reported incidences of related SAEs, including mortality (n=4), transfusion-associated circulatory overload (TACO; n=7), transfusion-related acute lung injury (TRALI; n=11), and severe allergic transfusion reactions (n=3); 2 (of 36) SAEs were judged as definitely related to the convalescent plasma transfusion by the treating physician. The seven-day mortality rate was 14.9%. Researchers suggested the CP is safe in a hospital setting to be used in COVID-19 and warrants further study. Note: large case-series, nonrandomized, confounded, optimal adjustments and steps such as stratification and masking not applied, not optimally comparative, sub-optimal reporting of methods and outcomes.	High; Did not apply GRADE
Liu [88]; prospective case-control; 2020	CP transfused patients; 39; 55 ± 13; 64% males Note 1:4 matching 156; 1:2 matching 74	Asthma 8%, cancer 5%, CKD 3%, COPD 3%, diabetes 21%, obesity 54%; not reported	CP patients were more likely than control patients to remain the same or have improvements in their supplemental oxygen requirements by post-transfusion day 14, with an odds ratio of 0.86 (95% CI: 0.75~0.98; p=0.028). Plasma recipients also demonstrated improved survival, compared to control patients (log-rank test: p=0.039). In a covariates-adjusted Cox model, convalescent plasma transfusion improved survival for non-intubated patients (hazard ratio 0.19 (95% CI: 0.05 ~0.72);	High; Very low certainty[1]

			p=0.015), but not for intubated patients (1.24 (0.33~4.67); p=0.752).	
Salazar [93]; observational case-series; 2020	CP in patients with severe and/or life-threatening COVID-19 disease; 25; ages ranged from 19 to 77 years (median 51, interquartile range [IQR] 42.5 to 60); 44% male	40% diabetes, hypertension 32%, CKD 4%, hyperlipidemia 20%; hydroxychloroquine 100%, tocilizumab 56%, corticosteroids 36%, remdesivir 8%	At day 7 post-transfusion with CP, 9 (36%) patients had at least a 1-point improvement in clinical scale, and seven of those were discharged. By day 14 post-transfusion, 19 (76%) patients had at least a 1-point improvement in clinical status and 11 were discharged. No adverse events as a result of plasma transfusion were observed. Whole genome sequencing data did not identify a strain genotype-disease severity correlation. The data indicate that administration of convalescent plasma is a safe treatment option for those with severe COVID-19 disease. Note: small case series of 25 patients, not adjusted for confounding.	High; Did not apply GRADE
Perotti [95]; one-arm multicenter interventional study; 2020	Hyperimmune plasma (CP); 46; mean age 63 years (SD 12); 61% male	Hypertension 46%, diabetes 17%, cardiovascular disease 14%, COPD 5%, CKD 9%, dyslipidemia 21%; antiviral 42%, antibiotics 84%, HCQ 86%, anticoagulant 98%	Twenty-four patients received one unit of plasma, 21 received two units and one patient received 3 units. Three patients (6.5%) died within 7 days (at 1, 4 and 6 days); two had important comorbidities, such as diabetes, hypertension and cancer, while the third had an extremely low PaO2/FiO2 level of 67 at the time of plasma infusion; among survivors, the severity of the condition at baseline was confirmed by the low oxygen saturation (mean 94%) and PaO2/FiO2 (mean 131); > than 89% of patients showed bilateral multilobe infiltrates at chest radiogram and all laboratory biomarkers were markedly elevated; at 7 days after plasma infusion PaO2/FiO2 increased by 112 units in survivors, the chest radiogram severity decreased in 23% of patients; CRP, Ferritin and LDH all decreased by 60, 36 and 20%, respectively; no or little improvement was present in the three deceased patients; five serious adverse events occurred in 4 patients. Note: nonrandomized, confounded, small case series of 46 patients, not optimally adjusted for confounding.	High; Very low certainty[1]
Joyner [118]; observational convenience sample; 2020	Data from 20,000 patients including the initial 5,000[78] and subsequent 15,000 transfused patients. By June 2, 2020, a total of 20,000 patients had been transfused with COVID-19 convalescent plasma, thus, 7-day mortality data is presented for all 20,000 patients; 20,000; 7.6% 18-39 years, 31.8% 40-59 years, 27.1% 60-69%, 20.6% 70-79, 12.8% 80 and over; 60.8% males	NR clearly, NR clearly	The incidence of all serious adverse events was quite low; including transfusion reactions (n=89, <1%); thromboembolic or thrombotic events (n=87,1%); cardiac events (n=680, ~3%), notably, the vast majority of the thromboembolic or thrombotic events (n=55) and cardiac events (n=562) were judged to be unrelated to the plasma transfusion per se; the seven-day mortality rate was 8.6% (8.2%, 9.0%), and was higher among more critically-ill patients relative to less ill counterparts, including patients admitted to the intensive care unit vs. not admitted (10.5% vs. 6.0%), mechanically ventilated vs. not ventilated (12.1% vs. 6.2%), and with septic shock or multiple organ dysfunction/failure vs. those without dysfunction/failure (14.0% vs. 7.6%).	High; Very low certainty[1]
Abolghasemi [161]; observational; 2020	189 patients, 115 plasma, 74 control; mean age 56; 55.6% male	Hypertension 21.9%, diabetes 22.9%	Comparison of outcomes including all-cause mortality, total hospitalization days and patients' need for intubation between the two patient groups shows that total of 98 (98.2 %) of patients who received convalescent plasma were discharged from hospital which is substantially higher compared to 56 (78.7 %) patients in control group. Length of hospitalization days was significantly lower (9.54 days) in convalescent plasma group compared with that of control group (12.88 days). Only 8 patients (7%) in convalescent plasma group required intubation while that was 20 % in control group. Note: nonrandomized, selection bias is an issue and confounding bias, small sample size and events; control group	High; Very low certainty[1]

			comprised of mainly milder patients and also co-interventions with antivirals etc.	
Chen [166]; observational case series; 2020	16 patients, case-series, all administered CP; age range 30-90; 68.7% males	Hypertension 25%, diabetes 19%, CHD 19%; NR	Among the 16 patients, 10 of them had a consistently positive result of viral NAA test before convalescent plasma transfusion. Eight patients (8/10) became negative from day 2 to day 8 after transfusion. Severe patients showed a shorter time for NAA test turning negative after transfusion (mean rank 2.17 vs 5.90, P = 0.036). Two critically ill patients transfused plasma with lower antibody level remained a positive result of NAA test. CRP level demonstrated a decline 1 day after convalescent plasma treatment, compared with the baseline (P = 0.017). No adverse events were observed during convalescent plasma transfusion. Note: case-series, small sample size, very provocative findings.	High; Very low certainty[1]
RCT (clinical)				
Li [97]; RCT; 2020	CP added to standard treatment (n=52) vs standard treatment alone (n=51); 103; median age, 70 years s (IQR, 62-78 years); 58.3% male	Hypertension 54.3%, cardiovascular disease 25%, cerebrovascular 17.5%, diabetes 10.6%, kidney disease 5.8%, liver disease 10.7%	Among those with severe disease, the primary outcome occurred in 91.3% (21/23) of the convalescent plasma group vs 68.2% (15/22) of the control group (HR, 2.15 [95% CI, 1.07-4.32]; *P* = .03); among those with life-threatening disease the primary outcome occurred in 20.7% (6/29) of the CP group vs 24.1% (7/29) of the control group (HR, 0.88 [95% CI, 0.30-2.63]; *P* = .83) (*P* for interaction = .17). There was no significant difference in 28-day mortality (15.7% vs 24.0%; OR, 0.65 [95% CI, 0.29-1.46]; *P* = .30) or time from randomization to discharge (51.0% vs 36.0% discharged by day 28; HR, 1.61 [95% CI, 0.88-2.93]; *P* = .12). CP treatment was associated with a negative conversion rate of viral PCR at 72 hours in 87.2% of the convalescent plasma group vs 37.5% of the control group (OR, 11.39 [95% CI, 3.91-33.18]; *P* < .001). Two patients in the CP group experienced adverse events within hours after transfusion that improved with supportive care. Researchers concluded that CP did not result in a statistically significant improvement in time to clinical improvement within 28 days, and no improvement in the risk of death. Note: the trial was terminated before it reached its targeted original sample size of 200 patients; only 103 were enrolled (for whom randomization was stratified by disease severity); the study was underpowered and many comparisons between the CP group and the control group were not statistically significant; open-label, randomization and concealment appeared reasonably well done. Methodologically an improvement from among the COVID-19 research published to date.	Low to moderate; Moderate[3]
Gharbharan [138]; RCT; 2020	CP (ConvP); 85 enrolled when trial halted; median age 63 (IQR 56 – 74) years; 72% male	Diabetes 25.5%, hypertension 31.3%, cardiac 24.4%, pulmonary 33.7%, cancer 9.3%, kidney disease 8.7%; NR	The adjusted OR for overall mortality for patients treated with ConvP was 0.95 (CI 0.20 – 4.67., p=0.95). Of the 43 patients randomized to ConvP 6 (14%) had died while 11 of the 43 (26%) control patients had died. At that time, all 86 patients had been followed for at least 15 days after inclusion and 75 and 32 for at least 30 and 60 days respectively. The trial was halted prematurely after 86 patients were enrolled. Although symptomatic for only 10 days (IQR 6-15) at the time of inclusion, 53 of 66 patients tested had anti-SARS-CoV-2 antibodies at baseline. A SARS-CoV-2 plaque reduction neutralization test showed neutralizing antibodies in 44 of the 56 (79%) patients tested with median titers comparable to the 115 donors (1:160 vs 1:160, p=0.40). These observations caused concerns about the potential benefit of convalescent plasma in the study population and after discussion with the data safety monitoring board, the study was discontinued. No difference in mortality (p=0.95), hospital stay (p=0.68) or day-	High; Very low certainty[1]

			15 disease severity (p=0.58) was observed between plasma treated patients and patients on standard of care. Note: stopped early and unclear; randomization and concealment, blinding not optimally reported. Small sample size and events.	
Systematic review				
Piechotta [149]; systematic-review; 2020	20 studies (1 RCT, 3 controlled NRSIs, 16 non-controlled NRSIs) with 5443 participants, of whom 5211 received convalescent plasma, and identified a further 98 ongoing studies evaluating convalescent plasma or hyperimmune immunoglobulin, of which 50 are randomised; hyperimmune immunoglobulin studies were found.	Not reported clearly; not reported clearly	4 controlled studies (1 RCT (stopped early) with 103 participants, of whom 52 received convalescent plasma; and 3 controlled NRSIs with 236 participants, of whom 55 received convalescent plasma) to assess effectiveness of convalescent plasma. Control groups received standard care at time of treatment without convalescent plasma. *All-cause mortality at hospital discharge (1 controlled NRSI, 21 participants);* very uncertain whether convalescent plasma has any effect on all-cause mortality at hospital discharge (risk ratio (RR) 0.89, 95% confidence interval (CI) 0.61 to 1.31; very low-certainty evidence). *Time to death (1 RCT, 103 participants; 1 controlled NRSI, 195 participants)*; very uncertain whether convalescent plasma prolongs time to death (RCT: hazard ratio (HR) 0.74, 95% CI 0.30 to 1.82; controlled NRSI: HR 0.46, 95% CI 0.22 to 0.96; very low-certainty evidence). *Improvement of clinical symptoms, assessed by need for respiratory support (1 RCT, 103 participants; 1 controlled NRSI, 195 participants)*; very uncertain whether convalescent plasma has any effect on improvement of clinical symptoms at seven days (RCT: RR 0.98, 95% CI 0.30 to 3.19), 14 days (RCT: RR 1.85, 95% CI 0.91 to 3.77; controlled NRSI: RR 1.08, 95% CI 0.91 to 1.29), and 28 days (RCT: RR 1.20, 95% CI 0.80 to 1.81; very low-certainty evidence). *Quality of life* No studies reported this outcome. Safety of convalescent plasma for people with COVID-19; 1 RCT, 3 controlled NRSIs and 10 non-controlled NRSIs assessing safety of convalescent plasma. Reporting of adverse events and serious adverse events was variable. The controlled studies reported on adverse events and serious adverse events only in participants receiving convalescent plasma. The duration of follow-up varied. Some, but not all, studies included death as a serious adverse event. *Grade 3 or 4 adverse events (13 studies, 201 participants)* The studies did not report the grade of adverse events. Thirteen studies (201 participants) reported on adverse events of possible grade 3 or 4 severity. The majority of these adverse events were allergic or respiratory events; very uncertain whether or not convalescent plasma therapy affects the risk of moderate to severe adverse events (very low-certainty evidence). *Serious adverse events (14 studies, 5201 participants)* Fourteen studies (5201 participants) reported on serious adverse events. The majority of participants were from one non-controlled NRSI (5000 participants), which reported only on serious adverse events limited to the first four hours after convalescent plasma transfusion. This study included death as a serious adverse event; they reported 15 deaths, four of which they classified as potentially, probably or definitely related to transfusion. Other serious adverse events reported in all studies were predominantly allergic or respiratory in nature, including anaphylaxis, transfusion-associated dyspnoea, and transfusion-related acute lung injury (TRALI); very uncertain whether or	AMSTAR II [7] critical appraisal of the review: high-quality

			not convalescent plasma affects the number of serious adverse events. Researchers concluded there is great uncertainty on whether convalescent plasma is beneficial for people admitted to hospital with COVID-19.	
Joyner [165]; review; 2020	12 studies including three RCTs, five matched control studies, and four case series studies containing 804 COVID-19 patient outcomes; 804; mean or median age of patients enrolled in these studies ranged from 48 to 70 years, with a greater proportion of men than women in most studies (proportion of women: 25% to 56%).	NR; NR	All case-series studies demonstrated relatively low mortality rates for COVID-19 patients transfused with convalescent plasma (0% to 13%). Among RCTs, patients transfused with convalescent plasma exhibited a reduced mortality rate (13%) compared to non-transfused COVID-19 patients (26%; OR: 0.46, P = 0.03). Among matched control studies, patients transfused with convalescent plasma exhibited a reduced mortality rate (12%) compared to non-transfused COVID-19 patients (25%; OR: 0.41, P = 0.001). When patient outcomes from controlled studies were aggregated, patients transfused with convalescent plasma exhibited a reduced mortality rate (13%) compared to non-transfused COVID-19 patients (25%; OR: 0.43, P < 0.001). Meta-regression analysis indicated that mean or median cohort age, proportion of cohort receiving mechanical ventilation, and duration of study follow up did not affect the aggregate OR computed for all controlled studies (all coefficients P > 0.22). The fixed effect OR (OR: 0.44, P<0.001)	AMSTAR II [7] critical appraisal of the review: high-quality
Umifenovir/arbidol (antiviral) **There is insufficient evidence to draw a conclusion on benefits and harms.** **The effectiveness is being evaluated in various randomized clinical trials.**				
RCT (clinical)				
Li[30]; RCT; 2020	Lopinavir/ritonavir (LPV/r) vs arbidol vs control; 44 (21, 16, 7 respectively); mean 49.4 years; 50%	Some type of underlying illnesses 34%; gamma globulin 11.3%, glucocorticoids 22.7%	The median time of positive-to-negative conversion of SARS-CoV-2 nucleic acid was 8.5 (IQR 3, 13) days in the LPV/r group, 7 (IQR 3, 10.5) days in the arbidol group and 4 (IQR 3, 10.5) days in the control group (p=0.751). Researchers reported that there were no statistical differences between the three groups in the rates of antipyresis, cough alleviation, improvement of chest CT or the deterioration rate of clinical status (all p > 0.05). Five (23.8%) patients in the LPV/r group experienced adverse events during the follow-up period versus none in the other groups. Note: pre-print, sub-optimal randomization, allocation concealment, blinding, small sample size, small event number, imbalanced co-treatment assignment and use of active comparator with unknown effectiveness for COVID-19.	High; Low certainty[1] See Figure 2, Table 2
Chen[31]; RCT; 2020	Favipiravir versus Arbidol open-label RCT; 236 (116 favipiravir, 120 arbidol); unclear; 46.6%	Hypertension 27.9%, 11.4% diabetes; moxifloxacin hydrochloride tablets, cephalosporins, antiviral drugs other than the experimental drugs, glucocorticoid and human serum albumin.	There was no significant difference in clinical recovery rate at day 7, whereby 71 (61%) recovered in the favipiravir arm and 62 (52%) in the arbidol group. In patients with hypertension and/or diabetes, 23 (54.76) recovered in the favipiravir arm and 18 (51.43) in the arbidol arm (no significant difference). There were no deaths in either arm and 1 respiratory failure in the favipiravir arm and 4 (3.33) in the arbidol arm. Researchers reported 37 adverse events in the favipiravir arm and 28 in the arbidol arm. The reporting in this study was very poor and the methodology was weak. This was described as a randomized study but it was not. No proper description of randomization, allocation concealment, or masking was provided. Note: pre-print, sub-optimal randomization, allocation concealment, blinding, small sample size, small event number, imbalanced co-treatment assignment and use of active comparator with unknown effectiveness for COVID-19.	High; Very low certainty[1]

Chang[7]; RCT (open-label); 2020	120 assigned to favipiravir group (116 assessed, routine treatment + 1600 mg on the first day twice a day, 600 mg from the second day to the end, twice a day) and 120 to arbidol group (120 assessed, 200 mg, 3 times a day to the end of the trial); 236; not reported clearly; 46.6%	27.9% hypertension, diabetes 11.4%, 95% COVID-19 pneumonia; none reported	Clinical recovery rate of day 7 between two groups, 61.2% favipiravir vs 5.7% arbidol (total patients), 71.4% vs 55.6% (moderate cases) respectively, 5.5% vs 0.0% (serious cases) respectively; patients with hypertension and/or diabetes 54.7% favipiravir vs 51.4% arbidol; adverse events 37/116 favipiravir vs 28/120 arbidol, note, 18 severe patients in the favipiravir group vs 9 severe patients in the arbidol group (imbalanced). Note: pre-print, sub-optimal randomization, allocation concealment, blinding, small sample size, small event number, and use of active comparator with unknown effectiveness for COVID-19.	High; Very low certainty[1]
OBSERVATIONAL (clinical)				
Deng[32]; observational (retrospective cohort study); 2020	Arbidol combined with LPV/r (n=16) vs LPV/r alone (n=17); 33; mean 44.5; 51.5%	Median number of comorbidities was 0 ·7 (range 0–2); corticosteroid therapy; a number of antibacterial therapy agents; vasopressors.	Researchers reported that COVID-19 was not detected for 12 of 16 patients' nasopharyngeal specimens (75%) in the combination group after 7 days, relative to 6 of 17 (35%) in the monotherapy group ($p < 0·05$). "After 14 days, 15 (94%) of 16 and 9 (52·9%) of 17, respectively, SARS-CoV-2 could not be detected ($p < 0·05$)". They reported that the chest CT scans were improving for 11 of 16 patients (69%) within the combination group following seven days relative to 5 of 17 (29%) in the monotherapy group ($p < 0·05$). Note: The sample was very small (n=33) and this was a nonrandomized retrospective design which is a weak design; overall, confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, not optimally comparative, sub-optimal reporting of methods and outcomes and use of active comparator with unknown effectiveness for COVID-19. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]
Wang[33]; observational (retrospective case series); 2020	Arbidol vs no arbidol; 67; median 42.0(35.0-62.0); 46%	Hypertension 13%, cardiovascular disease 12%, diabetes 10%, COPD 6%, malignancy 6%, asthma 3%, chronic hepatitis 1%; antivirals, antibiotics, antifungals, corticosteroids	Mortality rate was 7.5%. Patients were divided into the SpO2≥90% group (n=55) and the SpO2 < 90% n=14; all deaths occurred in SpO2 < 90%, median age of the SpO2 <90% was 70.5, IQR 62-77, SpO2 <90% had more comorbidities (included the 5 that died) than SpO2≥90% group, 36% vs 7%, p=0.014, cardiovascular disease 36% vs 5%, p=0.07, diabetes 43% vs 2% p<0.001. SpO2 < 90% group had more fever and dyspnea; no persons died who were treated with arbidol (n=36 patients), and all 5 deaths occurred in the group that received no arbidol (n=31 patients). The study showed that elderly persons (older) with underlying medical conditions were at increased risk of death. Note: nonrandomized, confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, not optimally comparative, and sub-optimal reporting of methods and outcomes.	High; Very low certainty[1]
Liu[37]; observational (retrospective cohort study); 2020	Arbidol vs no arbidol; 257; mean 59.1; 51.4%	52.1% pre-existing conditions; not clearly reported	Patients receiving arbidol had slightly higher SpO2 level and smaller lesion area. Mortality was 7% among patients taking arbidol vs. 24.70% among patients who did not; adjustment for gender, pre-existing condition, log(age), log (SpO2), log (lesion size), log (admission data) and hospital, the OR was 0.169 (95% CI, 0.07 to 0.34) for arbidol; in terms of lesion size based on chest CT and adjusting for patients' characteristics and antiviral medication use, the ratio of the lesion size after the treatment vs before was 85.2% (95% CI, 74.4- 97.5; p=0.02) of that among patients not taking arbidol, indicative of much quicker lesion absorption. While the methods and analysis were very confusing and generally poor, it reported that arbidol is significantly related to a reduction in mortality among	High; Very low certainty[1] See Figure 4

			hospitalized COVID-19 patients; also reported was the combination of arbidol and oseltamivir being linked to a reduction in mortality, with no benefit with Lopinavir/Ritonavir. Note: nonrandomized, confounded, optimal adjustments and steps such as stratification and masking not applied, sample not necessarily representative of clinical population, small events, not optimally comparative, and sub-optimal reporting of methods and outcomes.	
Zhu [50]; observational retrospective cohort; 2020	Arbidol group (16 cases) 0.2g arbidol, three times a day vs lopinavir/ritonavir group received 400mg/100mg of Lopinavir/ritonavir, twice a day for a week; 50; 36.02; 52%	None reported, none reported	No significant difference in baseline Ct values between the two groups (both p >0.05), day 7 following admission, viral load was undetectable in 50% of patients receiving arbidol and in 23.5% of the patients treated with lopinavir/ritonavir, day 14 after admission, viral load was undetectable in 100% patients in arbidol group vs found in 44.1% of patients who received lopinavir/ritonavir, arbidol group had a shorter duration of positive RNA test compared to those in the lopinavir/ritonavir group ($p < 0.01$), 3 in the lopinavir/ritonavir group and three patients in the arbidol group had an elevated level (< 125 U/L) of ALT in the first week of admission ($\chi 2 = 0.047$, $p = 0.99$). 1 patient in lopinavir/ritonavir group and two in the arbidol group diagnosed with leucopenia. Researchers suggested that a arbidol monotherapy may be potentially superior to lopinavir/ritonavir for COVID-19 patients. Note: active-comparator, nonrandomized, confounded, optimal adjustments and steps such as stratification and masking not applied, small events, and sub-optimal reporting of methods and outcomes.	High; Very low certainty[1]
Zhou [100]; observational retrospective; 2020	238 patients; arbidol 82, arbidol plus interferon 139; median age 55.5 years (IQR, 35-67.3 years); 42.9% male	Hypertension 28.2%, cardiovascular disease 5.5%, diabetes 9.2%, chronic lung disease 3.4%, kidney disease 0.8%; antibiotics 96.2%, corticosteroids 22.7%, interferon/lopinavir 2.1%	92.9% (221/238) administered arbidol, 58.4% (139/238) used arbidol combination with interferon; median time from illness onset to start arbidol was 8 days (IQR, 5-14 days) and the median duration of SARS-CoV-2 virus shedding was 23 days (IQR, 17.8–30 days). SARS-CoV-2 RNA clearance was significantly delayed in patients who received arbidol >7 days after illness onset, compared with those in whom arbidol treatment was started≤7 days after illness onset (HR, 1.738 [95% CI, 1.339–2.257], P < .001). Multivariate regression analysis revealed that prolonged viral shedding was significantly associated with initiation arbidol more than seven days after symptom onset (OR 2.078, 95% CI [1.114-3.876], P .004), more than 7 days from onset of symptoms to first medical visitation (OR 3.321, 95% CI[1.559-7.073], P .002), illness onset before Jan.31, 2020 (OR 3.223, 95% CI[1.450-7.163], P .021). Arbidol combination with interferon was also significantly associated with shorter virus shedding (OR .402, 95% CI [.206-.787], P .008). Note: nonrandomized, potentially biased due to selection bias and residual confounding, small events, not optimally comparative, and sub-optimal reporting of methods and outcomes. Adjusted analysis and generally, an improvement, methods wise.	High; Low certainty[1]
SYSTEMATIC REVIEW/META-ANALYSIS (clinical evidence)				
Huang [136]; SR/meta-analysis; 2020	12 studies with 1052 patients SR/meta-analysis, arbidol vs control; NR; NR clearly	Not reported clearly; not reported clearly	Compared with control group, arbidol (umifenovir) is associated with higher negative rate of PCR on day 14 (RR:1.27; 95% CI: 1.04 to 1.55). However, umifenovir is not related to nucleus acid negative conversion time(MD: 0.09; 95% CI: -1.48 to 1.65), negative rate on day 7(RR:1.09; 95% CI: 0.91 to 1.31), incidence of composite endpoint (RR:1.20; 95% CI: 0.61 to 2.37), rate of fever alleviation on day 7 (RR:1.00; 95% CI: 0.91	AMSTAR II [7] critical appraisal of the review: high-quality

			to 1.10), rate of cough alleviation on day 7 (RR:1.00; 95% CI: 0.85 to 1.18), or hospital length of stay (LOS) (MD: 1.34; 95% CI: -2.08 to 4.76). Additionally, umifenovir was safe in COVID-19 patients (RR for incidence of adverse events:1.29; 95% CI: 0.57 to 2.92). The results of sensitivity analysis and subgroup analysis were similar to pooled results.	
Lopinavir/ritonavir (LPV/r) protease inhibitor **Studies show no significant benefit in reducing mortality or other primary outcomes**				
RCT (clinical)				
Li[30]; RCT; 2020	Lopinavir/ritonavir (LPV/r) vs arbidol vs control; 44 (21, 16, 7 respectively); mean 49.4 years; 50%	Some type of underlying illnesses 34%; gamma globulin 11.3%, glucocorticoids 22.7%	The median time of positive-to-negative conversion of SARS-CoV-2 nucleic acid was 8.5 (IQR 3, 13) days in the LPV/r group, 7 (IQR 3, 10.5) days in the arbidol group and 4 (IQR 3, 10.5) days in the control group (p=0.751). Researchers reported that there were no statistical differences between the three groups in the rates of antipyresis, cough alleviation, improvement of chest CT or the deterioration rate of clinical status (all $p > 0.05$). Five (23.8%) patients in the LPV/r group experienced adverse events during the follow-up period versus none in the other groups. Note: pre-print, sub-optimal randomization, allocation concealment, blinding, small sample size, small event number, imbalanced co-treatment assignment and use of active comparator with unknown effectiveness for COVID-19.	High; Low certainty[1]
Huang[14]; RCT; 2020	Twice-daily oral of 500 mg Chloroquine (n=10) versus 400/100mg Lopinavir/Ritonavir (n=12) for 10 days; 22; 44.0 mean (36.5 to 57.5); 59.1%	None reported; none reported	Using RT-PCR, on day 13, all patients in the chloroquine group were negative, and 11 of 12 in the control group (lopinavir/ritonavir) were negative on day 14. Via lung CT on day 9, 6 patients in chloroquine group achieved lung clearance versus 3 in the comparison group. At day 14, the rate ratio based on CT imaging from the Chloroquine group was 2.21, 95% CI 0.81-6.62) relative to the control group. Five patients in the chloroquine group had adverse events versus no patients in the control group. Note: this small RCT appeared to show better effectiveness of chloroquine over lopinavir/ritonavir in moderate to severely ill COVID-19 patients; overall, sub-optimal randomization, allocation concealment, blinding, small sample size, small event number, and use of active comparator with uncertain treatment effectiveness against COVID-19.	High; Very low certainty[1]
Cao[36]; RCT; 2020	LPV/r (400 mg and 100 mg, respectively) twice a day for 14 days, in addition to standard care vs standard care alone; 199 (99 intervention 100 control); median 58 years IQR 49 to 68 years; 60.3%	Diabetes 11.6%, cerebrovascular 6.5%, cancer 3%; interferon on enrollment 11.1%, vasopressors 22.1%, glucocorticoid 33.7%, antibiotic 95%	Time to clinical improvement — median no. of days (IQR) 16.0 (13.0 to 17.0) vs 16.0 (15.0 to 18.0); Day 28 mortality — no. (%) n=19 (19.2) vs 25 (25.0) intervention vs control respectively; clinical improvement - no. (%) day 28 n=78 (78.8) vs 70 (70.0); ICU length of stay - median no. of days (IQR) 6 (2 to 11) vs 11 (7 to 17); hospital stay - median no. of days (IQR) 14 (12 to 17) vs 16 (13 to 18); the median interval time between symptom onset and randomization was 13 days (IQR, 11 to 16 days). Note: open-label, no blinding, imbalanced viral loads between groups with higher baseline viral loads in the LPV/r group, small sample size, and small event number.	High; Low certainty[4]
OBSERVATIONAL (clinical)				
Ye[35]; observational; 2020	LPV/r vs plus adjuvant drugs only no LPV/r (adjuvant drugs only); 47 (42 treatment vs 5 control); aged between 5 and 68, of which 9 were under 30 and 38 were over 30; 42%	Hypertension 17%, diabetes 17%; arbidol, moxifloxacin	Improvement in body temperature for both groups admission to the 10th day treatment; body temperature of intervention group declined faster than control, some reductions in proportions of white blood cells, lymphocytes and C-reactive protein in intervention vs control, proportion with abnormal alanine aminotransferase and aspartate aminotransferase in	High; Very low certainty[1]

			intervention lower than control; reduced number of days testing negative in intervention group. Note: Non-randomized, confounded, optimal adjustments and steps such as stratification and masking not applied, sample not necessarily representative of clinical population, small events, not optimally comparative, and sub-optimal reporting of methods and outcomes.	
Deng[32]; observational (retrospective cohort study); 2020	Arbidol combined with LPV/r (n=16) vs LPV/r alone (n=17); 33; mean 44.5; 51.5%	Median number of comorbidities was 0.7 (range 0-2); corticosteroid therapy; a number of antibacterial therapy agents; vasopressors.	COVID-19 was not detected for 12 of 16 patients' nasopharyngeal specimens (75%) in the combination group arbidol plus LPV/r following 7 days, relative to 6 of 17 (35%) in the monotherapy group ($p < 0{\cdot}05$). "After 14 days, 15 (94%) of 16 and 9 (52·9%) of 17, respectively, SARS-CoV-2 could not be detected ($p < 0{\cdot}05$)". They reported that the chest CT scans were improving for 11 of 16 patients (69%) within the combination group following seven days relative to 5 of 17 (29%) in the monotherapy group ($p < 0{\cdot}05$). The sample was very small (n=33) and this was a nonrandomized retrospective design which is a weak design. Note: nonrandomized, confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, not optimally comparative, sub-optimal reporting of methods and outcomes and use of active comparator with unknown effectiveness for COVID-19.	High; Very low certainty[1]
Lan [65]; observational (retrospective); 2020	Lopinavir/ritonavir vs Lopinavir/ritonavir plus arbidol; 73 (LR 34 vs LR + Arbidol 39); mean age LR+ Arbidol 52.3±15.8 years (range, 21-81 years), 66.7% males vs mean age of LR 59.5±13.6 years (range, 30-87 years), 32.4% male.	Not reported adequately; not reported adequately	Researchers reported no indication that lopinavir–ritonavir when combined with abidol treatment improved the clinical symptoms and accelerated the virological inhibition when compared with single antiviral drug lopinavir–ritonavir treatment; moreover, time to virus turning negative and the duration of fever and cough in the combined group were greater than lopinavir–ritonavir treatment group. Note: nonrandomized, potentially biased due to selection bias and residual confounding, small events, not optimally comparative, and sub-optimal reporting of methods and outcomes. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]
Macias [168]; observational; 2020	n=125 given lopinavir/ritonavir; median age 63 (53-76); 48% male	Hypertension 20%, diabetes 2 8.8%, cardiovascular 14%, renal 3.2%, lung 4.8%, cancer 5.6%	Twelve (36%) patients with major DDI (drug-drug interaction) and 14 (15%) individuals without major DDI died (p=0.010). After adjustment, only the Charlson index was independently associated with death [adjusted OR (95% CI) for Charlson index ≥5: 85 (10-731), p <0.001]. LPV-r was discontinued due to side effects in 31 (25%) patients. Management by the Infectious Diseases Unit was associated with a lower likelihood of major DDI [adjusted odds ratio (95% CI): 0.14 (0.04-0.53), p=0.003). Note: nonrandomized, potentially biased due to selection bias and residual confounding, small events, not optimally comparative, and sub-optimal reporting of methods and outcomes.	High; Very low certainty[1]
Interferon-alpha α **There is no quality evidence to support a recommendation on its therapeutic use** **The effectiveness is being evaluated in randomized clinical trials.**				
OBSERVATIONAL (clinical)				
Meng[38]; observational (retrospective); 2020	Medical personnel, low-risk group received rhIFN-α nasal drops for 28 days (n=2,415) vs the high-risk	Not reported; not reported	There were no new cases of COVID-19 pneumonia during follow-up in low-risk group, and no new cases were found in the high-risk group. Adverse effects among a few personnel included transient irritation which resolved soon after it began.	High; Very low certainty[1]

	group who received rhIFN-α nasal drops combined with thymosin-α1, once a week (n=529); 2,944; 34.6; 30%		Researchers suggest that in low and high-risk level hospital personnel, with the proper protective equipment (first and second-level) and at low risk to begin, when given IFN-α nasal drops with or without thymosin alpha, are effectively prevented from developing COVID-19 disease. The data on testing prior to the study and post study ending is not available which raises many questions about this study. Note: nonrandomized, confounded, optimal adjustments and steps such as stratification and masking not applied, small events, not optimally comparative, and sub-optimal reporting of methods and outcomes. In addition, the use of thymosin-α, an agent with unknown effectiveness for COVID-19 obscures the treatment effect. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	
Zhou[59]; observational (retrospective); 2020	Nebulized IFN-α2b (5mU b.i.d.), arbidol (ARB) (200mg t.i.d.) or a combination of IFN-α2b plus arbidol; 77; n=7 IFN median IQR 41.3 (27-68), n=46 IFN + ARB 40.4 (25-80), n=24 ARB 64.5 (37-73); 40%	Fever 62.3%, cough 50%, fatigue 27%, myalgia 18%, headache 6.5%, chest pain 12%, expectoration 14%, diarrhea 10.4%	IFN-α2b therapy shortens duration of viral shedding; reduction of markers of acute inflammation e.g. CRP and IL6 correlated with this shortened viral shedding. Days from symptom onset to hospital admission IFN, IFN+ARB, ARB 8.0 [5.5, 15.5], 6.5 [3.0, 10.0], 10.0 [4.5, 19.5]; Days from symptom onset to treatment 8.0 [6.5, 16.0], 17.0 [10.0, 22.0], and 8.0 [5.0, 11.0] respectively. Note: nonrandomized, confounded, small events, not optimally comparative, and sub-optimal reporting of methods and outcomes. Adjustments sub-optimal. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]
Pereda [104]; observational prospective; 2020	Interferon-alpha 2b (n=761) vs no interferon (n=53); 814; mean age 44.3, age IFN 42.9 (2-96) vs no IFN 66.9 (1-101); 50% male	3.2% co-morbidities in IFN group vs 56.6% in no-IFN	The proportion of fully recovered patients was higher in the IFN-treated compared with non-IFN treated group (95.4% vs 26.1%, p<0.01); the CFR for all patients was 2.95%, and for those patients who received IFN-α2b the CFR was reduce to 0.92. Note: nonrandomized, confounded, small events, not optimally comparative, and sub-optimal reporting of methods and outcomes.	High; Very low certainty[1]
Wang [155]; observational; 2020	Early IFN (n = 216), No IFN (n = 204), Late IFN (n = 26); 476; median 50 years, 53% males	Hypertension 21.3%, diabetes 7.4%; NR clearly	446 COVID-19 patients; regression models estimated that early administration (%5 days after admission) of IFN-a2b was associated with reduced in-hospital mortality in comparison with no admission of IFN-a2b, whereas late administration of IFN-a2b was associated with increased mortality; among survivors, early IFN-a2b was not associated with hospital discharge or computed tomography (CT) scan improvement, whereas late IFN-a2b was associated with delayed recovery early IFN-a2b and umifenovir alone or together were associated with reduced mortality and accelerated recovery in comparison with treatment with lopinavir/ritonavir (LPV/r) alone. Note: nonrandomized, confounded, small events, not optimally comparative, and sub-optimal reporting of methods and outcomes.	High; Very low certainty[1]

Interferon-beta β

There is no quality evidence to support a recommendation on its therapeutic use
The effectiveness is being evaluated in various randomized clinical trials.

SYSTEMATIC REVIEW/META-ANALYSIS (clinical evidence)

Mammen[40]; meta-analysis; 2020	2 RCTs focusing on ARDS and not directly on the COVID-19 patient with	Not studied, not studied	Use of IFNβ had no significant difference on 28-day hospital mortality (risk ratio [RR] 0.59, 95% CI: 0.13 to 2.67, p=0.49, or on ventilator-free days (VFD) (MD 4.85 days, 95% CI: -3.25	Low[5];

	ARDS; examining interferon-beta vs no interferon-beta; n=392 patients; not reported; not reported		days to 12.93 days, p=0.24), compared to no IFNβ. IFNβ also had no significant impact on the risk of adverse events (RR 0.98%, 95% CI: 0.94 to 1.03, p=0.47). The use of IFNβ does not appear to improve mortality, VFD or adverse events in ARDS patients; based on two small studies with limited numbers of events, which raises uncertainties in IFNβ true effects. The analysis of one study reveals increased mortality with the concomitant use of corticosteroids and IFNβ, suggesting careful consideration of drug-drug interactions with this combination.	i) mortality 28-day, very low certainty ii) ventilator-free days, very low certainty iii) adverse events, low certainty AMSTAR II [7] critical appraisal of the review: high-quality
RCT (clinical)				
Fan-Ngai Hung [73]; open-label Phase II RCT; 2020	n=127 combination of lopinavir 400 mg and ritonavir 100 mg every 12 h, ribavirin 400 mg every 12 h, and three doses of 8 million international units of interferon beta-1b on alternate days (combination group) or to 14 days of lopinavir 400 mg and ritonavir 100 mg every 12 h (control group); 127 (86 combination and 41 control); median 52 years (IQR 32–62); 68 (54%) male	Diabetes 13.3%, 28.3% hypertension, CAD 7.9%, cerebrovascular disease 1.5%, 22.8% hyperlipidemia, malignancy 1.5%; 53.3% antibiotics, corticosteroids 6.2%	There were no deaths; combination group revealed significantly shorter median time from start of study treatment to negative nasopharyngeal swab (7 days, IQR 5–11) vs the control group (12 days [8–15]; HR 4·37 [95% CI 1·86–10·24], p=0·0010); the adverse events included self-limited nausea and diarrhoea with no difference between the two groups. One patient in the control group discontinued lopinavir–ritonavir because of biochemical hepatitis. Note: randomization and concealment appeared reasonable, open-label which is a limitation, no placebo group, young ages for both groups limit generalizability to elderly populations, small sample sizes, small events, indicative of a needed Phase III study, manipulating interferon as the base treatment.	Low-moderate; Low certainty[4]
Davoudi-Monfared [140]; RCT; 2020	Interferon vs control; 81; mean 57.5; 53% males	Hypertension 38%, diabetes 27%, ischemic heart disease 28%, malignancy 9%, kidney disease 3.7%, liver disease 3.7%	Time to the clinical response was not significantly different between the IFN and the control groups (9.7 ± 5.8 vs. 8.3 ± 4.9 days respectively, P=0.95). On day 14, 66.7% vs. 43.6% of patients in the IFN group and the control group were discharged, respectively (OR= 2.5; 95% CI: 1.05- 6.37). The 28-day overall mortality was significantly lower in the IFN then the control group (19% vs. 43.6% respectively, p= 0.015). Early administration significantly reduced mortality (OR=13.5; 95% CI: 1.5-118). Note: very small number of patients, very small events, randomization, allocation concealment not optimal or as clear.	Low-moderate; Low certainty[4]
SNG001 [157]; RCT; 2020	Double-blind placebo-controlled trial recruited 101 patients from 9 specialist hospital sites in the UK during the period 30 March to 27 May 2020. Patient groups were evenly matched in terms of average age (56.5 years for placebo and 57.8 years for SNG001), comorbidities and average duration of COVID-19 symptoms prior to enrolment (9.8 days for placebo and 9.6 days for SNG001).	NR; NR	The odds of developing severe disease (e.g. requiring ventilation or resulting in death) during the treatment period (day 1 to day 16) were significantly reduced by 79% for patients receiving SNG001 compared to patients who received placebo (OR 0.21 [95% CI 0.04-0.97]; p=0.046). Patients who received SNG001 were more than twice as likely to recover (defined as 'no limitation of activities' or 'no clinical or virological evidence of infection') over the course of the treatment period compared to those receiving placebo (HR 2.19 [95% CI 1.03-4.69]; p=0.043). Over the treatment period, the measure of breathlessness was markedly reduced in patients who received SNG001 compared to those receiving placebo (p=0.007). Three subjects (6%) died after being randomised to placebo. There were no deaths among subjects treated with SNG001. In the patients with more severe disease at time of admission (i.e. requiring treatment with supplemental oxygen), SNG001 treatment increased the likelihood of hospital discharge during the study, although the difference was not statistically significant (HR 1.72 [95% CI 0.91-3.25]; p=0.096). Median time to discharge was 6	Unable to adequately assess RoB and quality as no published manuscript at this time

			days for patients treated with SNG001 and 9 days for those receiving placebo. Furthermore, patients receiving SNG001 appeared to be more than twice as likely to have recovered by the end of the treatment period (HR 2.60 [95% CI 0.95-7.07]; p=0.062), although this strong trend did not reach statistical significance. By day 28, patients receiving SNG001 treatment had statistically significantly better odds of recovery (OR 3.86 [95% CI 1.27-11.75]; p=0.017).	
OBSERVATIONAL (clinical)				
Estébanez [82]; observational retrospective; 2020	Interferon beta1b (n=106) was given by subcutaneous injection at a dose of 250 µg on alternate days vs no interferon beta (N=150); 256; mean 63.7 (17); 59.4% males	Dyslipidaemia 30.6%, Cardiopathy 22.4%, cancer 11.4%, Pulmonary disease 14.5%; Hydroxychloroquine 77%, Lopinavir/ ritonavir 36.1%, Azythromycin 62.9%, Corticosteroids 25.8%	The overall mortality rate is 24.6% (63/256). Twenty-two patients (20.8%) in the interferon group died and 41 (27.3%) in the control group (p=0.229). In the multivariate analysis, the predictors of in-hospital mortality were i) age, ii) severity of clinical picture at admission and iii) hydroxychloroquine treatment. Note: nonrandomized, potentially confounded, optimal adjustments not applied though there was some adjusted analysis, small sample size, small events. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]
Pereda [164]; observational; 2020	IFN vs no IFN; 2295; median age IFN 44 (0-100) vs no IFN 68 (0-101); males 51%	NR; NR	The proportion of fully recovered patients was higher in the IFN-treated compared with non-IFN treated group. Prior IFN treatment decreases the likelihood of intensive care and increases the survival after severe or critical diseases. The benefits of IFN were significantly supported by time variables analyzed.1.9% serious disease IFN vs 36% in no IFN; ARDS 1% vs 20% IFN vs no IFN Note: Note: nonrandomized, potentially confounded, optimal adjustments not applied though there was some adjusted analysis, small sample size, small events. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]
Anakinra **There is no quality evidence to support a recommendation on its therapeutic use** **The effectiveness is being evaluated in various randomized clinical trials.**				
OBSERVATIONAL (clinical)				
Huet [172]; observational (retrospective) with historical control; 2020	Anakinra was dosed as 100 mg subcutaneous (SQ) twice daily for 72 hours, followed by anakinra 100 mg SQ daily for 7 days.	Hypertension (60% for intervention vs. 66% for controls), diabetes (27% for intervention vs. 36% for controls), cardiopathy (17% for intervention vs. 25% for controls), stroke (8% for intervention vs. 16% for controls), pulmonary disease (15% for intervention vs. 27% for controls) ;Hydroxychloroquine (90% for intervention vs. 61% for controls), azithromycin (49% for intervention vs. 34% for controls),	After adjusting for potential confounding variables (not specified), the effect of anakinra vs control on the primary outcome of admission to the intensive care unit for mechanical ventilation or death was hazard ratio 0.22; 95% confidence interval, 0.10 to 0.49. Note: nonrandomized, confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, and not optimally comparative. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]

		or parenteral beta-lactam antibiotics (98% in both arms), corticosteroids (4% for intervention vs. 0% for controls).		

Heparin

There are specific recommendations on the use of antithrombotic agents.[46 47]
Studies are ongoing to evaluate the preventive and therapeutic use of antithrombotic agents to mitigate the thrombotic and hemorrhagic events and assess the potential drug interactions with investigational drugs.

OBSERVATIONAL (clinical)

Negri[43]; observational, case-series; 2020	Enoxaparin 1 mg/kg SC every 24 hours (OD). Patients with a creatinine clearance under 30 mL/min received subcutaneous unfractionated heparin at a dose of 5,000 units every 8 or 6 hours; 27; mean 56 ± 17; 70%	n=15 patients had diabetes 11%, hypertension 26%, heart disease 11%, previous lung disease 7%, cancer 4%, other 26%; 10-day course of azithromycin (500mg on day 1, then 250mg daily), methylprednisolone 40mg daily if a worsening radiological pattern increase in serum LDH levels	15 (56%) discharged after an average 7.3 (± 4.0) days, 1 discharged and lost follow-up, 9 patients (33%) admitted to ICU, 3 (33%) then discharged to the ward after an average 9.3 (±4.5) days, 8 (30%) required intubation, half of which (4 patients) successfully extubated after an average 10.3 (± 1.5) days of mechanical ventilation and other half (4 patients) currently being weaned off the ventilator, 2 required a tracheostomy; no deaths or haemorrhagic complications due to heparin anticoagulation. Note: nonrandomized, confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, and not optimally comparative. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]
Ayerbe [94]; observational (retrospective); 2020	Heparin; 2075; mean age 67.57(15.5); 60.5% male	Not reported; hydroxychloroquine, azithromycin, steroids, tocilizumab, a combination of lopinavir with ritonavir, and oseltamivir	There were 301 deaths (14%); researchers found that heparin was associated with lower mortality when their model was adjusted for age and gender, with OR (95%CI): 0.55 (0.37-0.82) p=0.003. This association remained significant when saturation of oxygen <90%, and temperature >37C were added to the model with OR: 0.54(0.36-0.82) p=0.003, and also when all the other drugs were included as covariates OR: 0.42 (0.26-0.66) p<0.001. Note: nonrandomized, confounded, optimal adjustments and steps such as stratification and masking not applied, though there was multivariate logistic regression with some adjustment, small sample size, small events, and not optimally comparative. This early data is also to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]
Tang [102]; observational, 2020	449 consecutive patients COVID-19 positive (severe); 99 heparin treated, 350 non-heparin treated; mean age 65.1 ± 12.0 years; 59.6% male	Hypertension 39.4%, diabetes 20.7%, heart disease 9.1%; NR	Ninety-nine (22.0%) patients received heparin treatment for at least 7 days, in which 94 received LMWH (40-60 mg enoxaparin/d) and five received unfractionated heparin (10 000-15 000 U/d), no anticoagulants other than heparin had been used for 7 days or longer in our patients. All patients received antiviral and appropriate supportive therapies after admission; D-dimer, prothrombin time, and age were positively, and platelet count was negatively, correlated with 28-day mortality in multivariate analysis. No difference in 28-day mortality was found between heparin users and nonusers (30.3% vs 29.7%, $P = 0.910$). But the 28-day mortality of heparin users was lower than nonusers in patients with SIC score ≥4 (40.0% vs 64.2%, $P = 0.029$), or D-dimer >6-fold of upper limit of normal (32.8% vs 52.4%, $P = 0.017$).	High; Very low certainty[1]

			Note: Consecutive patients, nonrandomized, confounded, small event number, sample size, not optimally adjusted.	
Trinh [105]; observational retrospective; 2020	244 patients were included in the analysis: 161 received therapeutic anticoagulation (heparin) and 83 received prophylactic anticoagulation; 244; mean 59.6±13.2; 66% male	Diabetes 36.9%, hypertension 50%, CKD 9.8%, CHD 2.5%, CAD 12.7%, asthma 12.3%, COPD 4.1%, cerebrovascular 6.2%, anticoagulation 3.3%, malignancy 7.8%; heparin 82.6%; antibiotics 99.2%, corticosteroids 83.2%, HCQ 88.4%, tocilizumab 14.3%, sarilumab 8.6%, remdesivir 4.5%, stem cell antibodies 3.3%	Propensity score (PS) weighted Kaplan-Meier plot demonstrated a survival advantage (57% vs. 25%) at 35 days from admission to the ICU in patients who received therapeutic anticoagulation for a minimum of 5 days compared to those who received prophylactic anticoagulation during their hospital course. A multivariate Cox proportional hazard regression model with PS weights to adjust for baseline differences found a 79% reduction in death in patients who were therapeutically anticoagulated HR 0.209, [95% CI (0.10, 0.46), p <0.0001. Bleeding complications were similar between both groups. A 26.7% [95% CI (1.16, 1.39), p <0.0001. Note: nonrandomized, confounded, but adjustments performed and a stronger methodology. Propensity score matched. This early data is also to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]
Motta [155]; observational; 2020	Prophylactic Anticoagulation vs Therapeutic Anticoagulation; 374; mean age 64.7 (18.1); 58.8% males	Diabetes 31.6%, heart disease 56.7%, pulmonary disease 25.1%, cancer 12.3%, kidney 10.7%, hyperlipidemia 36.6%; NR	In comparing preemptive therapeutic to prophylactic anticoagulation through multi-variable analysis, risk of in-hospital mortality was 2.3 times greater in patients receiving preemptive therapeutic anticoagulation (95% CI = 1.0, 4.9; p = 0.04). Researchers recommend additional research and cautious use of preemptive therapeutic over prophylactic anticoagulation. Note: nonrandomized, confounded by selection bias, residual confounding bias, not optimally adjusted. Small study size and events.	High; Very low certainty[1]
α-Lipoic acid **There is no quality evidence to support a recommendation on its therapeutic use** **The effectiveness is being evaluated in various randomized clinical trials.**				
RCT (clinical)				
Zhong[44]; RCT, single-blind; 2020	α-Lipoic acid (ALA) n=8 1200 mg/d, intravenous infusion) once daily plus for 7 days plus standard care vs placebo n=9 saline infusion plus standard care for 7 days; median (IQR) 63 (59-66); 76.5%	Hypertension 47%, diabetes 23.5%, coronary heart disease 5.9%; none reported	Researchers found no significant difference in SOFA score between the placebo group and the ALA group (p=0.36); the 30-day all-cause mortality was 77.8% (7/9) in the placebo group, and 37.5% (3/8) in the ALA group (p=0.09). Note: single-blind (participants and study personnel were aware of the study-group assignments), very small number of patients, very small events, randomization, allocation concealment not optimal or clear.	High; Very low[6]
Intravenous immunoglobulin (IVIG) **There is no quality evidence to support a recommendation on its therapeutic use** **The effectiveness is being evaluated in various randomized clinical trials.**				
OBSERVATIONAL (clinical)				
Xie[49]; observational retrospective; 2020	When the absolute lymphocyte count fell to < 0.5× 109 /L at 20 g/day, patients given IVIG and correction for hypoalbuminemia; 58; mean 62; 62%	Not reported; all given oxygen therapy and abidor and initially given moxifloxacin, low molecular heparin anticoagulation; thymosin and	23/58 patients died within 28 days admission, 7 in ≤48 h group and 16 in > 48 h group; statistically significant difference in 28-day mortality between the two groups (p=0.009); length of stay in hospital of the ≤48 h group significantly shorter than in the > 48 h group (11.50 ±1.03 vs 16.96 ±1.62 days, p=0.005), and the length of stay in the ICU of the ≤48 h group was also significantly shorter than that of the > 48 h group (9.53±1.09 vs 13.50 ±1.63 days, p=0.045); proportion of patients requiring	High; Very low certainty[1]

	Note: > 48 h group and ≤48 h group were divided according to the use of intravenous immunoglobulin within 48 h after admission	glucocorticoids with IVIG	mechanical ventilation in the ≤48 h group significantly lower than in the > 48 h group (6.7% vs 32.1%, p=0.016). Note: nonrandomized, potentially confounded, optimal adjustments and steps such as stratification and masking not applied, small sample size, small events, and not optimally comparative. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	
RCT (clinical)				
Sakoulas [163]; RCT; 2020	IVIG vs SoC; 33; mean age 54; 63% males	Diabetes 36%, hypertension 33%; remdesivir, convalescent plasma, corticosteroid	Among subjects with A-a gradient of >200 mm Hg at enrollment, the IVIG group showed i) a lower rate of progression to requiring mechanical ventilation (2/14 vs 7/12, p=0.038 Fisher exact test), ii) shorter median hospital length of stay (11 vs 19 days, p=0.01 Mann Whitney U), iii) shorter median ICU stay (2.5 vs 12.5 days, p=0.006 Mann Whitey U), and iv) greater improvement in PaO2/FiO2 at 7 days (median [range] change from time of enrollment +131 [+35 to +330] vs +44.5 [-115 to +157], p=0.01, Mann Whitney-U test) than SOC. Note: small sample size so lacked power, small events, methods not optimal in terms of randomization, concealment etc. Pilot study in a minority population so this is worthwhile and needs further study. Unblinded so a problem with bias and the use of corticosteroid confounds the results.	High; Very low certainty[1]

Sarilumab (IL-6 receptor antagonist)

There is no quality evidence to support a recommendation on its therapeutic use
The effectiveness is being evaluated in various randomized clinical trials

OBSERVATIONAL (clinical)				
Gremese [80]; observational case-series; 2020	IV sarilumab medical ward vs ICU care (final injectable solution was obtained combining 2 Sarilumab 200 mg prefilled syringes mixed in 100 ml 0.9% sodium chloride solution for intravenous use); 53; median and IQR medical wards 68.0 (55.0-75.0) vs ICU care 60.5 (53.8-68.0); 90.5%	Diabetes 20.7%, hypertension 50.9%, cardiovascular disease 21.7%, COPD 8.7%, cancer 4.3%, dyslipidemia 11.7%; lopinavir/ritonavir 400/100 mg BID or darunavir/ritonavir 800/100 mg QD, orally); hydroxychloroquine, azithromycin, heparin.	Within medical wards, 7(17.9%) required ICU admission, 4 of whom were re-admitted to the ward within 5-8 days. At 19 days median follow-up, 89.7% of medical inpatients significantly improved (46.1% after 24 hours, 61.5% after 3 days), 70.6% were discharged from the hospital and 85.7% no longer needed oxygen therapy; within patients receiving sarilumab in ICU, 64.2% were discharged from ICU to the ward and 35.8% were still alive at the last follow-up. Overall mortality rate was 5.7% after sarilumab administration: 1(2.5%) patient died in the Medical Ward whilst 2(14.2%) patients died in ICU, respectively. Note: nonrandomized, potentially confounded, adjustments conducted but considered not optimal, small sample size, small events, and not optimally comparative. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]

Ruxolitinib

There is no quality evidence to support a recommendation on its therapeutic use
The effectiveness is being evaluated in various randomized clinical trials

RCT (clinical)				
Cao [92]; RCT; 2020	Ruxolitinib 5mg (n=22) twice a day plus standard-of-care (SoC); the control group (group A) (n=21), which was treated with placebo (100mg vitamin C) twice a day with SoC; 43; median 63 years	Hypertension 39%, diabetes 19.5%, CAD 7.3%; vasopressor 7.3%, glucocorticoid 70.7%, IVIG 43.9%, antivirals 90.2%, antibiotics 48.8%,	Researchers found that treatment with ruxolitinib plus SoC was not significantly associated with accelerated clinical improvement in severe patients with COVID-19, although the ruxolitinib group had a numerically faster clinical improvement; 18 (90%) patients from the ruxolitinib group showed CT improvement at D14 compared with 13 (61.9%) patients from the control group (P = 0.049); three patients in the control group died of respiratory failure, with 14.3% overall mortality at	Low-moderate; Low certainty[8]

	(interquartile range [IQR], 58 to 68 years); 58.5%	arbidol 73%, oseltamivir 27%	D28; no patients died in the ruxolitinib group; overall, ruxolitinib was reportedly well tolerated with low toxicities and no new safety signals; researchers found that the levels of 7 cytokines were significantly decreased in the ruxolitinib group in comparison to the control group. Note: RCT (randomization and allocation concealment relatively well done and describe), small sample size and events. This study has yielded promising results and warrants further RCT study with larger sample sizes.	
Famotidine **There is no quality evidence to support a recommendation on its therapeutic use** **The effectiveness is being evaluated in various randomized clinical trials**				
OBSERVATIONAL (clinical)				
Freedberg [96]; observational (retrospective); 2020	Famotidine, classified as present if famotidine was received within 24 hours of hospital admission and otherwise classified as absent; 1,620; unclear, 43.8% male	Diabetes 20.6%, hypertension 28.2%, CAD 7.2%, pulmonary disorders 7.5%, CKD 8.7%	142 (8.8%) patients were intubated and 238 (15%) died; 340 (21%) patients met the composite study outcome (death or intubation); researchers found that the use of famotidine was associated with reduced risk for death or intubation (adjusted hazard ratio (aHR) 0.42, 95% CI 0.21-0.85) and also with reduced risk for death alone (aHR 0.30, 95% CI 0.11-0.80). After balancing baseline patient characteristics using propensity score matching, these relationships were unchanged (HR for famotidine and death or intubation 0.43, 95% CI 0.21-0.88). Proton pump inhibitors, which also suppress gastric acid, were not associated with reduced risk for death or intubation. Note: nonrandomized, potentially confounded, propensity score matched but considered not optimal, small sample size, small events, and not optimally comparative. This early data is to be considered hypothesis generating, calling for well-designed randomised clinical studies.	High; Very low certainty[1]
Lenzilumab **There is no quality evidence to support a recommendation on its therapeutic use** **The effectiveness is being evaluated in various randomized clinical trials**				
OBSERVATIONAL (clinical)				
Temesgen [106]; observational case-series; 2020	Lenzilumab 600 mg intravenously; 12; median 65 (52-70); 67% males	Diabetes 58%, hypertension 58%, obesity 50%, CKD 17%, CAD 17%, COPD 17%; not clearly reported	Clinical improvement was observed in 11 out of 12 (92%) patients treated with lenzilumab; median time to discharge of 5 days; researches report a significant improvement in oxygenation; proportion of patients with SpO2/FiO2 < 315 at the end of observation was 8% vs. compared to 67% at baseline (p=0.00015). A significant improvement in mean CRP and IL-6 values on day 3 following lenzilumab administration was also observed (137.3 mg/L vs 51.2 mg/L, p = 0.040; 26.8 pg/mL vs 16.1 pg/mL, p = 0.035; respectively). Cytokine analysis showed a reduction in inflammatory myeloid cells two days after lenzilumab treatment. There were no treatment-emergent adverse events attributable to lenzilumab, and no mortality in this cohort of patients with severe and critical COVID-19 pneumonia. Note: Case-series, nonrandomized, confounded, small sample size, no adjustments, uncertain findings, but suggests further research examination	High; Very low certainty[1]
Leflunomide **There is no quality evidence to support a recommendation on its therapeutic use** **The effectiveness is being evaluated in various randomized clinical trials**				
OBSERVATIONAL (clinical)				

Wang [117]; observational comparative; 2020	Hospitalized adult patients (≥18 years of age) with radiologically confirmed pneumonia and SARS-CoV-2 positive for more than 28 days despite standard care were assigned to receive standard of care (SOC, grp I) or leflunomide + SOC (grp 2), 12 in group 1 vs 15 group 2; 27; median age 62 (43-70); 52% male	Hypertension 26%, diabetes 7%, hyperlipidemia 19%, cardiovascular 11%, cancer 4%; NR	By day 14, the median time to SARS-CoV-2 clearance was 6.0 days (range 1-12, IQR 1-12) for grp 2 patients. In grp 1, two patients converted to viral negative on days 1 and 6 (P=0.002). The 14-day discharge rate was 73.3% (11/15) for the grp 2 versus 8.3% (1/12) for grp 1 (P=0.001). The 30-day discharge rate was 100% (15/15) for the grp 2 versus 66.7% (8/12) for grp 1. No severe adverse events or deaths were reported. Researchers concluded that leflunomide is effective in enhancing SARS-CoV-2 clearance and hospital discharge in refractory COVID-19 patients. The addition of leflunomide to SOC did not increase adverse events versus SOC. Note: nonrandomized, selection bias, small sample size and events, single center. Findings suggest the need for further RCT study.	High; Very low certainty[1]
NSAIDS **There is no quality evidence to support a recommendation on its therapeutic use** **The effectiveness is being evaluated in various randomized clinical trials**				
OBSERVATIONAL (clinical)				
Jeong [123]; observational cohort; 2020	354 were NSAIDs users and 1,470 were non-users (hospitalized for COVID-19); mean age 49·0 years, standard deviation 19·0 years; 41% males	Hypertension 20%, hyperlipidemia 19%, diabtets 12%, malignancy 6%, asthma 6%, COPD 16%, renal failure 2%, liver disease 4%; ACE/ARBs 17%, beta blockers 10%, calcium channle blockers 15%	Compared with non-use, NSAIDs use was associated with increased risks of the primary composite outcome (OR 1.65, 95% CI 1.21-2.24) and of cardiovascular or renal complications (OR 1.87, 95% CI 1.25-2.80); findings remained consistent when we extended the exposure ascertainment window to include the first three days of hospitalisation (OR 1.87, 95% CI 1.06-3.29). NSAIDS in COVID-19 is associated with worse outcomes among hospitalised COVID-19 patients; it should be used with caution among patients with COVID-19 as the harms associated with their use may outweigh their benefits in this population. Notes: Nonrandomized, confounded, mis-classification, confounded by indication, small sample sized.	High; Very low certainty[1]
Statins **There is no quality evidence to support a recommendation on its therapeutic use** **The effectiveness is being evaluated in various randomized clinical trials**				
OBSERVATIONAL (clinical)				
Zhang [132]; observational retrospective; 2020	1,219 had in-hospital use of statins (statin group) and the remaining 12,762 had no statin treatment (non-statin group); 13981; median age statin 66.0 (59.0–72.0) vs 57.0 (45.0–67.0) control; males 48.8%	Hypertension 34.7%, diabetes 16.3%, CHD 8.3%, cerebrovascular 2.8%, liver disease 2%, kidney disease 3%; types of statins were Atorvastatin, Rosuvastatin, Simvastatin, Pravastatin, Fluvastatin, Pitavastatin, ACEi/ARB	Based on a mixed-effect Cox model after propensity score-matching, researchers found that the risk for 28-day all-cause mortality was 5.2% and 9.4% in the matched statin and non-statin groups, respectively, with an adjusted hazard ratio of 0.58; statin use-associated lower risk of mortality was also observed in the Cox time-varying model and marginal structural model analysis. These results give support for the completion of ongoing prospective studies and RCTs involving statin treatment for COVID-19, which are needed to further validate the utility of this class of drugs to combat the mortality of this pandemic. Researchers concluded that statins were significantly associated with a lower risk of death and a less inflammatory response during the entire hospitalization period; the findings support the notion that the potential benefits of statin therapy for COVID-19 might outweigh the risks. Note: Nonrandomized, confounded, mis-classification, confounded by indication, small sample sized.	High; Very low certainty[1]
Kinin-kallikrein system inhibitors **There is no quality evidence to support a recommendation on its therapeutic use**				

Further research is needed				
RCT (clinical)				
Mansour [173]; RCT (open-label); 2020	Standard medical treatment (n=10), icatibant (n=10) or iC1e/K (n=9); Median age 51.6 ± 11.5, 53.3% males	Hypertension 50%, diabetes 46.7%, Obesity 43.3%, dyslipidemia 16.6%, Hypothyroidism 86.67%, asthma 3.3%;	Neither icatibant nor iC1e/K pharmacological interventions significantly modified primary outcomes as compared to the standard care group. Overall, there were two deaths, one in the standard care group (on day 17) and one in the iC1e/K group (on day 21). Times from admission to discharge were 10.5, 11.0 and 14.2 days in the standard care, icatibant and iC1e/K groups, respectively (p=0.62), whereas times in the ICU were 4.6, 6.2 and 8.7 days in the standard care, icatibant and iC1e/K groups, respectively (p=0.71). Clinical improvement was similar among the groups, as determined by the qSOFA and TTCI score. Notes: Only data management staff were blinded, small sample size, small number of events (not suitably powered)	Moderate; Very low certainty[6]

Colchicine

There is no quality evidence to support a recommendation on its therapeutic use
The effectiveness is being evaluated in various randomized clinical trials

RCT (clinical)				
Deftereos [133]; RCT (open-label); 2020	Standard medical treatment (n=50) or colchicine with standard medical treatment (n=55); 105; median age median [interquartile range] age, 64 [54-76] years); 58.1% males	Diabetes 20%, dyslipidemia 31.4%, CAD 13.3%, COPD 4.8%; HCQ/CQ 98%, azithromycin 92%, lopinavir/ritonavir 31.4%, tocilizumab 3.8%	Median (interquartile range) peak high-sensitivity cardiac troponin values were 0.0112 (0.0043-0.0093) ng/mL in the control group and 0.008 (0.004-0.0135) ng/mL in the colchicine group (P = .34). Median (interquartile range) maximum C-reactive protein levels were 4.5 (1.4-8.9) mg/dL vs 3.1 (0.8-9.8) mg/dL (P = .73), respectively. The clinical primary end point rate was 14.0% in the control group (7 of 50 patients) and 1.8% in the colchicine group (1 of 55 patients) (odds ratio, 0.11; 95% CI, 0.01-0.96; P = .02). Mean (SD) event-free survival time was 18.6 (0.83) days the in the control group vs 20.7 (0.31) in the colchicine group (log rank P = .03). Adverse events were similar in the 2 groups, except for diarrhea, which was more frequent with colchicine group than the control group (25 patients [45.5%] vs 9 patients [18.0%]; P = .003). Researchers reported overall that colchicine had statistically significantly improved time to clinical deterioration. There were no significant differences in high-sensitivity cardiac troponin or C-reactive protein levels and called for caution in interpretation. Notes: open-label RCT, small sample size, small number of events (not suitably powered)	High; Very low certainty[4]

COMBINATIONS

This section pertains to drug combinations compared to controls

RCT (clinical)				
Hill [144]; observational; 2020	66 study participants moderate to severe COVID-19 and were treated with standard care, which consisted of hydroxychloroquine 200 mg twice daily with or without the combination of lopinavir plus ritonavir 250 mg twice daily; 33 patients randomized to the treatment group also received the combination of sofosbuvir plus daclatasvir 460 mg once daily; slightly	NR; NR	Treated for 14 days; more patients in the treatment group than in the standard-care group recovered at 14 days (88% vs 67%), difference n/s; median time to clinical recovery, which took into account death as a competing risk, was significantly faster in the treatment group than in the standard-care group (6 vs 11 days; *P* = .041).	Unable to assess RoB or apply GRADE due to no published report

	younger and more likely to be men than those in the standard-care group			
Nitric Oxide **There is no quality evidence to support a recommendation on its therapeutic use** **The effectiveness is being evaluated in various randomized clinical trials**				
OBSERVATIONAL (clinical)				
Hedenstierna [152]; observational; 2020	NR	NR	Despite smoking being listed as a risk factor to contract Covid-19, only a low proportion of the smokers suffered from SARS-corona infection in China 2003, and from Covid-19 in China, Europe and the US; researchers hypothesized that the intermittent bursts of high NO concentration in cigarette smoke may be a mechanism in protecting against the virus. low PaO_2/FIO_2 ratio (110 mmHg) was also reported in another study with a larger number of patients; suggests that the SARS patients benefitted more by iNO with marked decrease in shunt through non-ventilated lung regions than in "typical" ARDS; turns out that pulmonary infiltrates were also reduced, suggesting an effect on the SARS pneumonia; *in vitro* tests have shown that NO inhibits the replication cycle of severe acute respiratory syndrome coronavirus; in addition to improved oxygenation, NO killed the SARS Corona virus in cell culture tests. The new pandemic, Covid-19, transmitted by the SARS-CoV-2 virus, has also caused severe impairment in oxygenation of blood. The PaO_2/FIO_2 ratio was as low as a median 77 mmHg in Covid-19 in a study from Wuhan, China, where the outbreak started	Commentary
Vitamin C **There is no quality evidence to support a recommendation on its therapeutic use** **Further research is needed**				
Zhang [174]; RCT; 2020	Randomized at a 1:1 ratio to receive either 24 g vitamin C per day (n=26) for 7 days or placebo (n=28); Mean age 67.4 ±12.4 years, 67% male.	Hypertension (44%), diabetes (30%), coronary heart disease (22%), chronic lung disease (5.6%), chronic renal failure (1.85%), cancer (5.6%), nervous system disease (20.4%); Corticosteroids (33.3%), antibiotics (94.4%)	The IMV free days at day 28 was 26.5 days[1.5-28.0] in HDIVC, and 10.5 days[0.0-28.0] in placebo group, but this difference was not statistically significant ((P=0.56, HR, 4.8[-2.3 to 11.9]). There was no statistically significant difference in the 28-day mortality between two gr (P=0.06, HR, 0.50 [95% CI 0.14-1.77]). During the 7-day infusion period, no study-related adverse events were reported, and no patients were withdrawn from the study due to these problems. Notes: Randomization possibly not appropriately concealed , small sample size, small number of events (not suitably powered)	High; Very low certainty[1]
Resveratrol **There is no quality evidence to support a recommendation on its therapeutic use** **Further clinical research is needed**				
OBSERVATIONAL (clinical)				
Mittra [169]; observational; 2020	Resveratrol 200, resveratrol with copper 30; 230; mean age 51 ±15.40; male 67%	52.6% comorbidities; NR	The number of deaths in resveratrol-copper and standard care only groups were 7/30 (23.3%, 95% CI 8.1%-38.4%) and 89/200 (44.5%, 95% CI 37.6%-51.3%), respectively. In multivariable analysis, age >50 years [odds ratio (OR) 2.558, 95% CI 1.454-4.302, P=0.0011] and female sex (OR 1.939, 95% CI 1.079-3.482, P=0.0267) were significantly associated, while presence of co-morbidities was not significantly associated (OR 0.713, 95% CI 0.405-1.256, P=0.2421) with death. There was a trend towards reduction in death in patients receiving resveratrol-copper (OR 0.413, 95% CI 0.164-1.039, P= 0.0604).	High; Very low certainty[1]

			Note: Note: Nonrandomized, confounded, mis-classification, confounded by indication, small sample sized.	
Bevacizumab **There is no quality evidence to support a recommendation on its therapeutic use** **Further clinical research is needed**				
OBSERVATIONAL (clinical)				
Pang [170]; quasi-experimental; 2020	N=26; median age 62 (55-66); male 77%	Heart disease 8%, hypertension 50%, diabetes 23%, COPD 12%	Relative to comparable control patients with severe Covid-19 admitted in the same centers, bevacizumab showed clinical efficacy by improving oxygenation and shortening oxygen-support duration. Among 26 hospitalized patients with severe Covid-19 (median age, 62 years, 20 [77%] males), bevacizumab plus standard care markedly improved the PaO2/FiO2 ratios at days 1 and 7 (elevated values, day 1, 50.5 [4.0,119.0], p<0.001; day 7, 111.0 [85.0,165.0], p<0.001). By day 28, 24 (92%) patients showed improvement in oxygen-support status, 17 (65%) patients were discharged, and none showed worsen oxygen-support status nor died. Significant reduction of lesion areas and ratios were shown in chest CT or X-ray analysis within 7 days. Of 14 patients with fever, body temperature normalized within 72 hours in 13 (93%) patients. Lymphocyte counts in peripheral blood were significantly increased and CRP levels were markedly decreased as shown in available data. Note: not ideally RCT, historical control; potential selection bias; residual confounding bias, small sample size and events	High; Very low certainty[1]
Mesenchymal stem cell transplantation **There is no quality evidence to support a recommendation on its therapeutic use** **Further clinical research is needed**				
OBSERVATIONAL (clinical)				
Leng [171]; quasi-experimental; 2020	N=10; median age 63; male 40%	NR	In one patient with critically severe disease, inflammatory markers improved significantly (C-reaction protein level decreased from 105.5 g/L (Jan 30) to 10.1 g/L) and oxygen saturation, without supplementary oxygen, rose from 89% (Jan 31) to 98%. No other clinical outcomes were reported. Note: not RCT, unmatched control; potential selection bias; residual confounding bias, small sample size and events	High; Very low certainty[1]

Notes and considerations:

*ratings are high vs moderate-low vs low RoB; note, high risk for RCTs would be for serious flaws in randomization, allocation concealment, blinding, severe data loss, baseline imbalances etc. and for observational non-randomized studies (single or two-arm), there could be no adjustment for confounders, no masking, stratification etc.
**ratings are high, moderate, low, very low certainty (GRADE); note using GRADE, RCTs start as high certainty/quality evidence, observational studies start as low certainty/quality; for imprecision, the focus is on sample size, number of reported events, width of confidence intervals (if reported); note also that the use of GRADE in this application for RCTs and observational studies focuses mainly on risk of bias and imprecision given we are dealing with single studies and domains of consistency (heterogeneity), indirectness, and publication bias are not ideally applicable. However, we would consider indirectness if the evidence emerged from a study that used a different patient group e.g. if looking at lopinavir/ritonavir in COVID-19 patients, but the evidence emerged from HIV infected persons, we would downgrade for indirectness. Though we are focusing at present on COVID-19 patients. We would consider the magnitude of effect, dose-response, and plausible residual confounding for observational study designs.
[1]risk of bias (potentially selection bias and residual confounding bias if observational and not randomized in design) and imprecision (small sample sizes, small event numbers, 95% CI spans both sides of line of no effect and thus a different decision could be made at either end), downgrade one level each (one may argue that since observational studies start as low certainty that the risk of bias due to lack of randomization etc. is already accounted for and no need to downgrade for risk of bias; in any case, one downgrade for imprecision still leads to very low; in some sense in the use of the ROBINS-I tool for risk of bias in nonrandomized studies that is suggested to start at high certainty, eventually, certainty will become low due to the challenges of nonrandomization, selection bias, confounding bias etc.).
[2]risk of bias for in vitro studies uses OHAT risk of bias tool/NTP

url: Handbook for Conducting a Literature-Based Health Assessment Using OHAT Approach for Systematic Review and Evidence Integration. Available online: http://ntp.niehs.nih.gov/ntp/ohat/pubs/handbookjan2015_508.pdf whereby questions such as i) was administered dose or exposure level adequately randomized ii) was allocation to study groups adequately concealed and iii) can we be confident in the exposure characterization, were answered. Rating are definitely high, probably high, probably low, definitely low.

[3]imprecision downgrade one level due to small sample size and/or events.

[4]risk of bias downgrade due to open-label and imprecision due to small sample size and events; down-grade of two levels

[5]Low risk of bias based on application of AMSTAR II tool (url: https://amstar.ca/Amstar_Checklist.php).

[6]Very low RCT due to single downgrade risk of bias and double for imprecision

[7]AMSTAR II critical appraisal of systematic review and/or meta-analysis, url: https://amstar.ca/docs/AMSTAR-2.pdf (Accessed on April 1st 2020); citation: Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, Moher D, Tugwell P, Welch V, Kristjansson E, Henry DA. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017 Sep 21; 358: j4008.

[8] Double-downgrade due to imprecision (small number of events and sample size)

Appendix

Arbidol

Figure 1: Adverse events combined in use of HCQ / CQ (pre-publications, non-peer review)



Table 1: GRADE certainty hydroxychloroquine/chloroquine adverse events (all combined)

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	hydroxychloroquine/chloroquine	no HCQ/CQ or control	Relative (95% CI)	Absolute (95% CI)		
Adverse outcomes (all combined)												
4	randomised trials	serious [a]	not serious	not serious	serious [b]	none	32/126 (25.4%)	10/133 (7.5%)	**RR 2.86** (1.51 to 5.45)	**140 more per 1,000** (from 38 more to 335 more)	⊕⊕◯◯ LOW	CRITICAL

CI: Confidence interval; **RR:** Risk ratio

Explanations

a. unclear/absent randomization, concealment, blinding, sub-optimal outcomes, imbalanced co-treatment assignment

b. small sample size, small number of events (OIS not met)

Arbidol

Figure 2: Adverse events combined in use of arbidol (pre-publications, non-peer review)



Table 2: GRADE certainty arbidol adverse events (all combined)

Certainty assessment							№ of patients		Effect		Certainty	Importance
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	arbidol	no arbidol/control	Relative (95% CI)	Absolute (95% CI)		
Adverse outcomes (combined)												
2	randomised trials	serious [a]	not serious	not serious	serious [b]	none	28/136 (20.6%)	42/137 (30.7%)	**RR 0.50** (0.11 to 2.23)	**153 fewer per 1,000** (from 273 fewer to 377 more)	⊕⊕◯◯ LOW	CRITICAL

CI: Confidence interval; **RR:** Risk ratio

Explanations

a. Sub-optimal randomization, allocation concealment, blinding etc.

b. Small sample size, small event number, OIS not met, wide CIs, 95% CI crosses benefits and harms

Corticosteroids

Figure 3: Adverse events combined in use of corticosteroids non-randomized (pre-publications, non-peer review)



Arbidol

Figure 4: Mortality using arbidol (pre-publications, non-peer review)



Remdesivir

Figures 5a-d: Remdesivir

a. Time to clinical improvement



b. Serious adverse events



c. All adverse events



d. Mortality

Study or Subgroup	Remdesivir Events	Total	Placebo/control Events	Total	Weight	Risk Ratio M-H, Fixed, 95% CI
Beigel 2020 (AC)	32	451	54	454	80.1%	0.60 [0.39, 0.91]
Wang 2020	22	158	10	78	19.9%	1.09 [0.54, 2.18]
Total (95% CI)		**609**		**532**	**100.0%**	**0.69 [0.49, 0.99]**
Total events	54		64			

Heterogeneity: $Chi^2 = 2.09$, df = 1 (P = 0.15); $I^2 = 52\%$

Test for overall effect: Z = 2.02 (P = 0.04)



Risk of bias for RCTs under review

Table: Risk of bias for RCTs in COVID-19 patients

Risk of bias tool: Evidence Partners, Guyatt et al. (modified Cochrane Risk of bias Tool) https://www.evidencepartners.com/wp-content/uploads/2017/09/Tool-to-Assess-Risk-of-Bias-in-Randomized-Controlled-Trials.pdf

Author; study design; year; drug	Was the allocation sequence adequately generated? *	Was the allocation adequately concealed?	Blinding: Was knowledge of the allocated interventions adequately prevented? (patients, healthcare providers and data collectors)	Blinding: Was knowledge of the allocated interventions adequately prevented? (outcome assessors and data analysts)	Was loss to follow-up (missing outcome data) infrequent?	Are reports of the study free of selective outcome reporting?	Was the study apparently free of other problems that could put it at a risk of bias?	Risk of bias judgement overall (GRADE rating of certainty of evidence)
Chen: RCT (open-label); 2020; Favipiravir	Probably no	Probably no	Probably no	Probably no	Probably yes	Probably yes	Probably no	High (very low certainty[1])
Beigel; RCT; 2020; remdesivir	Probably yes	Probably yes	Probably yes	Probably yes	Yes	Probably yes	Yes	Low (moderate[2])
Wang; RCT; 2020; remdesivir	Yes	Probably yes	Yes	Probably yes	Probably yes	Probably yes	Yes	Low (moderate[2])
Goldman; RCT; 2020; remdesivir	Probably yes	Probably yes	Probably yes	Probably yes	Probably yes	Probably yes	Yes	Low (moderate[2])
Chen; RCT; 2020; HCQ**	Probably no	Probably no	Probably no	Probably no	Probably no	Probably yes	Probably no	High (very low certainty[3])
Chen; RCT; 2020; HCQ	Probably no	Probably no	Probably no	Probably no	Probably no	Probably yes	Probably no	High (very low certainty[3])
Huang; RCT; 2020; CQ*** **Chloroquine**	Probably no	Probably no	Probably no	Probably no	Probably no	Probably yes	Probably no	High (very low certainty[3])
Borba; RCT; 2020; CQ	Probably yes	Probably yes	Probably yes	Probably yes	Probably yes	Probably yes	Yes	Low-moderate (moderate certainty[2])
Tang; RCT open-label); 2020; HCQ	Probably no	Probably no	Probably no	Probably no	Probably yes	Probably yes	Probably no	High (very low certainty[1])

Horby; RCT (RECOVERY); 2020; HCQ	Not fully reported	Not fully reported	Not fully reported	Not fully reported	Not fully reported	Not fully reported	Not fully reported	Unable to conduct risk of bias assessment or GRADE
Boulware; RCT; 2020; HCQ	Probably yes	Probably yes	Probably yes	Probably yes	Probably yes	Probably yes	Yes	Low-moderate (moderate certainty[2])
Chen; RCT open-label; 2020; HCQ	Probably no	Probably no	Probably no	Probably no	Probably no	Probably yes	Probably no	High (very low certainty[1])
Horby; RCT (RECOVERY); 2020; dexamethasone (corticosteroid)	Not fully reported	Not fully reported	Not fully reported	Not fully reported	Not fully reported	Not fully reported	Not fully reported	Unable to conduct risk of bias assessment or GRADE
Li; RCT; 2020; convalescent plasma (CP)	Probably yes	Probably yes	Probably yes	Probably yes	Probably yes	Probably yes	Yes	Low-moderate (moderate certainty[2])
Li; RCT; 2020; Umifenovir/ arbidol	Probably no	Probably no	Probably no	Probably no	Probably no	Probably yes	Probably no	High (very low certainty[1])
Chen; RCT; 2020; arbidol	Probably no	Probably no	Probably no	Probably no	Probably no	Probably yes	Probably no	High (very low certainty[1])
Huang; RCT; 2020; Lopinavir/ Ritonavir	Probably no	Probably no	Probably no	Probably no	Probably no	Probably yes	Probably no	High (very low certainty[1])
Cao; RCT; 2020; Lopinavir/ Ritonavir	Probably no	No	No	No	Probably no	Probably yes	Probably no	High (very low certainty[1])
Hung; RCT open-label; 2020; Interferon-beta β	Yes	Probably yes	Probably yes	Probably yes	Probably yes	Probably yes	Yes	Low-moderate (moderate certainty[2])
Zhong; RCT (single-blind); 2020; α-Lipoic acid (ALA)	Probably yes	Probably yes	No	No	Probably no	Probably yes	Probably no	High (very low certainty[1])
Cao; RCT; 2020; Ruxolitinib	Yes	Probably yes	Probably yes	Probably yes	Probably yes	Probably yes	Yes	Low-moderate (moderate certainty[2])
Deftereos; RCT open-label; 2020; Colchicine	Probably no	No	No	No	Probably no	Probably yes	Probably no	High (very low certainty[1])
Mitja; RCT; 2020 HCQ	Yes	Probably yes	Probably yes	Probably yes	Probably yes	Probably yes	Probably yes	Low-moderate

								(moderate certainty[2])
Mitja; RCT; 2020 HCQ	Yes	Probably yes	Probably yes	Probably yes	Probably yes	Probably yes	Probably yes	Low-moderate
Cavalcanti; RCT; 2020; HCQ	Yes	Probably yes	Probably yes	Probably yes	Probably yes	Probably yes	Probably yes	Low-moderate
Ivashchenko; RCT; 2020; AVIFAVIR	Probably yes	Probably no	No	No	Probably no	Probably yes	Probably no	High (very low certainty[1])
Sakoulas; RCT; 2020; IVIG	Probably yes	Probably no	No	No	Probably no	Probably yes	Probably no	High (very low certainty[1])
Mansour [173]; RCT (open-label); 2020; kinin-kallikrein system inhibitors	Yes	Probably yes	No	Probably yes	Probably yes	Probably yes	Probably yes	Low-moderate
Zhang [174]; RCT; 2020; Vit. C	Probably yes	Probably no	Probably yes	Probably no	Probably yes	Probably yes	Probably yes	High (very low certainty[3])

***** Response options were 'yes, probably yes, probably no, and no'.
****** HCQ=hydroxychloroquine; *******CQ=chloroquine; ******** CP=convalescent plasma
[1]risk of bias downgrade due to open-label and risk of bias concerns (randomization and allocation concealment and blinding), and imprecision due to small sample size and events (downgrade 2 levels)
[2] imprecision downgrade one level due to small sample size and/or events
[3] risk of bias (sub-optimal randomization, allocation concealment, blinding), imprecision (double-downgrade due to small sample size, small event number), and imbalanced co-treatment assignment.

References

1. Bian et al. (2020). Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial. url: https://doi.org/10.1101/2020.03.21.20040691 (Accessed on April 5th 2020).

2. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. ***Antiviral Res.*** **2020;178:104787. doi:10.1016/j.antiviral.2020.104787.**

3. Gritti et al. Use of siltuximab in patients with COVID-19 pneumonia requiring ventilatory Support. url: https://doi.org/10.1101/2020.04.01.20048561 (Accessed on April 6th 2020).

4. Chen et al. First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naïve and Experienced COVID-19 Patients. url: https://doi.org/10.1101/2020.03.22.20034041 (2020).

5. Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, Zhang X. Effective treatment of severe COVID-19 patients with tocilizumab. ChinaXiv. 2020 Feb 14;202003(00026): V1.

6. Cai Q, Yang M, Liu D, et al. Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study [published online ahead of print, 2020 Mar 18]. *Engineering (Beijing).* 2020;10.1016/j.eng.2020.03.007. doi:10.1016/j.eng.2020.03.007

7. Chang Chen et al. Pre-publication. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. medRxiv. url: https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v1 (Accessed on March 22nd, 2020).

8. De Meyer et al. Lack of Antiviral Activity of Darunavir against SARS-CoV. url: https://doi.org/10.1101/2020.04.03.20052548doi (Accessed on April 8th 2020).

9. Yamamoto et al. Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro.url: https://doi.org/10.1101/2020.04.06.026476 (Accessed on April 8th 2020).

10. Holshue ML, DeBolt C, Lindquist S, Lofy KH, Wiesman J, Bruce H, Spitters C, Ericson K, Wilkerson S, Tural A, Diaz G, Cohn A, Fox L, Patel A, Gerber SI, Kim L, Tong S, Lu X, Lindstrom S, Pallansch MA, Weldon WC, Biggs HM, Uyeki TM, Pillai SK; Washington State 2019-nCoV Case Investigation Team. First Case of 2019 Novel Coronavirus in the United States. ***N Engl J Med.*** **2020 Mar 5;382(10):929-936.**

11. Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. *N Engl J Med.* 2020;382(24):2327-2336. doi:10.1056/NEJMoa2007016.

12. Chen et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19). ***J Zhejiang Univ (Med Sci)*** **2020, Vol. 49 Issue (1): 0-0. DOI: 10.3785/j.issn.1008-9292.2020.03.03.**

13. Chen et al. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial url: med Rxiv preprint doi: https://doi.org/10.1101/2020.03.22.20040758 (March 30th 2020). Pre-publication. Not peer-reviewed.

14. Huang M, Tang T, Pang P, et al. Treating COVID-19 with Chloroquine. *J Mol Cell Biol.* 2020;12(4):322-325. doi:10.1093/jmcb/mjaa014.

15. Borba MGS, Val FFA, Sampaio VS, et al. Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. ***JAMA Netw Open.* 2020;3(4):e208857. Published 2020 Apr 1. doi:10.1001/jamanetworkopen.2020.8857.**

16. Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. *BMJ*. 2020;369:m1849. Published 2020 May 14. doi:10.1136/bmj.m1849.

17. Gautret et al. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. ***International Journal of Antimicrobial Agents – In Press 17 March 2020 .***

18. Gautret et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study; pre-publication. ***In Press.***

19. Molina JM, Delaugerre C, Goff JL, Mela-Lima B, Ponscarme D, Goldwirt L, de Castro N, No Evidence of Rapid Antiviral Clearance or Clinical Benefit with the Combination of Hydroxychloroquine and Azithromycin in Patients with Severe COVID-19 Infection, ***M´edecine et Maladies Infectieuses* (2020),** doi**:** https://doi.org/10.1016/j.medmal.2020.03.006.

20. Lane et al. Safety of hydroxychloroquine, alone and in combination with azithromycin, in light of rapid wide-spread use for COVID-19: a multinational, network cohort and self-controlled case series study, pre-publication. url: https://doi.org/10.1101/2020.04.08.20054551 (Accessed on April 12th 2020).

21. Chorin et al. The QT Interval in Patients with SARS-CoV-2 Infection Treated with Hydroxychloroquine/Azithromycin. url: https://www.medrxiv.org/content/10.1101/2020.04.02.20047050v1 (Accessed on April 13th 2020).

22. Mahévas M, Tran VT, Roumier M, Chabrol A, Paule R, Guillaud C, Fois E, Lepeule R, Szwebel TA, Lescure FX, Schlemmer F, Matignon M, Khellaf M, Crickx E, Terrier B, Morbieu C, Legendre P, Dang J, Schoindre Y, Pawlotsky JM, Michel M, Perrodeau E, Carlier N, Roche N, de Lastours V, Ourghanlian C, Kerneis S, Ménager P, Mouthon L, Audureau E, Ravaud P, Godeau B, Gallien S, Costedoat-Chalumeau N. Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data. ***BMJ.* 2020 May 14;369:m1844. doi: 10.1136/bmj.m1844.**

23. Lu et al. Adjuvant corticosteroid therapy for critically ill patients with COVID-19. url: https://doi.org/10.1101/2020.04.07.20056390 (Accessed on April 13th 2020).

24. Patel, Amit and Desai, Sapan, Ivermectin in COVID-19 Related Critical Illness (April 6, 2020). Available at
SSRN: https://ssrn.com/abstract=3570270 or http://dx.doi.org/10.2139/ssrn.3570270.

25. Shen et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma ***JAMA.*** **Published online March 27, 2020. doi:10.1001/jama.2020.4783.**

26. Duan K, Liu B, Li C, Zhang H, Yu T, Qu J, Zhou M, Chen L, Meng S, Hu Y, Peng C. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences. 2020 Apr 6. https://doi.org/10.1073/pnas.2004168117.

27. Zhang B, Liu S, Tan T, Huang W, Dong Y, Chen L, Chen Q, Zhang L, Zhong Q, Zhang X, Zou Y, Zhang S, Treatment with convalescent plasma for critically ill patients with SARSCoV-2 infection, ***CHEST*** **(2020), doi: https://doi.org/10.1016/j.chest.2020.03.039.**

28. Barbosa et al. Clinical outcomes of hydroxychloroquine in hospitalized patients with COVID-19: A quasi-randomized comparative study. Submitted to the New England Journal of Medicine. (April 11th 2020); also, it may be that the NEJM is a confidential release and should not be in the public space; thus this blog may be a source: https://blogs.sciencemag.org/pipeline/about-derek-lowe.

29. Pei et al. Convalescent Plasma to Treat COVID-19: Chinese Strategy and Experiences. url: https://doi.org/10.1101/2020.04.07.20056440 (Accessed on April 15th 2020).

30. Li et al. An exploratory randomized, controlled study on the efficacy and safety of lopinavir/ritonavir or arbidol treating adult patients hospitalized with mild/moderate COVID-19 (ELACOI). url: https://doi.org/10.1101/2020.03.19.20038984.

31. Chen et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. url: https://doi.org/10.1101/2020.03.17.20037432.

32. Deng L, Li C, Zeng Q, Liu X, Li X, Zhang H, Hong Z, Xia J. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. ***J Infect.*** **2020 Mar 11. pii: S0163-4453(20)30113-4. doi: 10.1016/j.jinf.2020.03.002.**

33. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. ***Clin Infect Dis.*** **2020 Mar 16. pii: ciaa272. doi: 10.1093/cid/ciaa272.**

34. Cellina M, Orsi M, Bombaci F, Sala M, Marino P, Oliva G, Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab, Diagnostic and Interventional Imaging (2020), doi:https://doi.org/10.1016/j.diii.2020.03.010.

35. Ye XT, Luo YL, Xia SC, Sun QF, Ding JG, Zhou Y, Chen W, Wang XF, Zhang WW, Du WJ, Ruan ZW, Hong L. Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease

2019. ***Eur Rev Med Pharmacol Sci.*** **2020 Mar;24(6):3390-3396. doi:10.26355/eurrev_202003_20706.**

36. Cao B et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. ***N Engl J Med.*** **2020 Mar 18. doi: 10.1056/NEJMoa2001282.**

37. Liu et al. The effect of Arbidol Hydrochloride on reducing mortality of Covid-19 patients: a retrospective study of real-world data from three hospitals in Wuhan. url: https://doi.org/10.1101/2020.04.11.20056523 (Accessed on April 17th 2020).

38. Meng et al. An experimental trial of recombinant human interferon alpha nasal drops to prevent coronavirus disease 2019 in medical staff in an epidemic area. url: https://doi.org/10.1101/2020.04.11.20061473 (Accessed on April 17th 2020).

39. Mammen MJ, Aryal K, Alhazzani W, Alexander PE. Corticosteroids for patients with acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials. ***Pol Arch Intern Med.*** **2020 Mar 18. doi: 10.20452/pamw.15239. [Epub ahead of print] PubMed PMID: 32186831.**

40. Mammen MJ, Aryal K, Alhazzani W, Deng DY, Alexander PE. Interferon-β-1a for patients with moderate to severe acute respiratory distress syndrome: a systematic review and meta-analysis of randomized trials. ***Pol Arch Intern Med.*** **2020 Apr 3. doi: 10.20452/pamw.15279.**

41. Patel et al. Usefulness of Ivermectin in COVID-19 Illness.
Department of Bioengineering, University of Utah, Salt Lake City, UT; HCA Research Institute, Florida (2020). Corresponding Author: Amit N. Patel -amit.patel@hsc.utah.edu or Mandeep R. Mehra, 75 Francis Street, Boston, MA 02115 or at MMEHRA@BWH.HARVARD.EDU, Fax: 617-264-5265; Tel: 617-732-8534; Twitter Handle: @MRMehraMD. url: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3580524 (Accessed on May 5th 2020).

42. Magagnoli et al. Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19. url: https://doi.org/10.1101/2020.04.16.20065920 (pre-publication). (Accessed on April 21st 2020).

43. Negri et al. Heparin therapy improving hypoxia in COVID-19 patients - a case series. url: https://doi.org/10.1101/2020.04.15.20067017. (Accessed on April 21, 2020).

44. Zhong et al. A Randomized, Single-blind, Group sequential, Active-controlled Study to evaluate the clinical efficacy and safety of α-Lipoic acid for critically ill patients with coronavirus disease 2019 （COVID-19). url: https://doi.org/10.1101/2020.04.15.20066266. (Accessed on April 21, 2020).

45. Roumier et al. Interleukin-6 blockade for severe COVID-19. :https://doi.org/10.1101/2020.04.20.20061861 (Accessed on April 22, 2020).

46. Pan American Health Organization. Guía para el cuidado crítico de pacientes adultos graves con Coronavirus (COVID-19) en las Américas (Versión larga) 2020. Available at:

https://www.paho.org/en/documents/guia-para-cuidado-critico-pacientes-adultos-graves-con-coronavirus-covid-19-americas
47. Bikdeli et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. url: https://doi.org /10.1016/j.jacc.2020.04.031 (Accessed on April 22, 2020)
48. Shi et al. Successful treatment of plasma exchange followed by intravenous immunogloblin in a critically ill patient with 2019 novel coronavirus infection. https://doi.org/10.1016/j.ijantimicag.2020.105974 (Accessed on April 22, 2020).
49. Yun Xie, Song Cao, Qingyun Li, Erzhen Chen, Hui Dong, Wenkai Zhang, Luyu Yang, Shouzhi Fu, Ruilan Wang, Effect of regular intravenous immunoglobulin therapy on prognosis of severe pneumonia in patients with COVID-19, ***Journal of Infection*** **(2020), doi: https://doi.org/10.1016/j.jinf.2020.03.044**
50. Z. Zhu, Z. Lu and T. Xu et al., Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19, ***Journal of Infection,*** **2020; https://doi.org/10.1016/j.jinf.2020.03.060.**

51. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 Mar 28;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3. Epub 2020 Mar 11. Erratum in: ***Lancet.*** **2020 Mar 28;395(10229):1038. Lancet. 2020 Mar 28;395(10229):1038.**

52. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, Huang H, Zhang L, Zhou X, Du C, Zhang Y, Song J, Wang S, Chao Y, Yang Z, Xu J, Zhou X, Chen D, Xiong W, Xu L, Zhou F, Jiang J, Bai C, Zheng J, Song Y. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. ***JAMA Intern Med.*** **2020 Mar 13. doi: 10.1001/jamainternmed.2020.0994.**

53. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS; China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. ***N Engl J Med.*** **2020 Feb 28. doi: 10.1056/NEJMoa2002032.**

54. Wang et al. Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China. url: https://doi.org/10.1101/2020.03.06.20032342 (Accessed on April 23, 2020).

55. Shang J, Du R, Lu Q, et al. The Treatment and Outcomes of Patients with COVID-19 in Hubei, China: A Multi-Centered, Retrospective, Observational Study (2/26/2020). SSRN 2020. Available online: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3546060. (Accessed on April 24th 2020).

56. Wang et al. No Clear Benefit to the Use of Corticosteroid as Treatment in Adult Patients with Coronavirus Disease 2019: A Retrospective Cohort Study. url: https://doi.org/10.1101/2020.04.21.20066258 (Accessed on April 25th 2020).

57. Ramireddy et al. Experience with Hydroxychloroquine and Azithromycin in the COVID-19 Pandemic: 1 Implications for QT Interval Monitoring. url: https://doi.org/10.1101/2020.04.22.20075671 (Accessed on April 27th 2020).

58. Kahn et al. A systematic review of Anakinra, Tocilizumab, Sarilumab and Siltuximab for coronavirus-related infections. url: https://doi.org/10.1101/2020.04.23.20076612 (Accessed on April 27th 2020).

59. Zhou et al. Interferon-α2b treatment for COVID-19. Frontiers in immunology. url: https://www.frontiersin.org/articles/10.3389/fimmu.2020.01061/full (Accessed on May 17th 2020).

60. Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial [published correction appears in Lancet. 2020 May 30;395(10238):1694]. ***Lancet.*** **2020;395(10236):1569-1578. doi:10.1016/S0140-6736(20)31022-9.**

61. Qing-Lei Zeng, Zu-Jiang Yu, Jian-Jun Gou, Guang-Ming Li, Shu-Huan Ma, Guo-Fan Zhang, Jiang-Hai Xu, Wan-Bao Lin, Guang-Lin Cui, Min-Min Zhang, Cheng Li, Ze-Shuai Wang, Zhi-Hao Zhang, Zhang-Suo Liu, Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in COVID-19 Patients, ***The Journal of Infectious Diseases*****, jiaa228, https://doi.org/10.1093/infdis/jiaa228.**

62. Mathian A, Mahevas M, Rohmer J, et al. ***BMJ Ann Rheum Dis Epub ahead of print: doi:10.1136/annrheumdis-2020-217566.***
url: https://ard.bmj.com/content/early/2020/04/24/annrheumdis-2020-217566.

63. Yu et al. Hydroxychloroquine application is associated with a decreased mortality in critically ill patients with COVID-19. url: https://doi.org/10.1101/2020.04.27.20073379 (Accessed on May 1st 2020).

64. Chorin et al. QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin. url: https://doi.org/10.1101/2020.04.27.20074583 (Accessed on May 1st 2020).

65. Lan et al. Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients withCOVID-19: a pilot retrospective study. url: https://doi.org/10.1101/2020.04.25.20079079 (Accessed on May 1st 2020).

66. Mallat et al. Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease: A retrospective study. url:https://doi.org/10.1101/2020.04.27.20082180 (Accessed on May 4th 2020).

67. Huang et al. Preliminary evidence from a multicenter prospective observational study of the safety and efficacy of chloroquine for the treatment of COVID-19. url: https://doi.org/10.1101/2020.04.26.20081059 (Accessed on May 5th 2020).

68. Fadel et al. Early Short Course Corticosteroids in Hospitalized Patients with COVID-19. url: https://doi.org/10.1101/2020.05.04.20074609 (Accessed on May 6th 2020).

69. Membrillo et al. Early Hydroxychloroquine Is Associated with an Increase of Survival in COVID-19 Patients: An Observational Study. url: https://www.preprints.org/manuscript/202005.0057/v1 (Accessed on May 6th 2020).

70. Quartuccio et al. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: results from a single Italian Centre study on tocilizumab versus standard of care. url: https://www.medrxiv.org/content/10.1101/2020.05.01.20078360v1.full.pdf (Accessed on May 6th 2020).

71. Geleris et al. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19. ***NEJM* 2020; DOI: 10.1056/NEJMoa2012410 (Accessed on May 8th 2020).**

72. Carlucci et al. Hydroxychloroquine and azithromycin plus zinc vs hydroxychloroquine and azithromycin alone: outcomes in hospitalized COVID-19 patients. url: https://doi.org/10.1101/2020.05.02.20080036 (Accessed on May 9th 2020).

73. Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. ***Lancet.* 2020;395(10238):1695-1704. doi:10.1016/S0140-6736(20)31042-4.**

74. Davido et al. Hydroxychloroquine plus azithromycin: a potential 1 interest in reducing in hospital morbidity due to COVID-19 pneumonia (HI-ZY-COVID)? url: https://doi.org/10.1101/2020.05.05.20088757 (Accessed on May 11th 2020).

75. Rosenberg ES, Dufort EM, Udo T, Wilberschied LA, Kumar J, Tesoriero J, Weinberg P, Kirkwood J, Muse A, DeHovitz J, Blog DS, Hutton B, Holtgrave DR, Zucker HA. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. ***JAMA.* 2020 May 11. doi: 10.1001/jama.2020.8630.** https://jamanetwork-com.libaccess.lib.mcmaster.ca/journals/jama/fullarticle/2766117

76. Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Baek YJ, Jeong SJ, Kim JH, Ku NS, Yeom JS, Roh J, Ahn MY, Chin BS, Kim YS, Lee H, Yong D, Kim HO, Kim S, Choi JY. Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea. ***J Korean Med Sci.* 2020 Apr 13;35(14):e149. doi: 10.3346/jkms.2020.35.e149.**

77. Wadud et al. Improved survival outcome in SARs-CoV-2 (COVID-19) Acute Respiratory Distress Syndrome patients with Tocilizumab administration. url: doi: https://doi.org/10.1101/2020.05.13.20100081.

78. Joyner et al. Early Safety Indicators of COVID-19 Convalescent Plasma in 5,000 Patients. url: https://doi.org/10.1101/2020.05.12.20099879.

79. Ramaswamy et al. Off-Label Real World Experience Using Tocilizumab for Patients Hospitalized with COVID-19 Disease in a Regional Community Health System: A Case-Control Study https://doi.org/10.1101/2020.05.14.20099234.

80. Gremese et al. Sarilumab use in severe SARS-CoV-2 pneumonia. url: https://doi.org/10.1101/2020.05.14.20094144.

81. Million M, Lagier JC, Gautret P, et al. Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France [published online ahead of print, 2020 May 5]. ***Travel Med Infect Dis.*** **2020;101738. doi:10.1016/j.tmaid.2020.101738.**

82. Estébanez et al. CLINICAL EVALUATION OF IFN BETA1B IN COVID-19 PNEUMONIA: A RETROSPECTIVE STUDY url: https://www.medrxiv.org/content/10.1101/2020.05.15.20084293v1.

83. Singh et al. Outcomes of Hydroxychloroquine Treatment Among Hospitalized COVID-19 Patients in the United States- Real-World Evidence From a Federated Electronic Medical Record Network. url: https://doi.org/10.1101/2020.05.12.20099028.

84. Yu B, Li C, Chen P, et al. Low dose of hydroxychloroquine reduces fatality of critically ill patients with COVID-19 [published online ahead of print, 2020 May 15]. *Sci China Life Sci.* 2020;1-7. doi:10.1007/s11427-020-1732-2.

85. Kimmig et al. IL6 inhibition in critically ill COVID-19 patients is associated with increased secondary infections. url: https://www.medrxiv.org/content/10.1101/2020.05.15.20103531v1.

86. Mehra et al. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. url: https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931180-6 (Accessed on May 22, 2020).

87. Beigel et al. Remdesivir for the Treatment of Covid-19 — Preliminary Report https://www.nejm.org/doi/full/10.1056/NEJMoa2007764.

88. Liu et al. Convalescent plasma treatment of severe COVID-19: A matched control study. url: https://www.medrxiv.org/content/10.1101/2020.05.20.20102236v1.

89. Ip et al. Hydroxychloroquine and Tocilizumab Therapy in COVID-19 Patients - An Observational Study. url: https://www.medrxiv.org/content/10.1101/2020.05.21.20109207v1.

90. Ahmad et al. Doxycycline and Hydroxychloroquine as Treatment for High-Risk COVID-19 Patients: Experience from Case Series of 54 Patients in Long-Term Care Facilities https://www.medrxiv.org/content/10.1101/2020.05.18.20066902v1.

91. Goldman et al. Remdesivir for 5 or 10 Days in Patients with Severe Covid-19. url: https://www.nejm.org/doi/full/10.1056/NEJMoa2015301?query=featured_home#article_citing_articles.

92. Cao Y, Wei J, Zou L, et al. Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial [published online ahead of print, 2020 May 26]. *J Allergy Clin Immunol.* 2020; S0091-6749(20)30738-7. doi:10.1016/j.jaci.2020.05.019.

93. Salazar E, Perez KK, Ashraf M, et al. Treatment of COVID-19 Patients with Convalescent Plasma [published online ahead of print, 2020 May 27]. *Am J Pathol.* 2020;S0002-9440(20)30257-1. doi:10.1016/j.ajpath.2020.05.014.

94. Ayerbe et al. The association between treatment with heparin and survival in patients with Covid-19. url: https://www.medrxiv.org/content/10.1101/2020.05.27.20114694v1

95. Perotti et al. Mortality reduction in 46 severe Covid-19 patients treated with hyperimmune plasma. A proof of concept single arm multicenter interventional trial. url: https://www.medrxiv.org/content/10.1101/2020.05.26.20113373v1

96. Freedberg et al. Famotidine Use is Associated with Improved Clinical Outcomes in Hospitalized COVID-19 Patients: A Propensity Score Matched Retrospective Cohort Study. url: https://www.medrxiv.org/content/10.1101/2020.05.01.20086694v2

97. Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial. ***JAMA.* Published online June 03, 2020. doi:10.1001/jama.2020.10044.**

98. Martinez-Sanz et al. Effects of Tocilizumab on Mortality in Hospitalized Patients with COVID-19: A Multicenter Cohort Study. url: https://www.medrxiv.org/content/10.1101/2020.06.08.20125245v1.

99. Garcia et al. Tocilizumab is associated with reduction of the risk of ICU admission and mortality in patients with SARS-CoV-2 infection. url: https://www.medrxiv.org/content/10.1101/2020.06.05.20113738v1.

100. Zhou et al. Prolonged SARS-CoV-2 Viral Shedding in Patients with COVID-19 was Associated with Delayed Initiation of Arbidol Treatment: a retrospective cohort study. url: https://doi.org/10.1101/2020.06.09.20076646.

101. Horby et al. Statement from the Chief Investigators of the Randomised Evaluation of COVid-19 thERapY (RECOVERY) Trial on hydroxychloroquine, 5 June 2020. url: https://www.recoverytrial.net/files/hcq-recovery-statement-050620-final-002.pdf. https://www.medrxiv.org/content/10.1101/2020.07.15.20151852v1

102. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. ***J Thromb Haemost.* 2020;18(5):1094-1099. doi:10.1111/jth.14817.**

103. Rajter et al. ICON (Ivermectin in COvid Nineteen) study: Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID19. url: https://www.medrxiv.org/content/10.1101/2020.06.06.20124461v2.

104. Pereda et al. Therapeutic effectiveness of interferon-alpha2b against COVID-19: the Cuban experience. url: https://www.medrxiv.org/content/10.1101/2020.05.29.20109199v1.

105. Trinh et al. Therapeutic Anticoagulation Is Associated with Decreased Mortality in Mechanically Ventilated COVID-19 Patients. url: https://www.medrxiv.org/content/10.1101/2020.05.30.20117929v1.

106. Temesgen et al. First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia.url: https://www.medrxiv.org/content/10.1101/2020.06.08.20125369v2.

107. Boulware DR, Pullen MF, Bangdiwala AS, et al. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19 [published online ahead of print, 2020 Jun 3]. *N Engl J Med.* 2020;10.1056/NEJMoa2016638. doi:10.1056/NEJMoa2016638.

108. Bhattacharya et al. Pre exposure Hydroxychloroquine use is associated with reduced COVID19 risk in healthcare workers. url: https://www.medrxiv.org/content/10.1101/2020.06.09.20116806v1.

109. Oteo et al. A short therapeutic regimen based on hydroxychloroquine plus azithromycin for the treatment of COVID-19 in patients with non-severe disease. A strategy associated with a reduction in hospital admissions and complications. url: https://www.medrxiv.org/content/10.1101/2020.06.10.20101105v1.

110. Magagnoli et al. Outcomes of HCQ usage in United States veterans hospitalized with covid-19. url: https://www.cell.com/med/fulltext/S2666-6340(20)30006-4.

111. Formina et al. Temporal clinical and laboratory response to interleukin-6 receptor blockade with Tocilizumab in 89 hospitalized patients with COVID-19 pneumonia. url: https://www.medrxiv.org/content/10.1101/2020.06.12.20122374v1.

112. Bhattacharyya et al. Chemoprophylaxis of COVID-19 with hydroxychloroquine - a study of health care workers attitude, adherence to regime and side effects. url: https://doi.org/10.1101/2020.06.11.20126359.

113. Macias et al. Similar incidence of Coronavirus Disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy. url: https://doi.org/10.1101/2020.05.16.20104141.

114. Giacomelli et al. Early administration of lopinavir/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study. url: https://www.medrxiv.org/content/10.1101/2020.06.05.20123299v1.

115. The RECOVERY Collaborative Group. Dexamethasone in Hospitalized Patients with Covid-19 — Preliminary Report. url: file:///C:/Users/Paul/Downloads/nejmoa2021436.pdf

116. RECOVERY trial. url: https://www.recoverytrial.net/. ISRCTN50189673 EudraCT 2020-001113-21.

117. Wang et al. Efficacy and Safety of Leflunomide for Refractory COVID-19: An Open-label Controlled Study. url: https://www.medrxiv.org/content/10.1101/2020.05.29.20114223v1.

118. Joyner et al. Safety Update: COVID-19 Convalescent Plasma in 20,000 Hospitalized Patients. url: https://mayoclinicproceedings.org/pb/assets/raw/Health%20Advance/journals/jmcp/jmcp_ft95_6_8.pdf.

119. Corral-Gudino et al. GLUCOCOVID: A controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia. url: https://doi.org/10.1101/2020.06.17.20133579.

120. Sbidian et al. Hydroxychloroquine with or without azithromycin and in-hospital mortality or discharge in patients hospitalized for COVID-19 infection: a cohort study of 4,642 in-patients in France. url: https://doi.org/10.1101/2020.06.16.20132597.

121. Salton et al. Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia. url: https://www.medrxiv.org/content/10.1101/2020.06.17.20134031v1.

122. Colaneri M, Bogliolo L, Valsecchi P, et al. Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE). *Microorganisms*. 2020;8(5):695. Published 2020 May 9. doi:10.3390/microorganisms8050695

123. Jeong et al. Association between NSAIDs use and adverse clinical outcomes among adults hospitalised with COVID-19 in South Korea: A nationwide study. url: https://www.medrxiv.org/content/10.1101/2020.06.01.20119768v2

124. Tleyjeh et al. The Cardiac Toxicity of Chloroquine or Hydroxychloroquine in COVID-19 Patients: A Systematic Review and Meta-regression Analysis. url: https://www.medrxiv.org/content/10.1101/2020.06.16.20132878v1

125. Patel TK, Barvaliya M, Kevadiya BD, Patel PB, Bhalla HL. Does Adding of Hydroxychloroquine to the Standard Care Provide any Benefit in Reducing the Mortality among COVID-19 Patients?: a Systematic Review [published online ahead of print, 2020 Jun 9]. *J Neuroimmune Pharmacol*. 2020;1-9. doi:10.1007/s11481-020-09930-x

126. Chen et al. Efficacy and safety of chloroquine or hydroxychloroquine in moderate type of COVID-19: a prospective open-label randomized controlled study url: https://www.medrxiv.org/content/10.1101/2020.06.19.20136093v1

127. Mikulska et al. Tocilizumab and steroid treatment in patients with severe Covid-19 pneumonia. url: https://www.medrxiv.org/content/10.1101/2020.06.22.20133413v1.

128. Nasir et al. Treatment of ARDS and hyperinflammation in COVID-19 with IL-6 antagonist Tocilizumab: a tertiary care experience from Pakistan. url: https://www.medrxiv.org/content/10.1101/2020.06.23.20134072v1**..**

129. Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. ***J Med Virol.*** **2020;92(7):814-818. doi:10.1002/jmv.25801.**

130. Guaraldi et al. Tocilizumab in patients with severe COVID-19: a retrospective cohort study. url: https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(20)30173-9/fulltext.

131. Price CC, Altice FL, Shyr Y, et al. Tocilizumab treatment for Cytokine Release Syndrome in hospitalized COVID-19 patients: survival and clinical outcomes [published online ahead of print, 2020 Jun 15]. ***Chest.*** **2020;S0012-3692(20)31670-6. doi:10.1016/j.chest.2020.06.006**

132. Zhang XJ, Qin JJ, Cheng X, et al. In-Hospital Use of Statins Is Associated with a Reduced Risk of Mortality among Individuals with COVID-19 [published online ahead of print, 2020 Jun 24]. ***Cell Metab.*** **2020;S1550-4131(20)30316-8. doi:10.1016/j.cmet.2020.06.015.**

133. Deftereos SG, Giannopoulos G, Vrachatis DA, et al. Effect of Colchicine vs Standard Care on Cardiac and Inflammatory Biomarkers and Clinical Outcomes in Patients Hospitalized With Coronavirus Disease 2019: The GRECCO-19 Randomized Clinical Trial. ***JAMA Netw Open.*** **2020;3(6):e2013136. Published 2020 Jun 1. doi:10.1001/jamanetworkopen.2020.13136**

134. Horby et al. RECOVERY. Lopinavir/ritonavir. url: https://www.recoverytrial.net/.

135. Arshad et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. url: https://www.ijidonline.com/article/S1201-9712(20)30534-8/fulltext

136. Huang D, Yu H, Wang T, Yang H, Yao R, Liang Z. Efficacy and safety of umifenovir for coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis [published online ahead of print, 2020 Jul 3]. ***J Med Virol.*** **2020;10.1002/jmv.26256. doi:10.1002/jmv.26256.**

137. Rattanaumpawan et al. Real-world Experience with Favipiravir for Treatment of COVID-19 in Thailand: Results from a Multi-center Observational Study. url: https://www.medrxiv.org/content/10.1101/2020.06.24.20133249v2

138. Gharbharan et al. Convalescent Plasma for COVID-19. A randomized clinical trial. url: https://www.medrxiv.org/content/10.1101/2020.07.01.20139857v1.

139. Carlo et al. Studio randomizzato multicentrico in aperto sull'efficacia della somministrazione precoce del Tocilizumab in pazienti affetti da polmonite da COVID-19. Multi-center randomized open-label study on the efficacy of the administration
early Tocilizumab in patients with COVID-19 pneumonia url: file:///C:/Users/Paul/Downloads/studio_RE_Toci_17.06.2020%20(3).pdf.

140. Davoudi-Monfared et al. Efficacy and safety of interferon β-1a in treatment of severe COVID-19: A randomized clinical trial. url: https://www.medrxiv.org/content/10.1101/2020.05.28.20116467v1.full.pdf

141. Boregowda et al. Addition of Tocilizumab to the standard of care reduces mortality in severe COVID-19: A systematic review and meta-analysis. url: https://www.medrxiv.org/content/10.1101/2020.07.10.20150680v1

142. Gorial et al. Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial) url: https://www.medrxiv.org/content/10.1101/2020.07.07.20145979v1

143. Feldman et al. Tocilizumab plus corticosteroid combination treatment, Drug Therapy Assists Critically Ill COVID-19 Patients url: https://www.texashealth.org/Newsroom/News-Releases/2020/Drug-Therapy-Assists-Critically-Ill-COVID-19-Patients

144. Hill et al. Hep C Sofosbuvir/Daclatasvir Combo Promising for COVID-19 https://www.medscape.com/viewarticle/933822

145. Kaye et al. The Efficacy of IL-6 Inhibitor Tocilizumab in Reducing Severe COVID-19 Mortality: A Systematic Review. url: https://www.medrxiv.org/content/10.1101/2020.07.10.20150938v1

146. Carvalho et al. Effects of Tocilizumab in Critically Ill Patients With COVID-19: A Quasi-Experimental Study url: https://www.medrxiv.org/content/10.1101/2020.07.13.20149328v1

147. Skipper CP, Pastick KA, Engen NW, et al. Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19: A Randomized Trial [published online ahead of print, 2020 Jul 16]. ***Ann Intern Med.*** **2020;10.7326/M20-4207. doi:10.7326/M20-4207.**

148. Monreal et al. HIGH VERSUS STANDARD DOSES OF CORTICOSTEROIDS IN COVID-19 PATIENTS WITH AN ACUTE RESPIRATORY DISTRESS SYNDROME: a controlled observational comparative study. url: https://www.medrxiv.org/content/10.1101/2020.07.17.20156315v1

149. Piechotta V, Chai KL, Valk SJ, et al. Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review. ***Cochrane Database Syst Rev.*** **2020;7:CD013600. Published 2020 Jul 10. doi:10.1002/14651858.CD013600.pub2**

150. Mitjà O, Corbacho-Monné M, Ubals M, et al. Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial [published online ahead of print, 2020 Jul 16]. ***Clin Infect Dis.*** **2020;ciaa1009. doi:10.1093/cid/ciaa1009.**

151. Glenmark Announces Top-Line Results From Phase 3 Clinical Trial of Favipiravir in Patients with Mild to Moderate COVID-19. url: file:///C:/Users/Paul/Downloads/Glenmark-Announces-Top-Line-Results-From-Phase-3%20-Clinical.pdf

152. Hedenstierna G, Chen L, Hedenstierna M, Lieberman R, Fine DH. Nitric oxide dosed in short bursts at high concentrations may protect against Covid 19 [published online ahead of print, 2020 Jun 23]. ***Nitric Oxide.*** **2020;103:1-3. doi:10.1016/j.niox.2020.06.005**

153. Marla J Keller, MD, Elizabeth A Kitsis, MD, MBE, Shitij Arora, MD, Jen-Ting Chen, MD, MS, Shivani Agarwal, MD, MPH, Michael J Ross, MD, Yaron Tomer, MD, William Southern, MD, MS, Effect of Systemic Glucocorticoids on Mortality or Mechanical Ventilation in Patients With COVID-19. J Hosp Med. Published Online First July 22, 2020. DOI: 10.12788/jhm.3497

154. Cavalcanti et al. Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19 url: DOI: 10.1056/NEJMoa2019014

155. Wang et al. Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients. url: https://doi.org/10.1016/j.chom.2020.07.005

156. LOFGREN et al. Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19 url: https://www.medrxiv.org/content/10.1101/2020.07.16.20155531v1

157. SNG001. Synairgen announces positive results from trial of SNG001 in hospitalised COVID-19 patients url: https://www.synairgen.com/wp-content/uploads/2020/07/200720-Synairgen-announces-positive-results-from-trial-of-SNG001-in-hospitalised-COVID-19-patients.pdf

158. Mitja et al. A Cluster-Randomized Trial of Hydroxychloroquine as Prevention of Covid-19 Transmission and Disease. https://www.medrxiv.org/content/10.1101/2020.07.20.20157651v1

159. Motta et al. Clinical Outcomes With the Use of Prophylactic Versus Therapeutic Anticoagulation in COVID-19. url: https://www.medrxiv.org/content/10.1101/2020.07.20.20147769v1

160. Strohbehn et al. COVIDOSE: Low-dose tocilizumab in the treatment of Covid-19. url: https://www.medrxiv.org/content/10.1101/2020.07.20.20157503v1

161. Abolghasemi H, Eshghi P, Cheraghali AM, et al. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study [published online ahead of print, 2020 Jul 15]. *Transfus Apher Sci.* 2020;102875. doi:10.1016/j.transci.2020.102875

162. Ivashchenko et al. AVIFAVIR for Treatment of Patients with Moderate COVID-19: Interim Results of a Phase II/III Multicenter Randomized Clinical Trial. url: https://www.medrxiv.org/content/10.1101/2020.07.26.20154724v2

163. Sakoulas et al. Intravenous Immunoglobulin (IVIG) Significantly Reduces Respiratory Morbidity in COVID-19 Pneumonia: A Prospective Randomized Trial. url: https://www.medrxiv.org/content/10.1101/2020.07.20.20157891v1

164. Pereda et al. Therapeutic effectiveness of interferon alpha 2b treatment for COVID-19 patient recovery. url: https://www.medrxiv.org/content/10.1101/2020.07.28.20157974v1

165. Joyner et al. Evidence favouring the efficacy of convalescent plasma for COVID-19 therapy. url: https://www.medrxiv.org/content/10.1101/2020.07.29.20162917v1.full.pdf

166. Chen et al. Effectiveness of Convalescent Plasma for Treatment of COVID-19 Patients. url: https://www.medrxiv.org/content/10.1101/2020.08.02.20166710v1

167. Rahman et al. Corticosteroid Use in Severely Hypoxemic COVID-19 Patients: An Observational Cohort Analysis of Dosing Patterns and Outcomes in the Early Phase of the Pandemic. https://www.medrxiv.org/content/10.1101/2020.07.29.20164277v1

168. Macias et al. High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment. url: https://www.medrxiv.org/content/10.1101/2020.07.30.20165027v1

169. Mittra et al. Resveratrol and Copper for treatment of severe COVID-19: an observational study (RESCU 002). url: https://www.medrxiv.org/content/10.1101/2020.07.21.20151423v1

170. Pang et al. Efficacy and tolerability of bevacizumab in patients with severe Covid -19. url: https://www.medrxiv.org/content/10.1101/2020.07.26.20159756v1

171. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2-Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia. Aging and disease. 2020;11(2):216.

172. Huet T, Beaussier H, Voisin O, Jouveshomme S, Dauriat G, Lazareth I, et al. Anakinra for severe forms of COVID-19: a cohort study. The Lancet Rheumatology. 2020 Jul;2(7):e393–400.

173. Mansour E, Palma AC, Ulaf RG, Ribeiro LC, Bernardes AF, Nunes TA, et al. Pharmacological inhibition of the kinin-kallikrein system in severe COVID-19 A proof-of-concept study [Internet]. Infectious Diseases (except HIV/AIDS); 2020 Aug [cited 2020 Aug 16]. Available from: http://medrxiv.org/lookup/doi/10.1101/2020.08.11.20167353

174. Zhang J, Rao X, Li Y, Zhu Y, Liu F, Guo G, et al. High-dose vitamin C infusion for the treatment of critically ill COVID-19 [Internet]. In Review; 2020 Aug [cited 2020 Aug 16]. Available from: https://www.researchsquare.com/article/rs-52778/v1

175. Jeronimo CMP, Farias MEL, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, et al. Methylprednisolone as Adjunctive Therapy for Patients Hospitalized With COVID-19 (Metcovid): A Randomised, Double-Blind, Phase IIb, Placebo-Controlled Trial. Clinical Infectious Diseases. 2020 Aug 12;ciaa1177.

PAHO/IMS/EIH/COVID-19/20-0016